REACTIVE IMINOQUINONE METABOLITES OF INDOMETHACIN · PDF fileREACTIVE IMINOQUINONE METABOLITES...
Transcript of REACTIVE IMINOQUINONE METABOLITES OF INDOMETHACIN · PDF fileREACTIVE IMINOQUINONE METABOLITES...
REACTIVE IMINOQUINONE METABOLITES OF
INDOMETHACIN AND CARBAMAZEPINE
Implications for drug-induced idiosyncratic reactions
Changqing Ju
A thesis subrnitted in conforrnity with the requirements
for the Degree of Doctor of Philosophy
Faculty of Pharmacy
University of Toronto
O Copyright by Changqing Su 1999
National Library 1*1 oi Canada Bibliothèque nationale du Canada
Acquisitions and Acquisitions et Bibliographie Services services bibliographiques 395 Wellington Street 395, rue Wellington Ottawa ON K I A ON4 Ottawa ON KI A ON4 Canada Canada
Your (ik Votre relerence
Our K& Notre retêrenw
The author has granted a non- L'auteur a accordé une licence non exclusive licence allowing the exclusive permettant à la National Library of Canada to Bibliothèque nationale du Canada de reproduce, loan, distribute or sell reproduire, prêter, distribuer ou copies of this thesis in microfom, vendre des copies de cette thèse sous paper or electronic formats. la forme de microfiche/film, de
reproduction sur papier ou sur format électronique.
The author retains ownership of the L'auteur conserve la propriété du copyright in this thesis. Neither the droit d'auteur qui protège cette thèse. thesis nor substantial extracts £iom it Ni la thèse ni des extraits substantiels may be p ~ t e d or otherwise de celle-ci ne doivent être imprimés reproduced without the author's ou autrement reproduits sans son permission. autorisation.
REACTIVE IMINOQUINONE METABOLITES OF INDOMETHACIN AND
CARBAMAZEPINE
Implications for drug-induced idiosyncratic reactions
Degree of Doctor of Philosophy, Faculty of Pharmacy, University of
Toronto
Changqing Ju, 1999
ABSTRACT
Indomethacin is a potent nonsteroidal anti-infiammatory drug. Its use has been
Limited because of a relatively high incidence of adverse reactions including
agranulocytosis. Carbarnazepine is an anticonvulsant and its use is associated with a range
of serious idiosyncratic adverse reactions including blood disorders. We postulated that
indomethacin and carbamazepine can be oxidized to reactive intermediates by
myeloperoxidase in activated neutrophils, which may be responsible for the adverse effects
caused by these two dmgs.
We found that desmethyldeschlorobenzoylindomethacin (DMBI), a major
metabolite of indomethacin, was oxidized to a reactive iminoquinone intermediate. This
irninoquinone intermediate could be trapped with glutathione (GSH) and N-acetylcysteine
(NAC) to form conjugates. The sarne oxidation was observed when DMBI was oxidized
by the MPO system or hypochlorous acid. The iminoquinone intermediate with a MH+ ion
at d z 204 was directly detected by mass spectrometry in the reaction between DMBI and
hypoc hlorous acid.
In the urine of patients taking carbamazepine, we detected 2-hydroxyiminostilbene
as its glucuronide conjugate and found that it is a major metabolite of carbarnazepine. We
iii
have also demonstrated that 2-hydroxyiminostilbene can undergo autoxidaiion to a reactive
iminoquinone intermediate. The irninoquinone intermediate reacts with sulfhydryl-
containing nucleophiles, such as GSH and NAC. To further investigate the role of the
iminoquinone intermediate in carbarnazepine-induced adverse reactions, we developed a
polyclonai antibody against the irninoquinone epitope and used it to study covalent binding
of the irninoquinone to proteins. The antibodies were able to detect covaient binding in
bone marrow cells of rats treated with carbarnazepine M vivo. This binding was inhibited
by 2-hydroxyiminostilbene but not by carbamazepine or iminostilbene, which suggested
that the polypeptides recognized by the antibodies were likely to be covalently modified by
the iminoquinone reactive intermediate. Furthemore, we also observed increased protein
oxidation in the liver from carbarnazepine-treated rats compared to that of control rats. This
implied that the iminoquinone, as an oxidizing agent. may undergo redox cycling and lead
to protein oxidation itz VIVO.
Our studies suggest that the iminoquinone intemediates inay react with protein
sulfhydryl groups NI vivo and play an important role in indomethacin- and carbamazepine-
induced idiosyncratic reactions.
ACKNOWLEDGMENTS
Dr. Jack Uetrecht is a great mentor. I am forninate to have had such an
understanding, supportive, patient and knowledgeable supervisor to guide me through my
Ph.D. degree. 1 owe a debt of gratinide to him for al the help he has given me and for an
example of a dedicated scientist he has set for me.
1 also would like to acknowledge and show my appreciation to Dr. Robert A.
McClelland. He was so generous with his thne and expertise whenever I asked him for
advice or had technicd problems in various experimental procedures.
1 am grateful to Dr. Iain Gardner and Mr. Nasir Zahid for sharing their technical
knowledge, without which it would have been impossible for me to complete this thesis.
1 would like to dearly thank Dr. Denis M. Grant and Dr. Peter J. O'Brien for their
roles as cornmittee members of my Ph.D. project and for their constructive criticism which
helped me better my work.
1 would also like to thank Dr. Steven Leeder for his vaiuable advice and
collaboration with the covalent binding studies.
1 am also grateful to Dr. Alastair E. Cnbb and Dr. Allan B. Okey for attending my
Senate Defense and their roles as my extemal appraiser.
1 would like to, finally, thank the following colleagues for giving their support and
friendship and sharing experiences with me through my Ph.D. degree: Ebrahim, Ian.
George, Miyamoto, Terrence, Hak. Kenny, John, Inga and Taras.
TABLE OF CONTENTS
Abstract
Ackno w ledamen ts
Table of content
List of Tables
List of Figures
List of Abbreviations
List of Publications
Chapter 1 General Introduction
1.1 An overview of research interests, rationale and objectives
1.2 Hypothesis
1.3 Dmg-induced idiosyncratic reactions
1.3.1 Clinical manifestations of drug-induced idiosyncratic reactions
1.3.1 a Systemic reactions
1,3. I b Cutaneous reactions
1.3. l c Hepatotoxicity
1.3.1 d Hernatological reactions
1.3.2 Carbarnazepine-induced idiosyncratic reactions
1.3.3 Indomethacin-induced idiosyncratic reactions
1.4 Possible mechanisms of idiosyncratic reactions
1.4.1 Relevance of the immune system to idiosyncratic dnig reactions
1.4.2 Hapten hypothesis
1.4.3 Reactive metabolites involved in idiosyncratic reactions
1.4.3a Hydroxylamines
1.4.3 b Quinones
1 .43 Cations and radicals
Page
ll
i v
v
ix
X
xiii
XV
1
3
4
5
6
6
8
9
10
13
14
15
15
18
3 1
24
29
37
1.4.3d Arene oxides
1.4.3e Miscellmeous
1.5 Metabolism of indomethacin and carbarnazepine
1 S. 1 Indomethacin
1 S.2 Carbarnazepine
Chapter 2 Oxidation of a metabolite of indomethacin (DMBI)
to reactive intermediates by activated neutrophils,
HOCI and the myeloperoxidase systern
2.1 Abstract
2.2 Introduction
2.3 Materials and Methods
2.3.1 Synthesis of DM1
2.3.2 Synthesis of DiMBI
2.3.3 Oxidation of DMBI by HOC1
2.3.4 Oxidation of indomethacin and DM1 by HOC1
2.3.5 Oxidation of D.MBI by the MPO system
2.3.6 Oxidation of D.WI, indomethacin and DM1 by activated neutrophils
2.3.7 Synthesis of reacrive intermediate-NAC adduct
2.3.8 Reaction kinetics determined by spectrophotornetry
2.3.9 Analytical Methods
2.4 Results
2.4.1 Oxidation of D . B I by activated neutrophils
2.4.2 Oxidation of DLMBI by HOCI
2.4.3 Oxidation of DMBI by MPO system
2.4.4 Oxidation of indomethach by HOC1 and activated neutrophils
2.4.5 Oxidation of D-W by HOC1 and activated neutrophils
2.5 Discussion
vi i
Chapter 3 Detection of 2-hydroxyiminostilbene in the urine
of patients taking car barnazepine and its oxidation
to a reactive iminoquinone intermediate
3.1 Abstract
3.2 Introduction
3.3 Materids and Methods
3.3.1 Synthesis of the irninoquinone intermediate
3.3.2 Synthesis of 2-hydroxyiminostilbene
3.3.3 Synthesis of NAC-adduct of the iminoquinone
3.3.4 Synthesis of 2-hyroxycarbamazepine
3.3.5 Treatment of the urine sample
3.3.6 Analytical methods
3.4 Results
3.4.1 Oxidation of 2-hydroxy irninostilbene
3 A.2 Reactivity of the irninoquinone intemediate
3.4.3 Patient urine sample analysis
3.5 Discussion
Chapter 4 lnvestigating the role of the reactive iminoquinone
metabolite of carbarnazepine in the mechanism of
carbarnazepine-induced idiosyncratic reactions
4.1 Abstract
4.2 Introduction
4.3 iMaterials and Methods
4.3.1 Synthesis of irninoquinone-NAC-conjugaied KLH and RSA
1.3.2 Production of anti-iminoquinone-NAC-KLH antiserum
S . .
V l l l
1.3.3 Activity of the anti-iminoquinone-NAC-KLH antiserum
4 3 . 4 Dosing of rats with carbarnazepine in vivo
4.3.5 Isolation of rat bone marrow cells
4.3.6 Preparation of subcellular fractions of rat liver
4.3.7 Preparation of rat skin homogenates
4 3 . 8 SDS-PAGE and imrnunoblotting
4.3.9 Determination of oxidatively modified proteins
4.4 Results
1.4.1 S ynthesis of irninoquinone-NAC-KLH (RS A) conjugate
44.2 Determination of the activity of the antiserum
4.4.3 hunoblot t ing of bone marrow cells isolated from rats
treated with carbarnazepine
4.4.4 Protein oxidation in subcellular fractions of rat liver
-1.45 hunoblot t ing of skin homogenate and subcellular
liver fractions from rats treated with carbarnazepine
4.5 Discussion
Chapter 5 Summary and Discussion
5.1 Surnmary
5.2 Discussion
LIST OF TABLES
Chapter 1 General Introduction
Table 1 - 1 Fonation of the reactive hydroxylarnine intermediates during
bioactivation of drugs by various oxidizing enzymes.
Table 1-2 Formation of the reactive iminoquinone intermediates during
bioactivation of drugs by various oxidizing enzymes.
Table 1-3 Formation of cation or free radicals during bioactivation
of drugs by various oxidizing enzymes.
Table 13 Formation of the reactive arene oxide intermediates during
bioactivation of xenobiotics by CYP450.
Table 1-5 Formation of the reactive metabolites during bioactivation of
drugs by various oxidizing enzymes.
Chapter 3 Detection of 2-hydroxyiminostilbene in the urine
of patients taking carbarnazepine and its oxidation
to a reactive iminoquinone intermediate
Table 3- 1 The ratios of the TIC of 2-hydroxyiminostilbene-glucuronide
( d z 386) to that of carbarnazepine-glucuronide (m/z 4 13),
monohydroxycarbamazepine-glucuronide (m/z 429) and
10.1 1 -dihydrodiol-carbarnazepine (m/z 27 1).
Page
19
LIST OF FIGURES
Page
Chapter 1 General Introduction
Figure 1 - 1 The major and minor antigenic determinants of benzylpenicillin. 20
Figure 1-2 The role of bioactivation in rnediating either direct (metabolic) 23
idiosyncrasy or immune-mediated idiosyncrasy.
Figure 1-3 Metabolism of procainamide by MPO in activated neutrophils. 27
Figure 1-4 Oxidation of arnodiaquine to a reactive irninoquinone interrnediate. 3 1
Figure 1-5 Proposed pathway of the oxidation of diclofenac to a reactive 33
irninoquinone.
Figure 1-6 Proposed parhway of the oxidation of vesnarinone to reactive 34
irninoquinone intermediates.
Figure 1 -7 Proposed mechanism for 1 ,Cbenzoquinone formation from the 36
MPO-catalyzed metabolism of CGS 12094.
Figure 1-8 Metabolic pathway for the bioactivation of tacrine to its posnilated 37
quinone methide reactive metabolite by CYPl A?.
Figure 1-9 Proposed scheme of the oxidation of arninopyrine to a cation 39
radical via a dication interrnediate.
Figure 1-10 Proposed pathway for the oxidation of clozapine to a reactive 3 1
nitreniurn ion or a cation radical by HRP and MPO.
Figure 1 - 1 1 Proposed mechanisms of forming the imidoirninium ion 43
intermediate of vesnarinone.
Figure 1 - 12 B ioactivation of benzo[a]pyrene to the diol-epoxides carcinogens. 17
Figure 1-13 Metabolism of tienilic acid to the sulfoxide metabolite by CYP2C9. 50
Figure 1-14 Metabolism of propylthiouracil by MPO to the reactive sulfonic 51
acid.
Chapter 2 Oxidation of a metabolite of indomethacin (DMBI)
Figure 2- 1
Figure 2-2
Figure 2-3
Figure 2-4
Figure 2-5
Figure 2-6
Figure 2-7
Figure 2-8
Figure 7-9
to reactive intermediates by activated neutrophils,
HOCl and the myeloperoxidase system
Major metabolic pathway of indomethacin.
Metabolisrn of DMBI by activated neutrophils as a fùnction
of t h e , initial DMBI concentration and neutrophil concentration.
MSMS spectra of the metabolites with MH+ ions at m/z 409 and 67
rn/z 407, formed dunng DMBI oxidation by activated neutrophils.
W absorption spectnim of the metabolite with a MH+ ion at 107, 65
during DM31 oxidation by activated neutrophils.
Proposed pathway of the formation of the two stable metabolites
dunng DMBI oxidation by activated neutrophils.
Repetitive absorption spectra from the reaction of DMBI with
HOCl.
Proton NMR spectmm of the iminoquinone-NAC conjugate.
Proposed scheme for DiMBI metabolism by activated neutrophils
and trapping the reactive intermediate by NAC.
Cosy specrrum of the iminoquinone-NAC conjugate.
Chapter 3 Detection of 2-hydroxyiminostilbene in the urine
of patients taking carbarnazepine and its oxidation
to a reactive iminoquinone intermediate
Figure 3- 1 Proposed bioactivation pathway of carbarnazepine which leads
to the formation of a reactive iminoquinone intermediate.
Figure 3-2 The W absorption spectra of the synthesized iminoquinone and
2-hydroxyiminostilbene before and after reaction with HOC1.
Figure 3-3 Proton NMR of the iminoquinone-NAC conjugate
xii
Figure 3-4 Oxidation of 2-hydroxyiminostilbene to the iminoquinone 93
intermediate and its reaction with NAC.
Figure 3-5 Cosy spectnirn of the iminoquinone-NAC conjugate 95
Figure 3-6 MSMS spectrum of the metabolite, which has the same molecular 98
weight as that of 4-methylthio-7-hydroxyirninostilbene, in its
glucuronide form (with a MH+ ion at m/z 432).
Figure 3-7 Selected ion current of the urinary metabolites from the LCfMS of a 99
patient's urine.
Fipre 3-9 MS/MS spectrum of the glucuronide conjugate of 1 O0
2-hydroxyiminostilbene.
Figure 3-9 LC/MS ion current at m/z 208 corresponding to the iminoquinone 10 1
intermediate in a urine sample before and after hydrolysis by
P-glucuronidase.
Chapter 4 Investigating the role of the reactive iminoquinone
metabolite of carbarnazepine in the mechanism of
carbarnazepine-induced idiosyncratic reactions
Figure 4- 1 The structure of the irninoquinone-NAC-Protein conjugate. 117
Figure 4-2 ELISA analysis showing binding of the anti-irninoquinone-NAC-KLH 120
antiserum to wells of microtiter plates coated with an
iminoquinone-NAC-RSA conjugate or RSA.
Figure 4-3 Immunochernical detection of protein binding in the bone marrow 12 1
from rats treated in vivo.
Fi jure 4-4 Immunoblotting expenment show ing protein oxidation in 122
subcellular fractions of rat liver in vivo.
Chapter 5 Summary and Discussion
Figure 5-1 Proposed pathway of carbarnazepine bioactivation to an arene
oxide intermediate and its reactions with GSH.
xiii
LIST OF ABBREVIATIONS
Abbreviation
ANA
BP
CGS 12094
CYP450
DBI
DL
DMBI
DMI
EDC
ELISA
FDA
GSH
HLA
HRP
HSR
k KLH
LCMS
MH+
MHC
MPO
NAC
NADPH
NSAID
Narne
an tinuclear antibody
benzo[a] pyrene
para-hydroxy metabolite of p ~ o m i d e
cytochrome P45O
deschlorobenzoylindomeihacin
drug-induced lupus
desrnethyldeschlorobenzoylindomethacin
desmethy lindomethacin
1 -ethyl-3-(3-dimethyi~nopropy1)carbodiimide
enzyme-linked immunosorbent assay
Food and Dmg Administration of U.S.
glu tathione
human leukocyte antigen
horseradish peroxidase
hypersensitivity syndrome reactions
imrnunoglobulin
Keyhole limpet hemocyanin
liquid chromatography/Mass spectrometry
protonated molecular ion
major histocompatibility genes
myeloperoxidase
n-acetylcysteine
nicotinamide adenine dinucleotide phosphate, reduced form
nonsteroidal anu-inflammatory dmg
xiv
PHs
RSA
SJS
SLE
SSLR
TCPO
TEN
TIC
prostaglandin H synthase
rabbit semm aibumin
Stevens-Johnson syndrome
systernic lupus erythematous
semm sickness-like reactions
trichloropropene oxide
toxic epidermal necrolysis
total ion current
LIST OF PUBLICATIONS
lu C and Uetrecht JP (1998) Detection of 2-hydroxyiminostilbene in the urine of patients
taking carbarnazepine and its oxidation to a reactive iminoquinone intermediate. J.
Pharmacol. Exp. Ther. 288: 5 1-56.
Ju C and Uetrecht JP (1998) Oxidation of a metabolite of indomethacin
(desmethyldeschlorobenzoylindomethacin) to reactive intermediates by activated
neutrophils, hypochlorous acid, and the myeloperoxidase system. Dnlg Merab. Dispos.
26: 676-680.
Chapter 1
General Introduction
1.1 An overview of research objectives and rationale
Adverse drug reactions represent a significant health problem. In a recent study by
Bruce Pomeranz and Jason Lazarou (Lazarou et al., 1998). they estirnated that adverse
dmg reactions h l1 an average of 100,000 people annually in the US.. making them the
founh leading cause of death. after heart disease. cancer and stroke (The Financial Post
Magazine, June 1998 Page 9). Some of the adverse dmg reactions are preventable, in
principle. because they are due to known pharmacological effects of the dmgs and would
be expected to occur in most patients at a sufficiently high dose. Another type of adverse
drug reaction is the so-called "idiosyncratic reaction" for which the mechanism is mostly
unknown. Idiosyncratic dnig reactions, which account for approximately 10% of al1
adverse drug reactions (Goldstein and Patterson. 1984), are often quite severe and
sometimes life threatening. Due to their unpredictable nature, drug-induced idiosyncratic
reactions have posed a difficult problern, both in medical practice and for present and Future
dmg development. Although the rnechanisms of most dmg-induced idiosyncratic reactions
are unknown. a large number of studies have suggested that reactive metabolites are
involwd. Several clinical characteristics of this type of adverse reaction ülso suggest the
involvernent of the immune system.
Indomethacin and carbarnazepine have been s h o w to cause idiosyncratic reactions
including drug-induced agranulocytosis. The formation of reactive metabolites is thought
to be a necessary step in the pathogenesis of these idiosyncratic reactions. Although liver is
the major organ responsible for drug metabolism. short-lived reactive metabolites generated
in the liver rnay not be able to escape the liver and induce clinical manifestations in other
areas of the body which are involved in idiosyncratic drug reactions. Therefore. it is
important to investigrite the formation of reactive metabolites in the txget organs of dmg-
induced adverse reactions. In indomethacin- and carbarnazepine-induced hematological
disorders reactive metabolites are more likely to be generated by the oxidative
myeloperoxidase system in neutrophils or other cells in the bone marrow than in the liver.
The objectives of this project were: a) to determine if indomethacin and
carbarnazepine c m be oxidized by myeloperoxidase in activated neutrophils; b) to identib
the reactive intermediates generated during the oxidation and characterize their chernical
reactivity as electrophiles; c) and to further investigate the possible role of the reactive
intermediates in the mechanism of idiosyncratic dmg reactions.
1.2 Hypothesis
Reactive iminoquinone metabolites are generated during the oxidation of
indomethacin and carbarnazepine in the targets of dmg-induced toxicity. These reactive
iminoquinone intermediates play an important role in the mechanism of indomethacin- and
carbarnazepine-inducrd idiosyncratic reactions via covalent binding to endogenous proteins
that induce an immune reaction.
1.3 Drug-induced idiosyncratic reactions
An adverse dmg reaction is defined as any undesirable response to a drug that
occurs at therapeutic doses (Park and Kitteringham, 1990). Adverse dru: reactions are
major complications of modem drug therapy; they account for significant patient rnorbidity
and death (Park et al. , 1992). Drug-induced adverse reactions can be classified into
predictable reactions and unpredictable reactions (Rieder, 1994). Predictable reactions +
include toxicity from overdose; dmg-dmg or dmg-disease interactions; and side effects that
occur at usual therapeutic doses such as nausea and dizziness. These reactions can often be
predicted from the chernical properties and the pharmacology of the drug; they ore often
host-independent, dose-dependent; and usually reproducible in animals (Pohl et al., 1988).
Such reactions should be anticipated and can often be eliminated by dose reduction.
Unpredictable reactions include hypersensitivity (or "allergie") reactions and idiosyncratic
reactions. The terms "dmg hypersensitivity reaction" and "idiosyncratic drug reaction"
have been used interchangeabl y, for example, "drug-induced hypersensitiviry reactions"
has been used to describe systemic idiosyncratic reactions with fever. rash and multiorpan
involvement. Ideally, "hypersensitivity reaction" should be used to describe adverse
reacrions associated with drug therapy which have a known immunological etioiogy;
however, The term "idiosyncratic dmg reactions" will be used, in this thesis. to descnbe
reactions with cornmon characteristics that include:
Occurrence in a relatively small number of patients. These reactions have been
rstimated to account for 6% to 10% of ail adverse drug reactions caused by a total of 90
million courses of dru; therapy per year among medical inpatients (Goldstein and
Patterson, 1984)
An apparent lack of dose-response curve for the risk of toxicity. In principle these
reactions must be dose-dependent; however, in many cases the dose that can cause
roxicity is much srnaller than the dose for desired pharmacological effect.
;ui unpredictable nature and lack of animal models. Idiosyncratic reactions occur in
humans with a relatively low incidence; therefore it is diffïcult to reproduce the s m e
reactions in laboratory anirnals, which are inbred strains, even if a large number of
animais are tested.
Involvement of specific organs, such as the skin, bone marrow and liver. These
reactions are often lirnited to specific organs, although generalized reactions may also
occur in which there is fever, skin rash and lymphadenopathy, dong with involvement
of specific organs.
1.3.1 Clinical manifestations of drug-induced idiosyncratic reactions
The patterns of idiosyncratic reactions are variable depending on both the patients
and the drugs. These reactions, although not very common, can be life-threatening and
have resulted in removal from the market of many potentially useful dmgs. For example,
practolol, benoxaprofen, ticrynafen, zomepirac and nomifensine were withdrawn shortly
after they were released because of an unacceptable risk of toxicity (Uetrecht, 1990). The
most comrnonly occumng idiosyncratic dmg reacrions involve the skin, various elements
of the blood and the liver. The kidney and nervous system may also be affected and
autoimmune syndromes such as drug-induced lupus can also occur.
1.3. l a Systemic reactions
In some cases idiosyncratic reactions show a rernarkable degree of organ
specificity. In other cases, multiple ogans may be affected simultaneously, such as in
hypersensitivity syndrome reaction (HSR), semm sickness-like reaction (SSLR) and drug-
induced lupus (DL).
CI
/
HSRs are serious and possibly life-threatening reactions that usually occur 2 to 4
weeks af'ter the stan of therapy. Although this type of reactions is termed "hypersensitivity
syndrome", their mechanisms are not fully understood. Drugs that are most often
associated with this type of adverse reaction include anticonvulsants, dapsone,
sulfonamides and allopurinol (Knowles et al., 1996). The initial sign of HSRs is often
fever, which is followed by a rash. The rash may be exanthematous; however, in severe
cases it c m be erythema multiforme, Stevens-Johnson syndrome (SJS), or toxic epidermal
necrolysis (TEN). Intemal organ involvement often develops 1 to 2 weeks later. Hepatic
injury is a commoo manifestation, although pulmonary, hematological or renal impairment
may also occur.
SSLRs are characterized clinically by fever, rash, anhralgia and occasionally with
associated lymphadenopathy (Parker, 1982). Clinical signs and symptoms of SSLRs
typically develop 1 to 3 weeks after the start of drug treatment. Unlike cllissical serum
sickness reactions, immune complexes have not been identified in SSLRs although they
share many clinical symptoms (Knowles er al., 1996). SSLRs have been shown to occur
with a nurnber of drugs including penicillin, cephalosporin, sulfonamides,
propylthiouracil, phenytoin, streptomycin, barbiturates, isoniazid, salicylates, captopril.
hydralazine and nonsteroidal antiinflammatory dmgs (NSAIDs) (Füeder, 1994).
Similar to idiopathic systernic lupus erythematous (SLE), D L is an autoimmune
disease characterized by antibodies that bind to "selft-antigens. However, in the case of
DL the symptorns are often milder (Anderson, 1992). In particular, the most serious
manifestations in SLE. involving the central nervous system and kidney, are uncornmon in
DIL (Anderson, 1992). Symptoms of D L are self-limiting once the offending drug has
been discontinued. Because it usually requires several months of therapy before lupus is
induced, a dnig would cause lupus only if it is used for a chronic illness. The drugs
comrnonly associated with DL are procainamide, isoniazid, hydralazine, chlorpromazine,
phenytoin, methyldopa, penicillamine, quinidine and minocycline (Gilliland, 1991;
8 Knowles et al., 1996). Of the dmgs associated with lupus, procainamide induces the
highest incidence (10 to 20% of patients on continuous procainamide therapy over 2 years)
(Rieder, 1994). The mechanism of D U is unknown. it has been shown to be associated
with antinuclear antibodies (ANA); however. only a minority of patients who develop a
positive ANA titer related to drug ingestion develop clinicai disease consistent with DIL
(Knowles et al., 1996).
1.3.lb Cutaneous Reactions
In cornparison with other organs, the skin is quite frequently a target of drug-
induced idiosyncratic reactions. The combination of metabolic activity and imrnunological
responsiveness may explain why skin is the organ most frequently affected by adverse
dmg reactions. In contrast with allergic contact dermatitis, dmg-induced skin reactions
have a large variability with regard io their pathophysiological pathways, clinical signs and
symptoms, severity and the drugs that can elicit these reactions (Merk and Henl, 1996).
Alrnost any type of skin disease or characteristic symptoms can be mimicked by drug-
induced skin reactions. Probably the most comrnon cutaneous manifestations of drug
reactions are a variety of maculopapular, morbilliform. scarlatiniform or exanthematous
emptions. Some of the most cornmon offenders being various antibiotics, anticonvulsants,
allopurinol, barbiturates, carbarnazepine, sulfonamides, gold salts, and antituberculosis
agents (Mathews, 1984). The more serious skin reactions due to drugs include erythema
multiforme, SJS and TEN. The incidence of SJS, TEN and SJSiTEN overlap has been
estirnated to be approximately 1.89 cases per one million people per year (Mockenhaupt
and Schopf, 1996). Although SJS and TEN occur very rareiy, a mortaiity rate of more
than 40% c m be calculated for patients suffering from TEN (Mockenhaupt and Schopf,
1996). The highest incidence has been implicated to be associated with three groups of
9
drugr, antibacterials (e.g. sulfonamides, penicillin), NSAIDs and anticonvulsants (Park et
al., 1992).
These severe type of skin reactions are thought to be immune-mediated. The
evidence for this include: the occurrence of TEN in acute graft-versus-host disease in which
the immune system is definitely involved. demonstration of anti-epidermal antibodies and
positive lymphocyte transformation tests and demonstration of epidermal infiltration by
CD8+ T-cells (Park et al., 1992).
1.3.1~ Hepatotoxicity
Adverse drug reactions affecting the liver are common with more than 600 drugs
having been reponed to cause hepatic injury (Stricker and Spoelsua, 1985). The types of
liver injury are variable and include hepatocellular necrosis, steatosis. cholestasis,
granuloma, chronic hepatitis and cirrhosis (Pohl, 1990). The fatality rate of drus-induced
hepatic injury is often hiph such that drugs are a major cause of hepatic failure
(Zirnmerman, 1978). For example, the case fatality rate from halothane-induced hepritic
failure may be as high as 50% (TimbreIl. 1983).
Drug-induced hepatotoxicities have been classified into two catesories: the
predictable acute response after an overdose and the idiosyncratic reaction following
chronic therapeutic doses. Predictable injury resulting in hepatocellular necrosis is the best
understood variety. It is dose-related. host-independent and usually reproducible in animal
models. It has been shown to be due ro the intrinsic toxicity of a drug or its metabolite
produced in the b e r . Hepatic necrosis induced by acetarninophen and carbon tetrachloride
are typical examples of this type (Kaplowitz e t al., 1986). Clinically, idiosyncratic hepatic
injury is seen more commonly than predictable toxicity (Kaplowitz et al., 1986). With
idiosyncratic hepatotoxicity, there seems to be no dose relationship, usually no animal
mode1 and it is often host dependent (Pohl, 1990). Dmgs that are associated with this type
10 of reaction include rifampin, halothane, chlorpromazine, isoniazid, hydantoins and
sulfonamides (Mathews, 1984; Timbrell, 1983).
Idiosyncntic hepatotoxicity may be due to direct toxicity of a chemically reactive
metabolite, such as isoniazid-induced hepatotoxicity. This is called "metabolic"
idiosyncrasy (Zimmerman, 1978). Another type of idiosyncratic hepatotoxicity is
secondary to an immune reaction (Pohl, 1990). A diagnosis of immunological liver injury
is supported by the association with multiple exposures, the pattern of fever, occasional
eosinophilia and skin rash and the reoccurrence of the same pathologic condition upon
rechallenging with the culprit dmg (Pohl, 1990).
1.3.ld Hematologicai Reactions
Blood cells are a cornmon target in idiosyncratic dmg reactions. Dmg-induced
hematological toxicity can affect either platelets, red cells, white cells or al1 fomed elements
of the bone marrow resulting in thrombocytopenia, hemolytic anemia, agranulocytosis or
aplastic anernia, respectively.
Agranulocytosis is characterized by an almost complete lack of granulocytic
leukocytes in the circulation - less than 500 cells compared to a normal count of 5.000-
10,000 cells per pl of blood. The granulocytic leukocytes are neutrophils, eosinophiis, iuid
basophils; the most abundant ce11 being the neutrophils. Agranulocytosis carries a high
monality rate because a patient without neutrophils has a very high nsk of infection that
cannot be controlled by antibiotics (Uetrecht. 1992). Drug-induced agranulocytosis is
usuaily reversible with an "overshoot" of the peripheral neutrophils approximately 1 week
after the dmg is stopped. Depletion of al1 elements of the bone marrow results in aplastic
anemia. The monality rate of aplastic anernia is much higher than that of agranulocytosis
and the time to recovery is usually longer. The estimates of eiiologic fractions of
agranulocytosis and aplasric anernia due to drus use have been reported in three case-
control studies: the International Agranulocytosis and Aplastic Anernia S tudy (IAAAS)
conducted in Israel and Europe, a study conducted in the northeast U.S. and a study
conducted in Thailand (Kaufman et al.. 1996). The overall etiologic fractions of
agranulocytosis due to drug use were 62% in IAAAS. 77% in the U.S. and 70% in
Thailand. Compare to agranulocytosis. the etiologic fractions of aplastic anemia due to
drug use were much less and they were 27% in the IAAAS, 17% in the U.S. and 2% in
Thailand. Drugs that have been associated with agranulocytosis include: acetaminophen,
aminopyrine, arnodiaquine, benzene, captopril, carbamazepine, chloramphenicol,
chlorpromazine, chlozapine, dapsone, indomethacin. methimazole, mianserin,
penicillamine, phenylbutazone, procainamide, propylthiouracil, sulfonamides,
trimethoprim, trimethoprim/sulfamethoxazole and vesnarinone (Kaufman et al., 199 1 ;
Uetrecht, 1992). Drugs that are often associated with aplastic anemia include allopurinol,
cûptopril, carbamazepine, chloramphenicol, dapsone, indomethacin, mephenytoin,
methimazole, phenylbutazone, phenytoin, propylthiouracil. sulfonamides, trimethadione
and trimethopnm/sulfamethoxazole (Kaufman et al., 199 1 ).
The mechanism of dmg-induced aganulocytosis is unknown; however, either an
imrnunologically-mediated destruction of neutrophils or a direct cytotoxici ty to bone
marrow has been sug_oested (Isildar et al., 1988). The clearest example of a drug that
causes antibody-mediated peripheral destruction of neutrophils is aminopyrine (Magis et
al., 1968: Moeschlin and Wagner, 1952; Uetrecht. 1990). The evidence for an immune-
mediated reaction includes: the discovery of a serum factor in patients with aminopyrine-
induced agranulocytosis that agglutinates neutrophils (Magis et al., 1968; Moeschlin and
Wagner, 1952), a rapid decline in neutrophils when blood from the patient was infused into
normal subjects with the same blood type and the rapid onset of agranulocytosis on
reexposure of a patient to even a small quantity of arninopyrine. In contrast,
chlorpromazine-induced agranulocytosis is considered an exarnple of a direct bone marrow
toxicity (Pisciotta et al., 1958). One piece of evident to suppon this is that the onset is
delayed upon reexposure. In addition, bone marrow examination demonstrated depletion
of al1 elements of the granulocyte senes (Uetrecht, 1992). The clinical characteristics of
drug-induced agranulocytosis associated with other drugs appear to fa11 somewhere
between those of arninopyrine and chlorpromazine, with some characteristics suggesting
more direct toxicity and others suggesting an immune-mediated reaction.
Thrornbocytopenia is characterized by bleeding and petechial hemorrhages in the
skin that are related directly to the fa11 in circulating platelet levels. The most commonly
proved or strongly suspected causes of immunologically-mediated thrombocytopenia are
chlorothiazide, digitoxin. gold, heparin, meprobarnate, quinidine, quinine, rifarnpin,
stibophen and sulfonamides (Petz and Fudenberg, 1976). A marked decrease in
rnegakaryocytes in the early phases of a reaction is usually considered to be indicative of a
toxic rather than imrnunologic reaction. However, decreased platelet synthesis and release
may also occur to a limited extent in immunologically mediated thrombocytopenia,
particularly when the reaction is prolonged. The immunological nature of the reaction has
been demonstrated both by passive transfer and irz vitro studies in thrombocytopenia
produced by apronalide, quinine, and quinidine (Ackroyd, 1975; Ackroyd, 1962;
Shulman, 1958). The sera and immunoglobulin (Ig) fraction of affected patients contain
antibodies that. in the presence of the drug, produce platelet lysis or agglutination.
A variety of dnigs, pmicularly penicillin and a-methyldopa. have been reponed to
produce an immune-mediated hemolytic anemia. Other agents include dipyrone, p-
aminosalicylic acid, stibophen, quinine, quinidine, phenacetin and nomifensine (Parker,
1982). a-methyldopa produces its effect on red blood cells by inducinj an autoantibody.
Penicillin-induced hemolytic anemia js an exarnple of an irnrnunodestnictive response in
which the dmg participates as a hapten. It is an occasional complication in individuals
receiving prolonged high dose penicillin therapy (Parker, 1982). In about 3% of
individuals enough antihapten antibody is produced to give a positive antiglobulin reaction
13 on the red cells. If enough of the right kind of antihapten antibody is present and the bone
marrow cannot compensate, anernia develops.
1.3.2 Carbarnazepine-induced idiosyncratic reactions
Carbarnazepine has become for many clinicians a dnig of choice for the treatment of
borh partial and generalized convulsive seizures. It has challenged the use of phenytoin
because it is considered by many to cause less cognitive impairment then phenytoin (Dodrill
and Troupin, 1977; Smith et al., 1987; Thompson and Trimple, 1982), although the two
dmgs share similar profiles of adverse effects. The incidence of side effects associated
with carbarnazepine treatment in adults and children ranges from 33 to 50%. Most of the
effects are rnild, transient and reversible if the dosage is reduced or if initiation of treatrnent
is gradual; however, 5% of the adverse reactions associated with carbamazepine can be
classified as idiosyncratic reactions (Durelli et al., 1989). These idiosyncratic adverse
reactions include skin rash (Crill, 1973), blood disorders (Gerson et al., 1983). hepatitis
(Horowitz et al., 1988) and the carbamazepine hypersensitivity syndrome (Carmela et al.,
1995; Shear and Spielberg, 1988). A Swedish survey of 505 reports of 7 13 idiosyncratic
reactions to carbamazepine from 1965 to 1987 reported skin reactions (48%).
hematological (12%) and hepatic disorders (10%) to b e the most frequent (Askmark and
Wholm, 1990).
S kin reactions were the most frequent adverse reaction associated with
carbarnazepine treatment that has been reported to Geigy Phmaceuticals and the Food and
Drug Administration (FDA) in the United States. For the years 1975 to 1986 there were a
total of 396 cases of rash and nonspecific derrnatological reactions reported. These
included 13 reported cases of SJS. 2 cases of TEN, 10 cases of exfoliative dermatitis and
12 cases of eryrhema multiforme (Pellock, 1987). In addition, carbamazepine is one of the
drugs most frequently implicated ro cause TEN (Park et ai., 1992).
In addition to derrnatological reactions, hematological adverse reactions to
carbamazepine, although rare, are important because of the serious and potentially fatal
consequences of protracted bone marrow depression. Of 80 significant cases of
carbarnazepine-associated hematological reactions reponed to Geigy Pharmaceuticals over
12 year, thrornbocytopenia ranked first with 3 1 cases. followed by aplastic anernia (27
cases), agranulocytosis (10 cases), pancytopenia (8 cases) and bone marrow depression (4
cases) (Pellock, 1987).
Most carbarnazepine-associated hepatic abnormalities are transient elevations of
liver enzymes (Pellock. 1987). However, carbarnazepine-induced hepatic injury has been
reponed to show a cholestatic or mixed pattern as well as a hepatocellular pattern. Cases of
granuiomatous hepatitis and cholangitis have also been descnbed (Askmark and Wiholm,
1 990).
Carbarnazepine hypersensitivity syndrome. similar to the hypersensitivity syndrome
associated with phenytoin and phenobarbital, is a potentially fatal reaction. In most cases,
the reaction invoives multiorgan abnormalities accompanied by fever, rash and
lymphadenopathy. The onset of the reaction usually occurs within 3 months of the initial
treatment. most ofren within 2 to 4 weeks. It occurs sooner in previously sensitized
individuals and occurs within 1 day on rechallenge in those with a history of carbamazepine
hypersensitivity syndrome (Carmela et ni., 1995).
1.3.3. Indomethacin-induced idiosyncratic reactions
indomethacin is a very effective NSAID, but its use is lirnited by a high incidence
of adverse reactions, including blood disorders. Adverse effecrs have been estimated to
occur in 30-604 of patients treated with indomethacin, and serious reactions requiring
discontinuance of the drug occur in about 10% of patients. Most comrnon side effects,
15 which appear to be dose-dependent, include gastro-intestinal disturbances, headache and
dizziness (Cuthbert, 1974).
Indomethacin also causes idiosyncratic hematological adverse effects in less than
1% of patients. These reactions include hemolytic anemia, bone marrow depression,
aplastic anemia, agranulocytosis, leukopenia, thrombocytopenia and thrombocytopenic
purpura. Of a total of 1,261 reports of adverse reactions to indomethacin reported to the
U.K. Cornmittee on Safety of Medicines between Iune 1964 and January 1973, blood
disorders were recorded in 157 cases (25 fatal) which included thrombocytopenia (35; 5
fatal), aplastic anemia ( 17; no fatalities), and agranulocytosis or leukopenia (2 1 ; 3 fatal)
(Cuthbert, 1 974). Subsequently . the First Report from the International Agranulocytosis
and Aplastic Anemia Study confirmed a signifiant relationship between the use of
indomethacin and agranulocytosis and aplastic anemia. In this population-based case-
control study conducted in Europe and Israel, the excess risk estimated for agranulocytosis
and aplastic anemia was 0.6 per million for indomethacin exposure in a one-week period
(Shapiro, 1986).
1.4 Possible mechanisms of idiosyncratic reactions
1.4.1 Relevance of the immune system to idiosyncratic drug reactions
Adverse drug reactions that involve a specific drug-induced immune response are
referred to as drug hypersensitivity reactions and they can be classified according to the
general scheme of Gel1 and Coombs (1963):
Type 1 (imrnediate hypersensitivity or anaphylacllc) reactions
This type of reactions result from the interaction (cross-linking) of drug antigen with
specific IgE antibody on the surface of mast cells and basophils to trigger the release of
chernical mediators such as histamine and leukotrienes. The chnical features include
generalized erythema. urticaria, angioedema, gastrointestinal disturbances,
bronchospasm, laryngoedema, and hypotension. To most clinicians, the term "allergy "
is synonymous with type 1 hypersensitivity. Anaphylactic reactions to penicillin are an
example of a type I reaction.
Type II (cytotoxic) reactions
This type of reactions are caused by binding of specific IgG or IgM antibody with
antigen associated with the surface of a cell, or to a ce11 surface altered antigenically by
a drug. The ce11 is destroyed by phagocytic cells or by activation of the complement
system leading to ce11 lysis. This may result in thrombocytopenia, anemia or
leucopenia. depending on the disposition of the antigen. Hemolytic anemia due to
quinine and penicillin are type II reactions.
Type IQ (immune compiex) reactions
This type of reaction involves the formation of circularing immune complexes, from
specific antigen and IgG or IgM antibodies, which c m precipitate in the vasculature and
rend glomeruli; tissue damage results from activation of complement and recruitment of
phagocytes. The classical example of type III hypersensitivity is serum sickness
reactions, w hich rnay presrnt clinically with lymphadenopathy. arthralgia. fever and
rash.
4 Type IV (hg-induced delayed hypersensitivity) reactions
This type of reaction usuaily occurs in the skin. The major ce11 types involved are T
lymphocytes and macrophages. Lymphokines are released following interaction of antigen
with specific T-cells; tissue darnage is caused by infiltrating mononuclear cells. Topically
applied dmg becomes nttached to a carrier protein in the skin; induces a cell-mediated
response and causes contact dermatitis. Such reactions can also occur nfter either oral or
parenteral administration of the drug.
Idiosyncratic dmg reactions have often been referred as drug hypersensitivity
reactions. However, there is not enough evidence to definitely prove that the immune
system is involved. The most convincing evidence for the involvement of the immune
system is demonstration that specific antiboaies or sensitized T lymphocytes are reacting
wirh the dmg or its metabolites. Dmg-related antibodies have been described in some
idiosy ncratic dmg reactions. For example, the evidence for an immune-mediated reaction
is strong in penicillin-induced anaphylaxis and aminopyrine-induced agranulocytosis.
Penicillin is chernically reactive due to the b-lactam ring and it can act as a hapten. There is
strong evidence that most of the antibodies in patients who are allergic to penicillin
recognize penicillin bound to lysine (Parker, 1982). In some patients the major type of
antibody induced is IgE, and this c m result in an anaphylactic reaction. Antibody-mediated
peripheral destruction of neutrophils has been suggested to be the mechanism of
aminopyrine-induced agranulocytosis by several pieces of evidence. For example,
incubation of semm from a patient who has the active disease with normal neutrophils Ied
to agglutination of the neutrophils (Moeschlin and Wagner, 1952). In addition, infusion of
blood frorn a sensitive patient 3 hours after a dose of aminopyrine into a normal subject
rnatched for blood type led to granulocytopenia (Moeschlin and Wagner, 1952). In another
study, the serum from a patient with aminopyrine-induced agranulocytosis inhibited
colonies cultured from a rnononuclear fraction of the patient's blood in the presence of
d r y , while serum from a normal control did not (Barrett et al., 1976). However. probably
due to the complexities of the immune systern. in most cases of idiosyncratic reacrions rhere
is no direct evidence for the involvement of the immune system, even when effort has been
made to search for such evidence. Furthemore, since not al1 drug-induced antibodies or
sensitized T lymphocytes will necessarily cause tissue damage, a definite proof that ri
toxicity has an allergic basis requires that it be produced in animals. where the
imrnunologica1 mechanisms of cellular damage can be thoroughly studied (Pohl et al.,
1988). However, there have been few animai models developed for studying the
mechanism of idiosyncratic dnig reactions.
1s Despite this lack of proof that the immune system is involved in the majority of
idiosyncratic drug reactions, the idiosyncratic nature of such reactions has led many
investigators to believe that most of these reactions are mediated by the immune system
(Parker, 1982: Pohl et al., 1988). Sorne of the clinical characteristics of many idiosyncratic
reactions also suggest that the immune systern is involved. Such characteristics include:
A requirement of prior exposures to the drug, or a lag period of more than a week
between starting the drug and the development of toxicity.
A lack of delay in toxicity on reexposure of a patient to the offending dmg.
No apparent correlation between dose and the risk of toxicity.
The presence of a skin rash and peripheral blood eosinophilia.
However, there is no reason to presume thar al1 idiosyncratic reactions have an
imrnunological mechanism. The role of direct cytotoxicity has not been ruled out and
remains a controversial issue. However, i t is unlikeiy that many idiosyncratic drug
reactions involve direct cytotoxicity of the drug or its metabolites. If such were tme, the
reaction would be expected to be more predictable and also to be detected in animal toxicity
tests with high doses. Direct cytotoxicity also may not explain the large intenndividual and
interspecies differences in the toxicity since differences in drug rnetabolism do not appear to
be the sole bais for the idiosyncratic character of these drug reactions.
1.4.2 Hapten hypothesis
Unfortunately, not enough is h o w n about the mechanism of many dmg-induced
idiosyncratic reactions to place them into the Gel1 and Coornbs classification scheme.
However, for a drug to cause any imrnunological reaction, it would probably have to act as
a hapten. The term "hapten" has been used to describe a substance which is not
imrnunogenic per se, but becomes immunogenic when conjugated to a rnacromolecuiar
carrier. In generd, in order for a molecule to be recognized as "nonself' and to induce an
immune response, it must have a minimum molecular weight of approximately 1000
daltons (Pohl et al., 1988). Since most drugs are not this large, they must bind to an
endogenous macromolecule. such as protein, to form a drug-protein conjugate before they
c m interact with the immune system. This binding of a drug to a macrornolecular carrier
must be essentially irreversible, usually covalent, for the adduct to be immunogenic. The
reason for the requirement of a covalent interaction is that. for an immune response to be
induced, the irnrnunogen must be processed and presented by antigen presenting cells (i.e.
macrophages). If the interactions between hapten and macromolecule were reversible, the
hapten would diffuse away from the macromolecule before fragments of the adduct could
be presented to T-cells. Therefore, central to the hapten hypothesis is the requirement for
the ability of a hapten to form a stable adduct with nucleophilic groups on proteins (e.g.
lysyl and cysteinyl residues) in aqueous conditions.
Some drugs are chemically reactive themselves so that they can react directly to
proteins, such as penicillin. Penicillin has a reactive structure and can bind covalently to
proteins and carbohydrates by reaction with nucleophilic arnino, hydroxyl, mercapto and
histidine groups. The principal mode of conjugation, referred as the "major" ontigenic
determinant, is the penicilloyl moiety bound to e-amino groups of lysine residues of
proteins. There are two possible routes for the formation of penicilloyl derivatives. One
pathway is the direct aminolysis of penicillin by the protein. An alternative pathway is
through remangement of penicillin to penicillenic acid (Schwartz, 1969). Penicillenic acid
contains a free thiol Croup that can also form mixed-disuifide bonds with cysteine residues
and this is one of the so called "minor determinants" (Figure 1-1). There is also evidence
that penicilloic acid and penamaldate are specific antigenic determinants in penicillin allergy
and they are included in the "rninor determinants" (Schwartz, 1969).
penicillin
1 Protein
Major antigenic determinant
Isornerization
penicillenic acid
penicilloic acid
Penamaldate
Minor antigenic determinants
Figure 1- 1 : The major and rninor antigenic deterrninants of benzylpenicillin (Park
and Kitteringham, 1990; Schwartz, 1969).
21 Some dmgs have a free sulfhydryl group that can react with disulfide linkages to
form mixed disulfides. For example, both D-penicillamine and captopril have a free
sulfhydryl group that can react with cysteine residues on proteins via disulfide linkages.
Imrnunochemical studies have shown that captopil linked by disulfide bonds to proteins
cm function as a hapten in humans and experimental animals (Park er al., 1987). Besides a
free sulfhydryl group, D-penicillamine also possesses a free amino group so that it can
react wirh biological intermediates that contain a free carbonyl group to form thiazolidine
derivatives. It has been shown that penicillamine interferes with collagen maturation by
chernicd reaction with free aldehyde group in pro-collagen (Park er al., 1987).
Unlike penicillin. captopril and penicillamine, most drugs are not chemically
reactive nor sufficiently electrophilic to bind to macromolecules. Therefore most dmgs
must be convened to reactive species within the body in order to act as haptens.
1.3.3 Reactive metabolites involved in idiosyncratic reactions
Although we do not have a complete understanding of the mechanism of drug-
induced idiosyncratic reactions, there are a large number of studies to suggesr that reüctive
metabolites are involved (Hinson and Roberts, 1992; Park et al., 1995) and scxeral
chxactenstics suggest the involvement of the immune system (Pohl et al., 1988).
In generaf, drug metabolism can be considered as a detoxification process in which
it convens therüpeutically active compounds to inactive. more polar metabolites that can
then be removed from the body. However, in cenain circumstances, the drug metabolizing
enzymes can convert a dnig to a chernically reactive metabolite. This process is referred as
"bioacrivaion" (Pirmohamed er al., 1994). Chemically reactive agents cm be cytotoxic by
reacting with critical biological molecules (Jerina and Daiay, 1974; Stadtman and Oliver,
199 1). In most cases. the chemically reactive metabolite will be detoxified before it can
initiate tissue damage. If inadequateiy detoxified, formation of a reactive metabolite as a
22 result of drug bioactivation is often the first step, although not necessarily the ultimate step,
in initiating idiosyncratic drug toxicity. The reactive metabolite may cause direct cellular
toxicity; cause ce11 stress and initiate innate immune responses; or it can act as a hapten and
initiate an immune reaction which may be due to a specific humoral (antibody) response, a
cellular response (T lymphocytes) or a combination of both (Park et al., 1987; Pohl et al.,
1988) (Figure 1-2).
Me tabolic Bioactivation
binding
Detoxification
/ Stable metabolite ]
T ce11 urnora response
Immune-mediated idiosyncrasy
Figure 1-2: The role of drug bioactivation in mediating either direct (metabolic)
idiosyncrasy or immune-mediated idiosyncrasy (Pirmohamed et 01.. 1996).
24 Reactive metabolites can be formed by most of the enzymes that are involved in
drug metabolism. the most important being the enzymes of cytochrome P450 (CYP450)
mixed function oxidase system. Other enzymes also play an important role in drug
bioactivation. In white blood cells and bone marrow cells, for example. MPO has been
shown to bioactivate a wide range of dmgs (Pirmohamed et of., 1996: Uetrecht, 1992) In
other tissues low in CYP450 activity (e.g. kidney, h g , skin), prostaglandin H synthase
(PHs) may also be responsible for bioactivation; e.g. in the kidney acetarninophen toxicity
is thought to result from activation via this enzyme (Pirmohamed et al., 1996).
For most drugs, the occurrence of bioactivation and the chemical nature of the
reactive metabolite have not been definitely determined. This is largely due to the lack of
techniques that allow the detection of in vivo bioactivation and determination of the nature
of the metabolites formed. However, a large arnount of indirect evidence suggests that
many dmgs are bioactivated to structurally different reactive metabolites that may play a
role in the mechanisrn of drug-induced idiosyncratic reactions.
In this discussion, dmgs will be categorized according to the chernical nature of
their reactive metabolites that are generated during the bioactivation of these drugs. Tables
1- 1, 1-2, 1-3, 1-4 and 1-5 are lisrs of dmgs and xenobiotics, the types of toxicity that they
cause and their reactive metabolites generated during bioactivation by various metabolizing
enzymes.
1.4.3a Hydroxylamines
Many drugs have an arylarnine moiety or can be metabolized to arylamines (either
primary or secondary). Studies by various research groups have demonsîrated that
arylamine-containing dmgs can usuaiiy be oxidized to reactive hydroxylamines or further to
the closely related nitroso derivatives. These studies have been carried out in various
enzyme systems (e.g. CYP15O and MPO), cells (i.e. human neutrophils) or tissue
25 homogenates (eg . human and mouse liver microsomes). Typical examples of this class of
dmgs include procainamide, dapsone and sulfonamides (Table 1- 1).
Table 1-1: Formation of the reactive hydroxylarnine intermediates during bioactivation of
dmgs by various oxidizing enzymes.
Idiosyncratic
Toxicity
Agranulocytosis,
Hepatotoxicity,
Drug-induced lupus
Methernoglobinernia,
"Hypersensitivity ",
Mononucleosis-like
syndrome,
Agranulocytosis
Hepatoxicity,
Skin rash,
Blood disorders,
"Hypersensitivity "
Reactive Metabolites
hydroxylarnine
hydroxy lamine
hydroxy lamine
Enzvmes
Procainamide is an
incidence of drug-induced
26 antiarrhythmic agent. but its chronic use is limited by a high
lupus and agranulocytosis (Ellrodt et al., 1984). It has been
shown that procainamide was metabolized to a hydroxylamine by both rat and human
hepatic microsornes and by activated human neutrophils (Uetrecht et al.. 1988a; Uetrecht et
al.. 1984). In vitro the hydroxylamine was oxidized nonenzymatically by hydrogen
peroxide to a nitroso denvative and funher to the nitro derivative (Figure 1-3). Of these
metabolites, the nitroso-procainamide was the most reactive and accounted for most of the
covalent binding to proteins (Uetrecht, 1985). When procainamide was oxidized by the
combination of myeloperoxidase and hydrogen peroxide in the presence of chloride ion, a
reactive N-chloroprocainamide metabolite was formed (Uetrecht and Zahid, 199 1) (Fig 1 -
3) .
Procainamide Hydroxy lamine
MPO/H,O,, CI' nonenzymatic 1
N-Chloro Nitroso
Figure 1-3: Metabolism of procainamide by MPO in activated neutrophils (Uetrecht
et al., 1988a; Uetrecht and Zahid, 199 1).
28 Dapsone is used in the treatment of leprosy and it is also effective in malarial
prophylaxis. Adverse reactions to dapsone include agranulocytosis and severe hemolytic
mernia (Coleman et al., 1989). The rnetabolism of dapsone by activated neutrophils leads
to the formation of the hydroxylamine and nitroso metabolites (Uetrecht et al.. 1988b).
Dapsone has also been shown to undergo bioactivation to a cytotoxic metabolite, in a
nicotinamide adenine dinucieotide phosphate (NADPH)-dependent reaction catalyzed by
microsornes prepared from nine individual human livers (Coleman et al.. 1989). The
kinetics of dapsone hydroxylamine formation in human liver microsornes were biphasic.
111 vitro metabolic studies using enzyme inhibitors, inhibitory antibodies, enzyme
expression systems and correlations with the levels of individual isozymes have detemiined
that CYP3A4 and CYP2El accounted largely for dapsone hydroxylamine formation at high
(100 pmol/l) and low (5 pmolA) substrate concentrations, respectively. These data also
suggested that C Y P X isoforms contribute to dapsone hydroxylamine formation at low
substrate concentration (Fleming et al.. 1992; Gill et al., 1995; Mitra et al., 1995).
Sulfonamides are antimicrobid agents that are associated with various idiosyncratic
reactions in humans which include hepatitis, nephritis, blood dyscrasias. drug-induced
lupus, serum sickness and the suifonamide hypersensitivity syndrome. It has been shown
that in humans. sulfarnethoxazole was metabolized to its hydroxylamine in the liver
predominantly by CYP2C9 (Cribb and Spielberg, 1990b; Cribb et al., 1995).
Sulfamethoxazole was also shown io be oxidized by activated monocytes and neutrophils
(human and canine) to form sulfarnethoxazole hydroxylarnine and nitrosulfamethoxazole;
the latter was presumably formed via the reactive nitroso-sulfamethoxazole intermediate
(Cribb et al., 1990a).
1.4.3b Quinones
A large number of drugs or their metabolites contain a phenyl ring with a hydroxyl
group in the para (or onho) position to another hydroxyl group or an amine or methyl
group. This structure renders the ability of these h g s (or their metabolites) to be oxidized
and convened to reactive quinones. iminoquinones or quinone methides depending on the
hinctional group that is para (or ortho) to the hydroxyl group on the arornatic ring. The
dmgs (or their metabolites) of this category are listed in Table 1-2.
Table 1-2: Formation of the reactive irninoquinone intermediate during bioactivation of
dmgs by various oxidizing enzymes.
Drug
Acetaminophen
Diclofenac
(5- hydroxyl
metabolite)
Vesnarinone
Benzene
(hydroquinone)
Prinornide
(parahydroxy
metabolite)
Idiosy ncratic
Toxicitv
Agrariulocytosis,
Hepato toxici ty
Hepatotoxicity ,
Nephrotoxicity
Hepatotoxicity,
Blood disorders
Aplastic anemia
Agranulocytosis
Reactive Metabolites
iminoquinone
N-ace ty lbenzo-
auinoneimine
irninoquinone
- - -
imidoiminium ion,
irninoquinone
quinone
quinone
--
quinone methide
Metabolizing
Enzvmes
MPO,
HRP
CYP 1A2, CYPSE1,
CYP3A4
MPO
MPO
32 Amodinquine is an antirnalarial agent associated with a high incidence of
agranulocytosis. A number of cases of fatal agranulocytosis, as well as hepatotoxicity. in
patients during prophylactic administration has led to its withdrawal fiom use (Hatton et
al., 1986; Laney et al., 1986; Neftel et al., 1986). Bioactivation of amodiaquine and
covalent binding to various proteins have been demonstrated in several systems: human
liver microsomes, horseradish peroxidase (HRP) I Hz02 or in the presence of chlorine and
activated neutrophils (Jewell et al., 1995; Maggs et al., 1988; Naisbitt et al., 1997). Ir was
shown that a reactive iminoquinone intermediate was formed from amodiaquine by
autoxidation at neutral pH, by peroxidases and by silver oxide oxidation, and by activated
neutrophils in vitro (Christie et al., 1989; Clarke et al.. 1990; Maggs et al., 1987; Maggs et
al., 1988) (Figure 1-4).
Amodiaquine
HRP or MPO/H202
nonenzymatic
lminoquinone
Figure 1-4: Oxidation of amodiaquine to a reactive irninoquinone intemediate
(Park and Kitteringham, 1990).
and hepatotoxicity after
large amount of evidence
Acetarninophen is an anaigesic agent. Renal toxicity
overdoses have been associated with acetaminophen. There is a
to support the involvement of the reactive N-acetylbenzoquinone imine in this toxicity. At
least three f o m of CYP450 (CYPlA2, CYP2El and CYP3A4), as well as MPO and PHs
enzyme systems, have been shown to be involved in acetaminophen bioactivation and the
formation of the reactive iminoquinone (Boyd and Eling, 198 1; Moldeus and Rahimtula,
1980; Potter and Hinson, 1987; Raucy et al., 1989; Thummel et al., 1993).
Formation of the reactive iminoquinone intermediates during bioactivation of
indomethacin and carbarnazepine will be discussed in detail in Chapter 2 and Chapter 3,
respec tively . Diclofenac is a NSAID, and is widely used in the treatment of rheumatoid anhntis
and other inflammatory diseases (Dunk et al., 1982). In rare incidences, diclofenac
appears to be associated with hepatitis (Dunk et al., 1982; Helfgott et al., 1990) and
hematological toxicity, such as aplastic anemia, neutropenia (Eustace et al., 1989; Kaufman
et al., 1991; Kim and Kovacs, 1995; Salama et al., 1989), hemolytic anemia and
thrombocytopenia (Epstein et al., 1990; Kim and Kovacs, 1995; Kramer et al., 1986;
Salama et al., 1991). It has been shown that when diclofenac is oxidized by MPO or
activated neutrophils, the major product was an iminoquinone (Figure 1-5). This
iminoquinone reacted with glutathione and it is also likely to react with protein sulfhydryl
groups which would contribute to covalent binding (Miyarnoto et al., 1997). In addition,
the phenolic precursor of the iminoquinone, 5-hydroxydiclofenac, is a significant hepatic
metabolite of diclofenac (Sawchuk et al., 1995). It was found that the irninoquinone was
also formed by the oxidation of 5-hydroxydiclofenac with rat hepatic microsomes, so it is
likely that the iminoquinone is formed both in the liver and in the bone marrow of humans
(Miyamoto et al., 1997).
Diclofenac
5- hydroxydiclofenac Iminoquinone
Figure 1-5: Proposed pathway of the oxidation of diclofenac to a reactive
iminoquinone (Miyarnoto et al., 1997).
Vesnarinone is used in congestive heart failure and its use is associated with
agranulocytosis. It was found that vesnarinone was metabolized to a reactive metabolite
that covalently bound to activated neutrophils (Uetrecht et al., 1994). The reactive
metabolite was identified as an imidoiminium ion (Figure 1-6). This reactive species can
either hydrolyze to form veratrylpiperazinamide or react with other nucleophiles, such as
34 GSH. Hydrolysis also leads to another reactive intermediate, an iminoquinone, which also
reacts with GSH (Uetrecht et al., 1994).
Vesnarinone
OCHB Imidoiminium ion
OCHj
Veratrylpiperazinamide
Figure 1-6: Proposed pathway of oxidation of vesnarinone
iminoquinone intermediates (Uetrecht et al., 1994).
to reactive
35 Benzene is an environmental toxicant. The most frequently observed toxic effect of
benzene in humans and in animal models has been bone marrow depression leading to
aplastic anemia (Snyder and Kocsis, 1975). Benzene is initially metabolized in the liver by
CYP2E 1 to hydroxylated products: phenols, catechols and hydroquinones. The bone
marrow has been shown to accumulate hydroquinone and catechol (Greenlee et al., 198 1;
Rickert et al., 1979). It has been suggested that the reactive intermediates, p-benzoquinone
and O-benzoquinone, are formed in the bone marrow during oxidation of hydroquinone and
catechol by MPO (Eastmond et al., 1987; Eastmond et al., 1986; Sadler et al., 1988).
These quinone reactive intermediates may be responsible for benzene-induced bone marrow
toxiciiy.
Prinornide is an mti-inflammatory dmg which was associated with a relatively high
incidence of agranulocytosis (< 0.3%) in clinical trials (Parrish et al., 1997). Metabolism
of pnnornide and its parahydroxy metabolite, CGS 12094, by MPO was studied (Parrish et
al., 1997). CGS12094 was found to be rapidly metabolized (> 90%; 2 min) and the
reaction was dependent on Hz02 and MPO and was inhibited by azide (a MPO inhibitor).
During the MPO-catalyzed metabolism of CGS 12094, reactive intermediates that
irreversibly bound to protein and cysteine were generated. One of the reactive metabolites
has been identified as 1,4-benzoquinone which is the same reactive intemediate implicated
in benzene toxicity (Figure 1-7).
Prinomide CGS 12094
Figure 1-7: Proposed mechanism for 1,4-benzoquinone formation from the MPO-
catalyzed metabolism of CGS 120% (Parrish et al., 1997).
Tacnne is a potent, centraily acting anticholinesterase currently used in the treatment
of Alzheimer's disease (Madden et al., 1995a) Tacrine therapy is associated with an
unpredictable hepatotoxic reaction in up to 50% of patients (Pimohamed et al., 1996).
initial in vitro studies dernonstrated hepatic rnicrosomal enzyme-dependent bioactivation of
tacnne to both cytotoxic and protein-reactive species (Madden et al., 1993). The formation
of these metabolites was inhibited by the addition of glutaihione and/or ascorbic acid to the
incubation medium, indicating that electrophilic species were being formed. The enzyme
involved in the generation of chernically reactive metabolites was shown to be CYPlA2
(Madden er al., 1993; Spaldin et al., 1994). A stable thioether conjugate of the reactive
37 species was formed when tacrine (or its 7-hydroxyi metabolite) was coincubated with
microsornes and mercaptoethanol. The reactive intermediate was identified as a quinone
methide (Madden et al., 1995a; Madden et al., 1995b) (Figure 1-8).
Tacrine 7-hydroxytacrine quinone methide
Figure 1-8: Metabolic pathway for the bioactivation of tacrine to its postulated
quinone methide reactive metabolite by CYPlA2 (Pimoharned et al., 1996).
1 .4 .3~ Cations and radicals
A large number of compounds, including many drugs can be oxidized under
appropriate conditions to potentially toxic free radical (or cation) intermediates. The cations
and radicals may cause protein adduct formation or oxidative stress that rnay further lead to
toxicity. Table 1-3 shows sorne examples of this category.
38 Table 1-3: Formation of cation or free radical intermediates dunng bioactivation of dmgs by
various oxidizing enzymes.
Idiosyncratic
Toxicitv
Aminopyrine
Clozapine
Agranulocytosis
Chlorpromazine
Agranulocytosis
Agranulocytosis
dication,
Rex tive Me taboli tes
cation radical 1 I
Metabolking
HRP
cation radical
nitrenium ion
imidoiminiurn ion 1 MPO 1
MPO 1
MPO,
Aminopyrine is an analgesic agent but its use has been lirnited by its association
with a high incidence of agranulocytosis (Madison and Squier, 1934). Aminopyrine has
been shown to be oxidized to a blue cation radical (Figure 2-8) by PHs, MPO and
hypochlorous acid (Eling et al., 1985; Sayo and Saito, 1990; Uetrecht et al., 1995). It has
been proposed by Sayo and Saito that the mechanism by which hypochlorous acid oxidizes
aminopyrine to a cation radical involves N-chlorination followed by the loss of a chlorine
radical (Sayo and Saito, 1990). However, a study by Uetrecht et al. (1995) later observed
a dication intermediate as the precursor for the cation radical. The dication was formed by
the loss of chlonde ion from N-chloroarninopyrine and it is very reactive (tl/z = 15 ms)
(Figure 1-9). The same pathway was suggested when arninopyrine was oxidized by the
combination of MPO, and chloride or activated neutrophils (Uetrecht et al., 1995).
Aminopyrine
Aminopyrine
Cation radical dication
Figure 1-9: Proposed scheme of the oxidation of arninopyrine to a cation radical via
a dication intemediate (Uetrecht et al., 1995).
40 Chlorpromazine, an antipsychotic agent, is known to induce agranulocytosis. It
was found that chlorpromazine can be oxidized by hypochlorous acid or MPO of activated
neutrophils to a free radical (Kalyanaraman and Sohnle, 1985). Covalent binding of 3H-
labeled chlorpromazine to proteins of stimulated polymorphonuclear leukocytes was also
observed (Kelder et al., 199 1). Van Zyl et al. ( 1990) also found that chlorpromazine was
oxidized to a relatively stable radical cation by the combination of MPO and H202.
However, it is not ciear whether the reaction involves a direct one-electron oxidation or
chlorination to forrn the two-electron oxidation product followed by coproportionation with
the parent dmg to fonn two radical cations.
Clozapine is a unique antipsychotic drug that is more effective than standard
neuroleptic drugs in the treatment of refractory schizophrenia. Unfortunately, its use has
been restricted due to a 0.8% incidence of drug induced agranulocytosis. Meiabolism of
clozapine by activated neutrophils, HRP/H202, and MPOIH202 has been studied (Fischer
et al., 1991; Liu and Uetrecht, 1995). Formation of a reactive metabolite was supported by
two pieces of evidence: covalent binding to activated neutrophils and formation of
glutathione conjugate of the reactive metabolites. The identity of the reactive metabolite hris
been suggested to be a free radical or a nitrenium ion (Figure 1- 10). The nitrenium ion
intermediate, which is 2 mass units less than the parent dmg, was detected by mass
spec trometry (Liu and Uetrecht, 1995). Indirect evidence t hat peroxidase systems also
activate clozapine to free radical intermediates stems from the detection of thiyl and ascorbyl
radicals in the presence of glutathione and ascorbate, respectively (Fischer et al., 1991).
Clozapine
,m'O HRP
Nitrenium ion
Cation radical
Fisure 1-10: Proposed pathway for the oxidation of clozapine to a reactive
nitrenium ion or a cation radical by HRP and MPO (Fischer er al., 1991: Liu and Uetrecht.
1995).
Studies of the metabolic pathway of vesnarinone by MPO or by HOC1 suggested
that a reactive imidoiminium ion was involved (Uetrecht et al., 1994). Formation of the
imidoiminium ion could involve a radical cation or chlorination of the nitrogen followed by
loss of HC1 (Figure 1-1 1).
A number of studies have suggested that free radical rnetabolic pathways exist for a
wide variety of compounds and free radical metabolites do seem to be implicated in the
toxic effects of those xenobiotics which are metabolized to free radicals (Mason, 1979).
However, it is rnuch more difficult to obtain direct evidence for free radical formation than
that for the formation of electrophilic intemediates. Even if the free radical intermediates
do exist, they are generally extremely rectctive so that it will be quenched by anything they
encounter first before reacting with important molecules (e.g. proreins). In addition, as has
been shown in many studies, the major reaction of free radicals with GSH is the abstraction
of a hydrogen atom rather than covalent binding. Presumably the same is true of its
reaction with other biological molecules. Therefore, the pattern of toxic effects caused by
free radical intermediates and by electrophilic intermediates are very likely to be different.
0CH3 Vesnarinone
L OCH, Radical cation
N-C hloro
0CH3
Imidoiminium ion
Figure 1 - 1 1 : Proposed mechanisms of forming the imidoiminium ion intermediate
of vesnarinone.
1.4.3d Arene Oxide
A major metabolic pathway for compounds that contain arornatic rings is aromatic
hydroxylation. It has been suggested that arene oxides may be intermediates in this
reaction. Arene oxides are chemically reactive species and their half-lives are usually very
short. For example, the half-life of benzene oxide is less than 2 minutes in water at pH 7
(lerina and Dalay, 1974). Arene oxides. once formed, rapidly undergo isomerization to
phenols or readily react with a variety of nucleophiles including such cellular
macromolecules as DNA, RNA and protein. Thus, arene oxides have become prime
candidates for the "reactive intermediates" responsible for the binding of aromatic
compounds to macrornolecules in the cell. Table 1-4 lists some examples of this category.
45 Table 1-1: Formation of the reactive arene oxide intermediates during bioactivation of
xenobiotics by CYP450.
Xenobiotics
PoIycycIic
hvdrocarbons
Phenytoin
Toxicity
Hepatotoxicity,
Bone marrow
toxicity
Carcinogenicity
- - - - - - - - - - - - - - -
Hepatotoxicity,
Blood disorders,
"Hypersensitivity "
Teratogenicity,
"Hypersensitivity"
- -
Reactive Metabolites
Arene oxide
*ne oxide
Arene oxide
Arene oxide
It has been shown that hepatotoxicities of simple
halobenzenes being metabolized to arene oxides which
(Brodie et al., 197 1). When radioactive brornobenzene
Metabolizing
Enzymes
CYP450
benzene compounds are caused by
covalently bind to hepatic protein
was administered to rats, massive
centrolobular necrosis resulted and the necrotic regions contained significant arnounts of
covalently bound radioactivity (Brodie et al.. 1971). Pior treatment of the animals with
phenobarbitd enhanced both the bornobenzene-induced necrosis and the hepatic binding
(Brodie et al., 1971; Reid and Krishna, 1973). Uthough bioactivation to form an arene
oxide intermediate may lead to benzene compound-induced liver damage, it is less likely to
be responsible for the bone marrow toxicity associated with these compounds since even if
46 smdl amounts can escape the liver, their concentrations at distant sites such as the bone
marrow are likely to be very low. In contrat, catechol-type metabolites can be readily
oxidised to quinone-tvpe metabolites in the bone marrow. Even in the liver microsomes, it
has been demonstrated that for bromobenzene, which does form an arene oxide, most of
the covalent binding is due to a quinone intermediate (Hanzlik et al., 1984; Rietjens et al.,
1997). This suggesrs that arene oxide, although it may be formed, may not be the most
likely reactive metabolite responsible for toxicity.
Polycyclic hydrocarbons are widespread environmental contaminants. Many of
these compounds are known to be carcinogenic in experimental mimals (Freudenthal and
Jones, 1976; Miller, 1978). It is now well established that metabolic activation is required
for the obsewed biolo_oical effects of polycyclic hydrocarbons (Gelboin and Ts'o, 1975;
Sims and Grover, 1974). Benzo[a]pyrene (BP), for example, is metabolized to a wide
variety of metabolites. such as epoxides, dihydrodiols. quinones and phenols (Gelboin.
1980). Evidence suggests that two of the BP-diol-epoxide metabolites (Figure 1 - 12), are
the ultimate carcinogenic forms of this polycyclic hydrocarbon. The two diastereomers,
BP-7. 8-diol-9,lO-epoxides. are highly carcinogenic to newbom mice (Kapitulnik er al.,
1977; Sims and Grover. 1974); are potential mutagens and cytotoxins to both mammalian
and bacterial cells (,Huberrnan et cd., 1976; Marnett and Bienkowski, 19S0; Wood rr rd.,
1977) and are chernically very reactive in binding to DNA (Jeffrey et al., 1977).
Figure 1- 12: Bioactivation of benzo[a]pyrene to the diol-epoxide cürcinogens.
It has been proposed that the reactive metabolite of carbamazepine. which may be
responsible for carbarnazepine-induced adverse reactions, is an arene oside. The evidence
to support this hypothesis is that carbamazepine can be bioactivated by mouse and human
liver microsornes to a cytotoxic and protein-reactive metabolite (Pirmohamed et al., 19921:
Pirmohamed e t ni., 1992b). The cytotoxicity and covalent binding were enhanced by
trichloropropene oxide (TCPO), which is an epoxide hydrolase inhibitor (Riley et al.,
48 1989). However, TCPO is not a specific inhibitor for epoxide hydrolase, it is also known
to deplete glutathione (Pessayre et cil.. 1979) and inhibit CYP4.50 (Ivanetich er al.. 1982).
Furthemore, studies have failed to find a consistent mutation, or pattern of mutations. in
the microsomal epoxide hydrolase gene which is common in patients with a history of
carbamazepine hypersensitivity reactions (Gaedigk et al., 1994; Green et al.. 1995). The
only direct evidence for the arene oxide formation in vivo is detection, in the bile, of the
GSH conjugate of the postulated arene oxide in rodents (Arnore et al., 1997; Madden et al.,
1996). However, in humans, the same GSH-conjugate was not detected nor were any of
its funher metabolized products, such as the NAC, cysteinyl or thiomethyl derivatives
Waggs et al., 1997).
Phenytoin is a cornmonly used anticonvuisant for the treatment of epilepsy.
Phenytoin causes a wide range of adverse reactions including hypersensitivity and i t has
been shown to be teratogenic in animals and humans (Winn and Wells. 1995). It has been
postulated that CYP450 bioactivation to an electrophilic arene oxide intemediate may play
an important role in the mechanism of phenytoin-induced toxicities. Evidence for the
formation of the arene oxide intermediate is supported by the ability of phenytoin to bind
covalently to molecular tnrgets. by the formation of the trans-dihydrodiol metabolite of
phenytoin (Ocsch. 1973) and by the formation of a catechol or its rnethylated derivative
(Billings, 1985; Billings and Fischer. 1983: .Maguire et al.. 1979). Nevenheless. none of
these observations are direct proof of the formation of an arene oxide intermediate (Brown
rr al.. 1986). It is known that arene oxides zenerally react readily with GSH to form stable
conjugates (Jerina and Dalay, 1974): however, to date neither the GSH adduct of the
putative arene oxide, nor its urinary mercapturate metabolite, has been found (Hansen,
1991 J. Recently, an alternative reactive metabolite, an O-quinone, has been proposed by
Gillarn and coworkers and it was demonstrated that the phenol and catechol metabolites
lead to more covalent binding than the parent drug in vitro (Munns et al., 1997).
1.4.3e Miscellaneous
There are many other drugs that can be bioactivated to chemically reactive
metabolites. The chernical nature of these reactive metabolites, however, are different from
those discussed earlier in this section. They are classified as miscellaneous drugs (Table 1-
5) and will be discussed individually.
Table 1-5: Formation of reactive metabolites during bioactivation of dmgs by various
oxidizing enzymes.
Tienilic acid
Halothane
Idiosyncntic
Toxic itv
Hepatotoxicity 1 trifluomacetyl
Reactive Metaboli tes
Hepato toxici ty sui foxide
Hepatotoxicity, 1 sulfonic acid
AgranuIocytosis,
Drug-induced lupus 1
sulfenyl chlonde,
Metabolizing
Enzvmes
Tienilic acid, a diuretic agent, was withdrawn from general use because of a high
incidence of hepatitis (Dansette er al., 1991). Bioactivation of tienilic acid has been shown
to involve CYP2C9 and to be inhibited by anti-human CYP2C antibodies. The reactive
metabolite has been postulated to be the sulfoxide of tienilic acid (Mansuy et al., 1991)
(Figure 1-13). It is likely that the bioactivation of tienilic acid to a sulfoxide metabolite by.
50 and subsequent binding to, the C Y P X proteins causes the antigenic alteration of this
CYP450 isoform resulting in antibody production.
Tienilic acid Sulfoxide
Figure 1 - 13: Metnbolism of tienilic x i d to the sulfoxide metabolite by CYP7C9
(Mansuy et ai., 199 1 ).
Halothane, a widely used anesthetic, i n thought to cause two forms of liver damage
(Neuberger and Kenna. 1987). The minor form is characterized by slightly raised
transaminases and perhaps mild necrosis which occurs in up to 20% of patients. The more
severe form of halothane hepatitis (Le. massive liver ce11 dmage) is observed in 1 :35,000
patients. The incidence of this reaction is increased (l:3.700) after multiple exposure to
halothane (Park and Kitteringham, 1990). Halothane is metabolized in the liver by
cytochrome P450 enzymes by oxidation and reduction to two chemically reactive
metabolites. trifluoroacetyl chloride (TFA) and the 1-chloro-2.2.3-trifluorocetyl radical. It
has been demonstrated that it is the trifluoroacetyl group which forms the neoantigen on
rnicrosomal protein and that sera from the majority of patients with halothane hepatitis
contain antibodies that recognize the trifluoroacetyl epitopes (Kenna et al.. 1988).
Propylthiouracil is a thioureylene antithyroid dru, and its use is associated with
several hypersensitivity reactions. The most cornmon serious reaction is agranulocytosis;
others include toxic hepatitis and a syndrome similar to SLE (Cooper, 1984)
51 Propylthiouracil is accumulated not only in the thyroid gland but also in phagocytizing
poiyrnorphonuclear leukocytes ( L m and Lindsay, 1979a; Lam and Lindsay, 1979b).
Propylthiouracil was found to be degraded by MPO or eosinophil peroxidase, purified
from rat bone marrow. in the presence of H2Oz and Cl-. One of the metabolites was
identified as propylthiouracil-sulfonic acid (Lee et al.. 1988). A study by Waldhauser and
Uetrecht (1991) has found that propyithiouraci1 was metabolized by activated neutrophils or
iMPO/H202/Cl- systrm. The first step is presumably the formation of the sulfenyl chloride.
This metabolite was expected to be reactive and was not detected directly. The disulfide
metabolite was isolated and it was funher oxidized to the sulfonic acid (Figure 1-14). The
sulfonic acid is also reactive and reacrs with thiols. such as glutathione, to form a thioether.
Propylthiouracil Sulfenyl chloride Suifonic acid
Figure 1- 14: Metabolism of propylthiouracil by MPO to the reactix sulfonic acid
(Wddhauser and Uetrecht, 199 1).
1.5 -Metabolism of indomethacin and carbamazepine
This section summarizes briefly the general pharmacokinetics and metabolism of
indomethacin and carbamazepine.
1.5.1 Indomethacin
Indomethacin is rapidly and almost compleiely absorbed from the gastro-intestinal
tract in healthy adults. Following oral administration, bioavailability is virtually 100%.
with 90% of a single dose being absorbed within 4 hrs. At therapeutic concentrations,
indomethacin is approximately 99% bound to plasma proteins.
In various laboratory anirnals, indomethacin has been found to undergo extensive
biodegradation via O-demethylation, N-deacylation or both (Harman et al., 1961: Hucker et
al., 1966). The respective products of these reactions are desmerhylindomethacin (DMII),
descNorobenzoylindomethacin (DBI) and DMBI. A study by Duggan et ni. ( 1972) has
also shown that in humans demethylation, followed by deacylation, constitues the major
pathivay. and direct deacylation is a minor parhway. Demethylation oppears to be
exclusively mediated by CYP2C9 in humans (Nakajima et al., 1998). An enzyme in pig
liver rnicrosomes that catalyzes the hydrolysis of amide-linkage of indomethacin has been
purified and characterized (Terashima et al., 1996). Due to the similar activity of
indomethacin hydrolysis in pigs and in humans, it is likely that the hydrolysis of amide-
linkage of indomethacin in humans would be associated with an enzyme similar to the
indomethacin hydrolyzing enzyme found in pig liver microsornes. Indomethacin and its
metabolites are excreted in urine and bile both in the free form and as conjugates. Fecal
excretion of radioactivity was shown to vary from 21 to 42% of the dose over (i period of
four days, but it was invariably comprised predominantly of the two deme thy lated
metabolites (> go%), almost entirely in their unconjugated forms.
1.5.2 Carbamazepine
Carbamazepine is slowly but almost completely absorbed from the gastrointestinal
tract. The peak concentration of the dmg occurs 4-10 hrs after a single-dose ingestion. In
normal healthy volunteers the apparent plasma half-life of carbarnazepine ranges from 25-
65 hrs (Morselli and Frigeno, 1975). Carbamazepine is extensively metabolized both in
human and rat and more than 30 metabolites have been isolated and identified. Following
the administration of 14C-carbarnazepine, 72% of the 14C-activity was recovered in urine;
the remaining radioactivity being recovered in feces (Eichelbaum et al., 1984). In ilirro and
NI vivo studies of the bioactivation of carbamazepine in man and rat have demonstrated that
epoxidation of the double bond in the 10,ll-position and hydration of this 10, l l -
carbamazepine epoxide to trans- l0,ll-dihydrodihydroxycarbamazepine is a major route of
carbamazepine metabolism (Eichelbaum et al., 1984). Other important pathways include
hydroxylation of the aromatic rings, N-giucuronidation of the carbamoyl side chain and
substitution of sulfur-containing groups on the aromatic rings (Lertratanangkoon and
Horning, 1982; Lynn et al., 1978). One of the major merabolites, which is generared frorn
hydroxylation of the aromatic rings, is 2-hydroxycarbamazepine (Eichelbaum et al., 1984).
It can be funher metabolized to 2-hydroxyiminostilbene, rither in the iiver or in other
tissues. Both 2-hydroxycarbmazepine and 2-hydroxyiminostilbene have been detected in
the urine of rats and hurnans after hydrolyzed from their glucuronide conjugates
(Lenratanangkoon and Homing, 1982).
It has been postulated that the reactive metabolite, which may be responsible for
carbarnazepine-induced toxicity, is an arene oxide (Pirmohamed et al., l992b; Shear and
Spielberg, 1988). The arene oxide is chemically remive and cannot be characterized by
routine analytical methods such as mass spectrometry and HPLC; therefore, its existence
can only be implied from the urinary excretion of unquantified phenols and catechols of
54 carbarnazepine (Lenratanangkoon and Horning, 1982; Regnaud et al., 1988). However,
the aromatic hydroxyl metabolites are not necessarily derived from an arene oxide
intermediate (Hanzlik et al., 1984). Furthermore, although the detection of glutathione
(GSH) conjugate of the postulated arene oxide intermediate in rodents has been reported
(Amore et al., 1997: Madden et al., 1996). in humans. the same GSH-conjugate was not
detected nor were any of its funher metabolized products, such as NAC or thiomethyl
derivatives (Maggs et al., 1997).
Chapter 2
Oxidation of a metabolite of indomethacin (DMBI) to reactive
intermediates by activated neutrophils, HOC1 and the
myeloperoxidase system.
The use of indomethacin is associated with a relatively high incidence of adverse
reactions such as ûgranulocytosis. Many other drugs associated with agranulocytosis are
metabolized to reactive metabolites by activnted neutrophils. Therefore. we studied the
oxidation of indomethacin and its metabolites by activated neutrophils, MPO (the major
oxidizing enzyme in neutrophils), and HOCl (the major oxidant produced by activated
neutrophils). No significant oxidation of indomethacin by activated neutrophils was
observed. However. DMBI, a major metabolite of indomethacin. was oxidized to a
reactive iminoquinone which could be trapped with GSH or NAC to form conjugates with
W H + ions at m/z 5 1 1 and m/z 367, respectively. No metabolism was detrcted in
neutrophils that had not been activated and the oxidation was inhibited by azide, which
inhibits .VPO, and by catalase, which catalyzes the breakdown of H202. In reactions with
HOCI. the same reactive intermediate was formed; its mass spectrum, with a MH+ ion at
m/z 201, was obtained by using a fIow system in which the reactants were fed into a
rnixing chamber and the products flowed directly into the mass spectrometer. The same
GSH and NAC conjugates were also observed when DMBI was oxidized by HOCl or by
the MPO system followed by addition of GSH or NAC. NMR data for the NAC conjugate
indicated that the sulfur was substituted in the 4 position on the aromatic ring. The reactive
intermediate generated from DMBI by activated neutrophils may be responsible for the
indomethacin-induced agranuloc y tosis.
2.2 Introduction
Indornethacin is a very effective nonsteroidal antiinflarnrnatory dmg, but its use is
limited by a high incidence of adverse reactions, including blood disorders. Of a total of
1,261 reports of adverse reactions to indomethacin reported to the United Kingdom.
Cornmittee on Safety of Medicines between June 1964 and January 1973, blood disorders
were recorded in 157 cases (with 25 fatalities) including thrombocytopenia (35 cases, with
5 fatalities), aplastic anemia (17 cases, with no fatalities), and agranulocytosis or
leukopenia (2 1 cases, with 3 fatalities) (Cuthbert, 1974). Subsequently, the First Report
from the International Agranulocytosis and Aplastic Anemia Study confirmed a significant
relationship between the use of indomethacin and agranulocytosis and aplastic anemia. In
this population-based case-control study conducted in Europe and Israel, the excess risk
estimated for agranulocytosis and aplastic anemia was 0.61106 for indomethacin exposure
in a 1-week period (Shapiro, 1986). The rnechanism of drug-induced agranulocytosis is
unknown: howe\*er. i t is speculated that reactive metabolites produced by activated
neutrophils or neutrophil precursors may be responsible for agranulocytosis, cither by
direct toxicity or via an immune rnechanism. It has been shown that several drugs that are
associated with agranulocytosis are metabolized to reactive intermediates by activated
neutrophils and monocytes (Uetrecht. 1990: Uetrecht. 1996; Uetrecht, 1992). When
activnted. neutrophils release MPO and generate Hz02 (Klebanoff, 1965; Weiss. 1989).
.MPO is the major oxidizing enzyme in neutrophils: HOCl is generated by the MPO system.
which uses Hz02 to oxidize Cl- to HOCl.
A study by Duggan et al. (1977) has demonstrated that the dominant pathways of
indomethacin metabolism in humans are demethylation and deacylation. The major
metabolites are D-MI and DMBI (Figure 3-1). The objectives of this work were to
derennine whether indomethacin and/or its major metabolites can be metaboIized to reactive
58 intermediates by activated neutrophils, HOC1 and the MPO system and, if so, to identify
the proposed reactive metabolite and to characterize its chernical reactivity.
Indomethacin
amide hydrolase or nonenzyrnatically
DiMBI
Fijure 7- 1 : Major metabolic pathway of indomethacin.
2.3 ,Materials and Methods
2.3.1 Synthesis of DMI.
DM1 was synthesized by demethyintion of indomethacin using a modification of the
method of McOmie et rd . (1 968). Indomethacin (0.7 g, Sigma Chernical Co., St. Louis.
MO) was dissolved in 200 ml of dichloromethane. To this solution, 10 ml of 1 M BBr3
was added dropwise. The reaction was protected from moisture by bubbling N? through
the reaction mixture. The reaction was carried out at room temperature for 3 hr. The
reaction mixture was then shaken with water to hydrolyze excess reagent and boron
complexes. DM1 was obtained by extraction into ether. The mass spectmm of the
synthesizrd DM1 included of a MH+ ion ar m/z 3-11. The synthesized DM1 demonstrated
the same HPLC retention time as did an authentic sample provided by Merck Research
Laboratories, and it was used to synthesize DMBI without further purification.
2.3.2 Synthesis of DMBI.
D.Ml (15 mg) was hydrolyzed in 3 ml of 1 'i sodium hydroxide. The reaction wüs
carried out at room temperature for 5 min. The reaction mixture was made ocidic with
concentrated hydrochloric acid and then extracted with ethyl acetate. The ethyl acerate layer
was drird with magnesium sulfate, and the solvent was evaporated under a Stream of 81.
The product was rhen purified by silica gel TLC. using a solvent of dichloromethane /
methmol (9: 1, v / v). The yield was approximately 10% [m.p.= 15 1 - 152°C; Rf = 0.35;
MS: m/z 706 (MH*) and 160 [(MH-HCOOH)']; 'H NMR (dirnethylçulfoxide-d6) 6 10.64
pprn ( iH. s); 6 8.50 pprn ( lH, bs); H-7. S 7.00 pprn ( 1H, d, J=8.54 Hz); H-4, 6 6.72
pprn ( 1H' d. J=2.20 Hz); H-6, 6 6.48 pprn (1H. dd, J=8.30 Hz, 2.20 Hz); methylene
protons. S 3.42 pprn (2H. s); methyl protons on the indole ring, 6 2.28 ppm (3H, s)].
2.3.3 Oxidation of DMBI by HOCI.
Sodium hypochlorite (various concentrations) was added to DMBI (final
concentration, 0.1 rnM) in 100 pl of 0.1 M phosphate buffer at room temperature. The pH
of the phosphate buffer was varied from 4.0 to 7.0. Aliquots (20 pl) of the solution were
analyzed by HPLC.
2.3.4 Oxidation of indomethacin and DM1 by HOCI.
Sodium hypochlorite (50 pl of a 4 mM solution) was added to indomethacin or
DM1 (final concentration, 1 mM) in 150 pl of 0.1 M phosphate buffer (pH = 6) at room
temperature. Aliquots (20 pl) of the solution were analyzed by HPLC.
2.3.5 Oxidation of DMBI by the MPO system.
DMBI (5 pl of a 10 mM methanolic solution) was added to 500 pL of phosphate
buffer (O. 1 M, pH 6 or 7) to yield a final concentration of 0.1 mM. MPO (2.5 units / mL)
was added. and then the renction was initiated by the addition of hydrogen peroxide (final
concentration. 0.4 miM1. Incubations were carried out in the absence or in the presence of
added chloride. Aliquots (20 pl) of the solution were analyzed by HPLC.
2.3.6 Oxidation of DMBI, indomethacin and DM1 by activated neutrophils.
Blood was drawn from normal volunteers, into heparinized syringes, and the
neutrophils were isolated by differential centrifugation on Ficoll-paque (Pharmacia,
Uppsala. Sweden) according to a standard procedure (Boyum, 1984). Briefly, whole
blood was rnixed with equal volumes of 3 8 dextran (wlv) made up in 0.9% saline. This
62 mixture was allowed to settle for 30 minutes and the supematant was then centrifuged
(SOOxg, 5 minutes). The pellet was resuspended and residual erythrocytes were lysed by a
brief exposure to 0.2% saline. The neutrophils were suspended in phosphate buffer saline,
underlaid w ith Ficoll-Paque and centri fuged for 25 minutes (500xg). Following
centrifugation, the neutrophil pellet was washed twice with Hank's buffer before use.
Neutrophils (1 x 106 cells / ml) were suspended in phosphate-buffered saline (pH 7.4.0.5
ml). Phorbol myristate acetate (10 ng / ml ; Sigma) was added. followed by DMBI (5 pl of
a 10 mM methanolic solution, to a finai concentration of IOOpM). The suspension was
then incubated at 37OC in a shaking water bath. After incubation for vanous periods, the
cells were centrifuged and 30 pl of the supematant was analyzed by HPLC. Indomethacin
and DM1 were dso incubated with activated neutrophils under the same conditions, except
that their concentrations were twice that of DMBI.
2.3.7 Synthesis of reactive intermediate-NAC adduct.
Sodium hypochlorite ( 1 ml of a 100 mM aqueous solution) was added to DMBI (50
mi of a 2 mM aqueous solution). The reacrion mixture was vortex-mixed for 10 sec, and
then NAC (0.5 ml of a 200 miM aqueous solution) was added. The mixture was then
concentrated on a rotary evaporator. The NAC adduct was purified by HPLC using a 10-
x 150-mm preparative column packed with 3-pM Spherisorb ODS 2 material. The solvent
consisted of water, acetonitrile, acetic acid, and triethylamine (89: 10: 1:0.05, v/v). The
flow rate was 3 rni/rnin, and the retention time of the NAC adduct was 9.4 min.
2.3.8 Reaction kinetics determined by spectrop hotometry.
A Hewlett-packard diode-array spectrophotometer (HP8452A, Hew lett-Packard,
Pa10 Alto, CA) was used to detemine the rate of oxidation of DMBI by HOCl. Scanning
63 of the reaction mixture was initiated immediately after the addition of sodium hypochlorite
(10 pl of a 10 mM aqueous solution) to DMBI (2 ml of a 50 pM aqueous solution), with
rapid stirring. The reaction was monitored at 1.0-sec intervals for S s e c . over a
wavelength range of 200-500 nm.
2.3.9 Analytical Methods.
HPLC was performed using a 2 x 100 mm Phenomenex Column (Phenornenex,
Torrance, CA) packed with 5-pM Ultracarb ODS 30 matenal. The solvent used to analyze
the products of DMBI oxidation by HOCl, MPO and activated neutrophils consisted of
water, acetonitnle and acetic acid (54: 15: 1. v 1 v) containing 1 rnM ammonium acetate. The
solvents used to analyze the products of indomethacin and DM1 oxidation by HOCl and
activated neutrophils consisted of water, acetonitrile and acetic acid (4950: 1 and 59:40: 1,
V/V, respectively). The flow rate was 0.2 N m i n .
A Sciex API III mass spectrometer (Perkin-Elmer Sciex, Thornhill. Ontario,
Canada) was used for LC/MS. Collisional activation spectra were obtained using the
LCLvfSMS mode, with argon as the target sas. A splitter was used to decrease the flow
inro the mass spectrometer to approximately 10 pl I min.
I H NMR spectra were recorded at 500 MHz with a Brucker AM 500 spectrometer
(Brucker Canada; Milton, Ontario). Spectra were obtained in D20 except for that for
D.MBI, which was obtained in a dimethylsulfoxide-dg. The structure of the NAC conjugate
of the iminoquinone intermediate was assigned by the conventional I H NMR as well as the
!H-1H and I H - ~ ~ C correlation experiments.
2.4 Results
2.4.1 Oxidation of DMBI by activated neutrophils.
DMBI was metabolized by neutrophils to a major metabolite with a MH+ ion at rn/z
409 and a minor metaboiite with a MHf ion at m/z 407. The retention times of the two
products with MHf ions at m/z 409 and m/z 407 were 5.8 min and 24.6 min. respectively.
No signifiant metabolism occurred in the absence of activation of the cells. The
metabolism increased with time, initial DMBI concentration and ce11 number (Figure 2-2).
and i t was inhibited by azide and catalase. The ûmount of the product with a MH+ ion at
m/z 409 was decreased by a factor of 2 and 10 when catalase (200 units./ ml) or azide (0.2
mM), respectively, was included in the incubation mixture.
The M S M S spectra of the metabolites with MH+ ions at rn/z 409 and m/z 407 are
shown in Figure 2-3. To obtain enough material for UV and NMR analysis. rnanganese
dioxide was used to oxidize DMBI; this procedure yielded the same products, except that
the amount of the product with a MH+ ion at m/z 107 was greater than that of the product
with a MH+ ion at rnfz 409. The UV absorption spectrum of the product with a MHf ion
at m/z 109 demonstrated hm,, values of 215 and 300 nm. The UV absorption spectrum of
the product with a MH+ ion at rnlz 407 showed an additional broad peak with a hm,, value
of approximately 480 nm (Figure 2-4). When the CV absorption spectrum was obtained at
a higher concentration, this broad peak was more obvious. The 'H NMR spectra of both
products were obtained. The NMR of the product with a MH+ ion at m/z 407 showed that
the aromatic region consisted of five protons, as follows: H-7. 6 7.38 ppm ( lH , d. 1 =
9.77 Hz); H-7', 6 7.29 ppm (1H. d, J = 8.55 Hz): H-6. 6 6.7 1 ppm ( lH, dl J = 8.55 Hz);
H-4, 6 6.70 pprn ( lH, d, J = 1.71 Hz); H-6', 6 6.65 pprn (IH, dd, I = 9.88 Hz, 1.58
Hz). The loss of the proton signal for the +position of the aromatic ring suggested the
stmcture shown in Figure 2-5. A GSH conjugate wirh a MHf ion at m/z 714 was formed
when this product (bWf ion at mlz 407) was reacted with GSH. This result is consistent
with the structure of this product having an iminoquinone moiety (Figure 2-5). The
simplicity of the NMR cf the product with a MH+ ion at m/z 409 indicated a highly
symmetncal moiecule [H-7. 6 7.32 ppm ( l H , d, J = 8.55 Hz); H-6. ô 6.78 ppm (1 H, a, J
= 8.55 Hz); methylene protons of the side chain, 6 2.88 pprn (2H, dd, J = 18.07 Hz);
protons of the methyl group, 62.22 pprn (3H. s)]. The NMR of the aromatic region
suggested that the proton in the 4 position was substituted by another identical molecule.
Figure 2-5 shows the postuiated pathway of the formation of the two stable metabolites
generated in the oxidation by activated neutrophils.
When GSH or NAC was included in the incubation mixture, the GSH or NAC
conjugates of a reactive intermediate were observed, with MH+ ions at rnfz 5 1 1 and m/z
367, respectively. At the same time, the amount of the product with a MH+ ion at rn/z 409
was markedly decreased (data not shown).
O 20 40 60 80 Time (min)
10 30 50 70 90
[DMBI] (PM)
0.0 2.0 4.0 6.0 8.0
[Neutrophil] (x 106 cells/mL)
Figure 2-2: Metabolism of DMBI by activated neutrophils as a function of time
(A), initial DMBI concentration (B), and neutrophil concentration (C) . showing decreases
in the DMBI concentration (open circle) and the production of the major product (filled
square), which has a MHf ion at m/z 409 by MS. Standard conditions were as follows:
neutrophil concentration, Ix 106 cells/mi; DMBI concentration, 40 pM; phorbol mynstate
acetate concentration. 40 ngml; incubation time, 30 min. The peak areas are in arbitrary
units, because we did not have enough materid to determine a standard curve. The values
are the mean + SD from three experiments.
Figure 2-3: i M S M S spectra of the metabolites with MHf ions at m/z 409 (.A) and
d z 107 (B), formed during DMBI oxidation by iictivated neutrophils.
Wavelength (nm)
Figure 2-4: UV absorption spectrurn of the metabolite wirh a MHf ion at 407.
during DM31 oxidation by activated neutrophils.
(M+1= 204) Iminoquinone
DMBI intermediate
H
U f' I AT -
Figure 2-5: Proposed pathway of the formation of the two stable metabolites
during DMBI oxidation by activated neutrophils.
2.4.2 Oxidation of DMBI by HOCl
DMBI was readily oxidized by HOCl. Scanning of the UV absorption spectrum of
this mixture at 1-sec intervals resulted in the pattern shown in Figure 2-6. The absorbance
of DMBI (Amax = 280 nm) decreased rapidly and a new species was generated, with
increased absorption at longer wavelengths.
A----O sec BI---1 sec C----2 sec D----3 sec E-0-4 sec F m - - 5 sec G---10 sec H--45 sec
Wavelength (nm)
Figure 2-6: Repetitive absorption spectra from the reaction of DMBI with HOCI.
The concentrations of both DMBI and HOCI were 50 pM.
When the products of the reaction between DMBI and HOC1 were analyzed by MS
in the flow system, so thar the short-lived intermediate could be detected, an intermediate
with a MH+ ion at m/z 204 was observed. Using the MSIMS mode. the major fragment
ions were at d z 176 [(MH- CO)^ and 158 [(MH-HCOOH)+J.
When GSH or NAC was added imrnediately to the reaction mixture of DMBI and
HOCI, the GSH or NAC conjugate of the intermediate with a MH+ ion at mlz 204 was
observed. The GSH and NAC conjugates formed by trapping the reactive intermediate
generated during DMBI oxidation by neutrophils and HOC1 were found to have the sarne
retention time and molecular weights and identical MS/MS spectra. In addition. a n-
butylamine conjugate of this intermediate with a MH+ ion at m/z 277 was observed by
LClMS when n-butylarnine, instead of NAC was added to the mixture of DMBI and HOCI.
The NAC conjugate was isolated and the NMR analysis was perfomed (Figure 2-7). The
H NMR data, combined with the finding from IH-IH and I H - ~ ~ C correlation experiments
(Figure 2-9), confirmed the structure of the conjugate where the sulfhydryl group of NAC
was substituted in the 4-position on the aromatic ring (Figure 2-8).
When DMBI was oxidized by HOCI, another product was formed, with a MH+ ion
at m/z 138 and a chlorine isotope peak for the MHf ion at m/z 240. The MS/MS specuum
of this product showed a major fragment ion at rn/z 202, resulting from the loss of HCl,
which suggested that this was a chlorinated species. This product was not observed when
the HOC1 concentration was lower than one fifth of the D m 1 concentration. It wris also
not observed when GSH or NAC was added irnrnediately to the reaction mixture of DLMBI
and HOC1. These results suggested that this chlorinated species was formed by funher
oxidation with excess HOCI.
(M+1 = 206) DMBI
O
(M+1= 204)
Iminoquinone intermediate
H
(M+1 = 367) Iminoquinone-NAC conjugate
Figure 2-8: Proposed scheme for DMBI rnetabolism by activated neutrophils and
trapping the reactive intermediate by NAC.
2.4.3 Oxidation of DMBI by MPO system
Compared with the oxidation by neutrophils, a sirnilar pattern of products was
obtained when DMBI was oxidized by the MPOM202 system without added Cl-. The
major product showed a MH+ ion at m/z 409. When GSH was included in the incubation
mixture, the sarne GSH conjugate, with a MH+ ion at m/z 5 1 1, was observed. When 0.15
rnM Cl- was added to the phosphate buffer, the reaction was more rapid and the major
product observed had a MH+ ion at d z 238. This is the same product as that observed
when DMBI was oxidized by higher concentrations of HOCl.
2.4.4 Oxidation of indomethacin by HOC1 and activated neutrophils
Indomethacin was oxidized by HOC1 to a major product with a molecular weight of
39 1, corresponding to indomethacin plus chlorine minus hydrogen. However, no GSH
conjugates were observed when GSH was added to the reaction mixture of indomethacin
and HOCI. When indomethacin was incubated with activated neutrophils under the same
conditions as those used for DMBI, no oxidation was observed.
2.4.5 Oxidation of DM1 by HOCl and activated neutrophils
DMI was oxidized by HOCl to two major products, with retention tirnes of 16 and
28 min. The molecular weight of the product with a retention time of 16 min was 2 rnass
units less than that of DMI. The other product, with a retention time of 28 min, showed a
molecular weight of 378, corresponding to DM1 plus chlorine minus hydrogen. No GSH
conjugates were observed when GSH was added to the reaction mixture of DM1 and
HOCI. When DM1 was incubated with activated neutrophils, only the product wirh a
retention time of 16 min was observed. When GSH was included in the incubation
mixture, no GSH conjugates were detected.
2.5 Discussion
DMBI was oxidized by neutrophils to a reactive intermediate that could be trapped
by glutathione. MPO appears to be the enzyme in activated neutrophils responsible for this
oxidation. This is supported by our observations that the MPO/H202 system generated the
sarne metabolites as did neutrophils, the metabolism by neutrophils required activation of
the cells (resulting in release of MPO and the generation of HzOz), and that the metabolism
by neutrophils was inhibited by azide (which inhibits MPO) and catalase (which catalyzes
the breakdown of H102).
The mechanism presumably involved N-chlorination. f~'olhved by the loss of HCl
to form an iminoquinone, as shown in Figure 2-8. The N-chloro-DMBI was not directly
observed. However, strong evidence for the identity of the reactive iminoquinone
intermediate was obtained. The diode-array UV spectrophotometric data showed that
DMBI absorbance (kmax= 280 nm) decreased rapidly upon addition of HOCl and a new
species, with absorbance at longer wavelengths (suggesting a quinone-like structure), was
formed within seconds. When the products of the reaction between DMBI and HOCl were
analyzed by MS in the flow system, the iminoquinone intermediate. with a MH+ ion at m/z
204, was observed. This irninoquinone intermediate was reactive with sulfhydryl-
containing molecules. such as GSH and NAC. The proton K-MR data confimed the
structure of the imnoquinone-NAC conjugate, in which the sulfur was substituted in the
ortlzo-position (relative to the hydroxyl group) on the aromatic ring.
When DMB 1 was oxidizrd by activated neutrophils. the final stable metabolites,
with MHf ions at m/z 409 and m/z 407, were formed. Both products were generated from
the irninoquinone intermediate reacting with another molecule of DLMBI. In the case of the
product with a MH+ ion at d z 409, the iminoquinone intermediate reacted with another
DMBI molecule in the 4-position, which is orrho to the hydroxyl group. The aromatic
carbon orrho to the hydroxyl group of DMBI rnolecule is expecred to be electron-rich and
78
could act as a nucleophile to attack the carbon-4 of the irninoquinone intermediate (Figure
2-5). Another possible mechanism for the formation of the product with a MHf ion of 409
involves a coproportionation reaction between DMBI and the iminoquinone to f o m two
radicals that couid dimerite. However, because of the solvent cage effect. the free radical
might not be able to react with other molecules and conuibute to the toxicity; even if a free
radical is formed, the major reaction with GSH involves the electrophilic attack of the
irninoquinone, rather than the abstraction of a hydrogen atom by a free radical. Presumably
the same is tme of the reaction between the reactive metabolite and other biological
molecules. In the case of the rninor product with a MH+ ion at rn/z 407, the iminoquinone
intermediate reacted with another molecule of DMBI, on the nitrogen of the indole ring, to
form a dimer. This is consistent with Our observation that the iminoquinone intermediate
can react with nitrogen-contoining nucleophiles (e.g. n-butylamine), in addition to
sulfhydryl-containing nucleophiles. The initially formed dimer can be further oxidized to
yield the product with a MH+ ion at rn/z 407 (Figure 2-5).
A product with a MH+ ion at rn/z 238 was observed only when DMBI was
oxidized by HOC1 at high concentrations (presumably yielding an cxcess of chlorine).
When GSH or NAC wiis added immediately into the reaction mixture of DMBI and HOCI,
this product with a iMH+ ion at m/z 238 was not observed, which suggested that it was a
downstream product where the iminoquinone was the initial reactive metabolite. This
product. with MHf ion at m/z 238, was not observed when DMBI was oxidized by
activated neutrophils or by purified MPO in the absence of added CI-. This product is
probably not a significant N i vivo metabolite.
The formation of reactive metabolites is centrai to most mechanistic theories of dnig
hypersensitivity reactions (Uerrecht, 1990). Studies frorn Our laboratory have found that
several dmgs that are associated with a relatively high incidence of hypersensitivity
reactions (especially agranulocytosis and lupus) are metabolized to reactive metabolites by
activated leukocytes. Similarly, we propose that the oxidation of DMBI to the
79 iminoquinone reactive intermediate by activated neutrophils is responsible for the
hypersensitivi ty reactions to indomethacin (i.e. agranulocytosis). There is evidence to
suggest that other iminoquinones generated by the MPO system or activated neutrophils
may cause hypersensitivity reactions (Maggs el al., 1987; Miyarnoto et al., 1997: Parrish et
al., 1997; Smith et al., 1989; Uetrecht et al.. 1994).
In summary, DMBI. a major metabolite of indomethacin in the Iiver, is metabolized
by the MPO enzyme system in activated neurrophils, forming a reactive iminoquinone
intermediate. We propose that the iminoquinone intermediate is responsibie for some of the
idiosyncratic reactions associated with indomethacin, especially agranulocytosis.
Chapter 3
Detection of 2-hydroxyiminostilbene in the urine of patients
taking carbarnazepine and its oxidation to a reactive
iminoquinone intermediate.
3.1 Abstract
Carbamazepine is one of the rnost widely used anticonvulsants in Nonh America;
however. its use is associated with a range of serious idiosyncratic adverse reactions.
These reactions are thought to result from the formation of chernically reactive metabolites.
Carbamazepine is extensively metabolized in the liver and one of the major metabolites is 2-
hydroxycarbamazepine. whic h has previously been detected as a urinary me tabolite
excreted by rats and hurnans along with its further metabolized product, 2-
hydroxyiminostilbene.
In this study, we found that the urine of patients taking carbarnazepine appeared to
contain more of the glucuronide of 2-hydroxyiminostilbene than that of 2-
hydroxycarbamazepine. We have also demonstrated that 2-hydroxyiminos til bene can be
oxidized readily to an irninoquinone species by HOCI, H202 or even on exposure to air.
The reactivity of this irninoquinone as an electrophile was studied. It was shown to react
with sulfhydryl-containing nucleophiles, such as GSH and NXC. We also found a
metabolite with the same molecular weight as 4-rnethylthio-2-hydroxyiminostilbene. but
not the correspondin_o cnrbamazepine derivative. in the urine of patients taking
carbnmazepine and this presurnrnably reflects the formation of a GSH conjugate of the
reactive irninoquinone i ~ i i*ir*o. This irninoquinone intermediate may play a role in
carbarnazepine-induced idiosyncratic reactions.
3.2 Introduction
Carbamazepine (jH-dibenzob,flazepine-5-carboxamide) is an effective dmg in the
trerttment of convu1sii.e disorders (Cereghino et al., 1974; Cereghino et cil.. 1973)
However. carbarnazepine-induced adverse reactions have been reponed in as many as one-
third to one-half of a11 patients treated with this drug (Durelli et rd. , 1989; Gram and
82 Jensen. 1989; Pellock, 1987). Arnong these adverse reactions. 5% of them can be
classified as idiosyncratic reactions (Askmark and Wiholrn, 1990). These idiosyncratic
adverse reactions include skin rash (Criil. 1973), blood disorders (Gerson et al., 1983) and
hepatitis (Horowitz et al.. 1988). ..\ Swedish survey of 505 reports of 7 13 idiosyncratic
reactions to carbamazepine from 1965 to 1987 reported skin reactions (48%),
hematological (12%) and hepatic disorders (10%) to be the most frequent. (Askmark and
Wiholm, 1990) Although the mechanism of carbarnazepine-induced adverse reactions is
not clear, they are thought to result from the formation of chemically reactive metabolites
(Riley et al., 1989; Shear et al.. 1988). An arene oxide intermediate has been postulated to
be responsible for the idiosyncratic toxicity of carbamazepine. This hypothesis is mostly
based on the observation that the metabolism-dependent cytotoxicity of carbamazepine in
vitro can be enhanced by an epoxide hydrolase inhibitor, TCPO (Riley et al., 1989).
However, this evidence is complicated by the fact that TCPO is also known to deplete
glutathione (Pessayre et al.. 1979) and inhibit cytochrome P350 (Ivanetich et al., 1982).
Funbermore, since the arene oxide is chernically reactive, it may not reach targets, such as
the skin and bone marrow, distanr from the liver in sufficient concentrations to cause
toxicities. It appears that most drugs associated with bone marrow toxicity are metabolized
to reactive metabolites by myeloperoxidase or other enzymes present in the bone marrow.
such as alcohol dehydrogenase (Uetrecht, 1996). These considerations led us to search for
alternative bioactivation pathways of carbarnazepine.
Carbarnazepine is extensively metabolized and more than 30 metabolites have been
identified in urine of patients taking the drug (Lertratanangkoon and Horning, 1982). The
major pathways involve N-glucuronidation on the carbamoyl side-chain of carbarnazepine,
formation of carbarnazepine-l0,l 1-epoxide and hydroxylation on the aromatic rings. One
of the major metabolites is 2-hydroxycarbamazepine (Eichelbaum el al., 1984) , and it can
be funher rnetabolized to 2-hydroxyiminostilbene, either in the liver or in other tissues.
Both 2-hydroxycarbamazepine and 2-hydroxyiminostilbene have been detected as
olucuronide conjugates in the urine of rats and humans (Lertratanangkoon and Horning, Li
1982). Ive hypothesized that Mydroxy irninostilbene can be funher oxidized to a reactive
iminoquinone intemediate (Figure 3- 1). which may be responsible for carbarnazepine-
induced idiosyncratic reactions.
Hydrolysis
fyJ=Je-, % / f-J==&OH \ /
Oxidation I Iminoquinone
H 2- hydroxyiminostilbene
Fisure 3- 1 : Proposed bioactivation pathway of carbarnazepine which leads to the
formation of a reactive iminoquinone intermediate.
3.3 Materials and Methods
3.3.1 Synthesis of the iminoquinone intermediate
The iminoquinone was synthesized by oxidation of iminostilbene using a
modification of the method of Islam e t al. (Islam and Skibo, 1991). Fremy's salt
((KS03)2NO, 2.6 g, Aldrich Chernical Co., Milwaukee, WI) was dissolved in 360 ml of
phosphate buffer (pH 7.1). To this solution, 1 g of iminostilbene (Aldrich), which was
dissolved in 260 ml of acetone. was added. The mixture was stirred at room temperature
for 5 min, and the resulting red solution was extracted with 3 x 200 ml portions of
chloroform. The combined extracts were washed with 3 x 100 ml portions of water and
then dried over magnesium sulfate. The solvent was evaporated by a rotary evaporator.
The iminoquinone was then purified by flash chromatography using hexane / ethyl acetate
(7:3, v/v) as the eluting solvent. The product was a red solid with a yield of 23% [rn.p. =
135-136°C; MS: d z 208 (MH+) and 180 [(MH-CO)+]; 'H-NMR (chloroform-d): 6 7.94
pprn (Hg or Hg. dl J = 7 . 8 1 Hz); 8 7.62 pprn (H7 or Hg, dd. J = 7.57 Hz; 1.63 Hz): 6
7.59 pprn (HJ, d, J = 9.77 Hz); 6 7.54 pprn (Hg or H7, dd, J = 7.57 Hz; 1.47 Hz); 6 7.48
pprn (H9 or &j, d. 1 = 7.51 Hz); 6 6.95 pprn (H3, dd, J = 9.76 Hz: 2.70 Hz); 6 6.96 pprn
(Hi0 or H l i , d, I = 11.00 Hz); 6 6.78 pprn (Hl1 or Hia, d. J = 11.48 Hz); 8 6.58 pprn
(Hi . ci. J = 2.14 Hz)]. This irninoquinone species has been synthesized and the chernical
analyses have been reponed: m.p. 135-136°C: the NMR spectrum consisted only of a
series of multiplets between r 1.8 and 3.6; the base peak in MS war the M-CO ion (Haque
and Proctor, 1968).
3.3.2 Synthesis of 2-Hydroxyiminostilbene
2-Hydroxyiminostilbene was synthesized by reduction of the irninoquinone using
the method of Chang (1983). A chloroform solution containing 40 mg of iminoquinone
was extracted with freshly prepared sodium hydrosulfite solution (in excess. Aldrich) until
the color of the organic layer changed from red to yellow. The chloroforrn layer was
washed with water and dried over magnesium sulfate. The solvent was then removed by a
rotary evaporator to yield 36 mg (89% yield) of 2-hydroxyiminostilbene as a yellow solid.
1rn.p. = 225-226OC; MS: mlz 210 (MH+); 'H NMR(chlorofom-d): 6 7.05 pprn (H7 or
H8, dd, J = 7.50 Hz; 1.41 Hz); 6 6.90 pprn (Hg or Hg, d, J = 7.57 Hz); 6 6.85 pprn (Hg
or H7, dd. J = 7.45 Hz: 1.60 Hz); 6 6.55 pprn (H3, dd, J = 8.3 Hz; 2.93 Hz); 6 6.54 pprn
(H9 or Hg, d. J = 7.81 Hz): 6 6.41 pprn (H4, d, J = 8.3 Hz); 6 6.42 pprn (Hi0 or H i 1 , d,
J = 12.00 Hz); 6 6.41 pprn ( H l , d, J = 2.68 Hz); 6 6.32 pprn (Hi1 or Hlo, ci, J = 11.72
Hz) and two broad peaks in the range of 6 4.9 ppm to 6 4.4 pprn due to the proton on the
nitrogen and the proton of the hydroxyl groupl. The chernical analyses of 2-
hydroxyirninostilbene reported in the literature were: m.p. 225226°C; NMR (chloroform-
d/dirnethylsulfoxide-dg): 6 8.27 pprn (s, IH, -OH), 6 7.5-6.2 pprn (m, 9H. ûromatic and
olefin), 6 5.41 (s, broad. 1H, -Ni); MS: rn/e 209 (M+) (Chang, 1983).
3.3.3 Synthesis of NAC-adduct of the iminoquinone
A methanolic solution (4.8 mlj of the iminoquinone (10 mg) was added to NAC (4
g), which was dissolved in 43.2 mi of phosphate buffer (pH 8). The mixture was stirred
for 10 min at room temperature and then concentrated by a rotary evaporator. The NAC
adduct of the iminoquinone was purified by silica gel TLC using a solvent of ethyl acetate /
methanol (7:3, v / v). The TLC band (RF = 0.3) that contained the irninoquinone-NAC
adduct was scraped off the TLC plate and the adduct was extracted with ethyl acetate. The
y ield was approxirnately 33%. The mass spectrum of the iminoquinone-NAC adduct
showed a MH+ ion at m/z 37 1.
3.3.4 Synthesis of 2-Hydroxycarbamazepine
The hydroxyl group on 2-hydroxyiminostilbene was first protected using a
modification of the method of Kendall et al. (Kendall et al., 1979). Imidazole (12 mg,
0.18 rnrnol, Aldrich) was added to a solution of 2-hydroxyiminostilbene ( 18.4 mg, 0.09
m o l ) and teri.-butyldimethylchlorosilane (26.4 mg, 0.18 mmol, Aldrich) in dry N, N-
dimethylformarnide (0.1 d). The mixture was stirred for 3 hr, followed by dilution with
5% aqueous sodium bicarbonate (0.5 ml). The reaction mixture was then extracted four
tirnes with hexane / dichloromethane (9 : 1, vhr) . The combined extracts were washed with
water and dried, the solvent was evaporated by a rotary evaporator.
Without further purification, the silylated 2-hydroxyiminostilbene (27 mg, 0.083
mmol) was reacted with 4-nitrophenylchloroformate (50 mg, 0.25 rnmol, Aldrich) in
chloroform ( 1 ml). Triethylamine (36 41, 0.076 rnrnol) was added at the beginning of the
reaction to neutralize the hydrochloric acid generated from the reaction. The mixture was
stirred for 3 days and water (1 ml) was then added to quench rhe excess 1-
nitrophenylchloroformate. The product was esuacted with chloroform three times and the
solvent was evaporated by a rotary evaporator. The product was dissolved in acetonitrile
(1 ml) and the ammonia solution (in excess) was added. The mixture was stirred for 3
days before it was neutralized by concentrûted hydrochloric acid. The product was
extracted into ethyl acetate (3 x 10 ml) and the solvent evaporated. 2-
hydroxycarbamazepine was purified by TLC using ethyl acetate : chloroform (8 : 2 , v I v)
as the eluring solvent. The product was a white solid and the yield was approximately 20%
[rn.p. = 231-237OC; RF = 0.35; MS: m/z 213 ()lHf) and 210 [(MH-HNCO)+]; 'H-XMR
(chloroform-d): 8 7.47 pprn (Hg or Hg. d, J = 7.08 Hz); 6 7.43 pprn (H7 or Hg, dd. J =
6.83 Hz; 1.71 Hz); 6 7.38 pprn (Hg or Hg, d. J = 7.08 Hz); 6 7.34 ppm (Hg or H7 , dd. J
= 6.84 Hz; 1.56 Hz); 6 7.32 ppm (H4, d, J = 8.54 Hz); 6 6.93 ppm (Hi0 or H i 1 , d, J =
11.72 Hz); 6 6.84 pprn (H3, d. J = 8.06 Hz); 6 6.83 ppm (Hl 1 or Hl0 , d, J = 11.32 Hz):
6 6.76 pprn (Hi , s): protons on the amide nitrogen, 6 4.5 ppm (2H,s) and a broad peak at
6 5.4 pprn due to the proton on the hydroxyl groupl. The chemical analyses of 2-
hydroxycarbamazepine reported in the literature were: m.p. 239-242°C; NMR
(dimethylsulfoxide-dg): 6 8.25 ppm (s, lH, -OH), 6 7.5-6.6 (m. 9H, aromatic and olefin),
8 5.45 (s, 2H, -CONH): MS: rn/e 252 (M+), 209 [(M+)-HNCO] (Chang, 1983).
3.3.5 Treatment of the urine sample
Random urine sarnples were obtained from two male patients (ages, 93 and 53,
respectively) who had received carbamazepine (250 and 200 mg/day, respectiveiy) for
more than 1 year. The urine sample (-100 ml) was concentrated to about 5 ml by
lyophilization. The concentrated urine sarnple was acidified to pH 4.5 and purified by C-
18 Prep-Sep solid phase extraction column (Fisher Scientific, Unionville, ON). The
sample was loaded ont0 the column followed by washing with 2 x IO-ml portions of
water. The desired urinary metabolites were then eluted from the column by 7 x IO-ml
portions of methanol. The methanol effluents were cornbined and concentrated to
approximately 1 ml. Aliquots (10 pl) were analyzed by LC/MS. Enzymatic hydrolysis
was carried out by incubating the urine samples with P-glucuronidase (100 U, Sigma) in
0.2 ml of pH 5.1 buffer for 20 hr at 37OC. The carbamazepine metabolites were then
extracted with ethyl acetate and the solvent was evaporated under a Stream of N2. The final
products were dissolved in methanol and aliquots of 10 pl were analyzed by LC/MS.
3.3.6 Analytical ~Methods
The analyses of carbarnazepine urinary metabolites were performed by interfacing
an Ultracarb C-18 colurnn (2- x 100-mm, Phenomenex, Torrance, CA) to a Sciex API III
mass spectrometer (Perkin-Elmer Sciex, Thomhill, Ontario, Canada). Aliquots of a urine
sample (IO pl) were eluted at a flow rate of 0.2 d m i n , with a solvent consisted of water,
acetonitrile and acetic acid (49:50: 1, v/v) containing 1 rnM ammonium acetate. When the
metabolites with s h o ~ e r retention times (e.g. the glucuronide conjugate of 4-methylthio-2-
hydroxyiminostilbene) were analyzed, the eluting solvent consisted of water, acetonitrile
and acetic acid (74% 1, vlv) containing 1 rnM ammonium acetate. When P-glucuronide
conjugates were analyzed. the eluting solvent consisted of water, acetonitrile and acetic acid
(84: 15: 1, v/v) includin; 1 mM ammonium acetate. A splitter was used to decrease the flow
to the LC/MS interface at approximately 10 pumin. The collisional activation spectra were
obtained by using the LCMSMS mode, with argon as the target gas.
~ H N M R spectra were recorded at 500 MHz with a Bmcker AM 500 spectrometer
(Bmcker Canada. Milton. Ontario, Canada). Spectra were obtained in chloroform-d except
that for the iminoquinone-NAC ndduct, which was obtained in deuterium oxide (DzO).
3.4 Results
3.4.1 Oxidation of 2-hydroxyiminostilbene
2-hydroxyiminostilbene was readily oxidized to the irninoquinone intermediate by
HOCI. When 2-hydroxyiminostilbene was reacted with HOCl at equal concentrations, the
color of the reaction mixture changed instantaneously from yellow to red, and a new Peak
due to the irninoquinone was obsewed by HPLC. Figure 3-2 shows the UV absorption
specua of 2-hydroxyiminosiilbene and that of the reaction mixture after HOCl was added.
The UV absorption spectrum of the oxidation product was similar to that of the
irninoquinone. H 2 0 2 was also able to oxidize 2-hydroxyiminostilbene to the irninoquinone
species; however, at a much slower rate than did HOCI. It was also observed thai 2-
hydroxyiminostilbene underwent autoxidation to the iminoquinone intermediate by air at
room temperature. The half-life of 2-hydroxyiminostilbene was approxirnately 2 hr in
phosphate buffer (pH 7.4).
200 300 400 500
Wavelength (nm)
Fioure - 3-2: The UV absorption spectra of the synthesized irninoquinone (dashed
line) and 2-hydroxyiminostilbene before (O sec) and after (10 sec) reaction with HOCI.
The concenuation of both 2-hydroxyiminostilbene and HOC1 were O. 1 mM.
3.4.2 Reactivity of the iminoquinone intermediate
The reactivity of the iminoquinone as an electrophile was studied. It was found to
react with sulfhydryl-containing nucieophiles, such as GSH and NAC, to f o n conjugates.
The iminoquinone-NAC conjugate was isolated and anaiyzed by NMR (Figure 3-3). The
'H NMR (D20) consisted of protons as follows: 6 7.17 pprn (H7 or Hg, dd, J = 7.9
Hz; 1.65 Hz); 6 6.99 pprn (Hg or Hg, d, J = 7.48 Hz); 6 6.97 ppm (H8 or H7, dd, J = 7.80
Hz; 1.70 Hz); 6 6.9 1 pprn (H3, d. J = 2.77Hz); 6 6.89 pprn (Hg or Hg, d, J = 7.56 Hz); 6
6.5 1 ppm (HIo or Hi 1, d, J= 1 1.72 Hz); 6 6.44 pprn (H,, d, J = 2.78 Hz); 6 6.40 pprn
(HI or H 10, d, J=11.75 Hz); NAC-CH, 6 4.28 pprn ( IH, dd, J = 7.05 Hz, 3.66 Hz);
NAC-CHzct, 6 3.34 pprn ( 1 H, dd, J = 14.1 1 Hz, 3.84 Hz); NAC-CH$, 6 3.13 pprn (1H.
dd. J = 14.10 Hz, 7.05 Hz); NAC-CH3,6 1.67 pprn (3H, s). Compared with the NMR
spectrum of 2-hydroxyiminostilbene, the proton signal on C4 disappeared in the
iminoquinone-NAC conjugate and the proton signal on C3 changed from a doublet of
doublets to a doublet. This suggested that the sulfur of NAC was substituted in the 4-
position on the aromatic ring (Figure 3-1). This assignment was also confirmed with the
findings from the 1H-lH and ' H - 1 3 ~ correlation expenments (Figure 3-5).
10 11
HOCI,H2O2 or O2 t
4
. . GSH or NAC
2- hydroxyiminostilbene Iminoquinone
NAC
Figure 3 4 : Oxidation of 3-hydroxyiminostilbene to the iminoquinone intermediate
and its reaction with NAC.
3.4.3 Analysis of urine samples from patients
When the urine sample was analyzed by LC/MS. neither the GSH nor the NAC
conjugate of irninoquinone was detected. However, a metabolite with MH+ ion at m/z 432
(RI = 5.7 min) was detected. This metabolite has the same molecular weight as the
glucuronide conjugate of 4-methylthio-2-hydroxyirninostilbene, which is a probable further
metabolite of the irninoquinone-GSH conjugate. The MSMS of the metabolite with MH+
ion at m/z 432 showed a fragment ion at m/z 256, corresponding to the loss of
dehydroglucuronic acid moiety ([M+I-176]+) (Figure 3-6). When the urine sample was
hydrolyzed by P-glucuronidase, a peak with a MHf ion at rnlz 254 was detected by
LC/MS. The molecular weight of this species was 2 mass units less than that of 4-
methylthio-3-hydroxyirninostilbene suggesting that it could be a further oxidized product of
4-methyl thio-3-hydroxyiminostilbene.
A glucuronide conjugate of 2-hydroxyiminostilbene was also detected, which
showed a MHf ion at m/z 386. Figure 3-7 shows the cornparison of the total ion curent
(TIC) of the 2-hydroxyiminostilbene glucuronide conjugate with that of other metabolites
excreted in the urine including the glucuronide conjugate of carbamazepine (with a MH+
ion at m/z 4 13). the glucuronide conjugates of monohydroxylated carbarnazepines. as well
as the N-glucuronide of carbamazepine 10.1 1-epoxide (with MH+ ions at m/z 429), and
the 10,l I-dihydrodiol-carbamazepine (with a MH+ ion at rn/z 27 1). The ratios of the TIC
of 2-hydroxyiminosrilbene glucuronide to that of other urinary metabolites are shown in
Table 3- 1.
MS/MS spectrum of 2-hydroxyiminostilbene glucuronide conjugate dernonstrated
that it undenvent charactenstic fragmentation with the major fra,gnent ion at rn/z 210 which
represents the loss of the dehydroglucuronic acid moiety ([M+ 1- 1 XI+) (Figure 3-8).
hterestingly, the irninoquinone intermediate was also observed by LC/MS and it showed
the same retention rime (Rt = 8.4 min) and MS/MS fragmentation pattern as that of the
97 synthesized iminoquinone. When NAC was added to the sample, the peak due to the
irninoquinone disappeared, suggesting that it reacted with sulfhydryl-containing
nucleophiles. When the urine samples were hydrolyzed by P-glucuronidase. the peak of
the irninoquinone increased dramatically (Figure 3-9). In addition, when the glucuronide
conjugates of rnonohydroxylated carbarnazepines were hydrolyzed. a peak due to 2-
hydroxycarbamazepine was observed, which has the same retention rime and MSlMS
specuum as that of the synthesized 2-hydroxycarbamazepine.
Figure 3-6: MS/MS spectrum of the metabolite, which has the same molecular
weight as that of 4-methylthio-2-hydroxyiminostilbene. in its glucuronide form (with a
.MH+ ion at d z 432).
0.0 10.0 20.0 30.0 40.0 50.0
Time (min)
Figure 3-7: Selected ion current of the urinary metabolites from the LC/MS of a
patient's urine: 7-hydroxyiminostilbene-glucuronide (A), carbarnazepine-glucuronide (B),
monohydroxycarbarnazepine-glucuronide (C) and 10.1 1 -dihydrodiol-carbarnazepine (D).
The ion current for each ion is provided in the upper right corner of each trace.
Figure 3-8: MS/MS spectrum of the glucuronide conjugate of 2-
hydroxyiminostilbene.
Time (min)
Figure 3-9: LCMS ion current at m/z 208 corresponding to the irninoquinone
intermediate in a urine sample before (A) and after (B) hydrolysis by P-glucuronidase.
Table 3-1: The ntios of the TIC of 2-hydroxyiminostilbene-glucuronide (m/z 386) to that of carbarnazepine-glucuronide (rn/z 4 13); rnonohydroxyc arbamazepine-gl ucuronide (m/z 429) and 10,ll- dihydrodiol-carbarnazepine (m/z 27 1).
Patient #1
Patient #2
miz 386
* The third urine sample was collected from a patient in chronic use of carbarnazepine. However. derailed information about this patient was not obtained.
3.5 Discussion
The mechanism(s) of the idiosyncratic reactions associated with carbamazepine
therapy are poorly understood. It has been postulated that bioactivation to a reactive arene
oxide metabolite is a prerequisite to toxicity (Pimohamed et al.. 1992; Shear et al., 1988)
and a risk factor for the adverse reactions is a deficiency of epoxide hydrolase (Spielberg et
al., 198 1) However, two good studies have failed to find a consistent mutation, or pattern
of mutations, in the rnicrosomal epoxide hydrolase gene that is common in patients with a
history of carbamazepine hypersensitivity reactions (Gaedigk et al., 1994: Green et c d . ,
1993). Carbarnazepine has been shown to be bioactivated to a protein-reactive metabolite
by human liver microsomes. however the covalent binding of 14C-carbarnazepine to human
liver microsomes was relatively low (Pirmohamed et al., 1992). The formation of the
arene oxide metabolite has only been inferred from the urinary excretion of unquantified
phenols and catechols of carbarnazepine (Lertratmangkoon and Horning, 1982; Regnaud et
al., 1988). However, the aromatic hydroxyl metabolites are not necessady derived from
an arene oxide intermediate (Hanzlik et al., 1984). A study by Lillibridge et al. ( 1996)
using mouse liver microsomes has shown that a quinone intermediate may also be forined
in carbarnazepine bioactivation. Furtherrnore, i t has been demonstrated thnt for
bromobenzene (which does form an arene oside) most of the covalent binding is due to a
quinone (Hanzlik el al., 1984; Rietjens et oz.. 1997). Although the detection of GSH
conjugate of the postulated arene oxide intemediate in rodrnts has been reported (Amore et
al.. 1997: .Madden et ni., 1996), in humans. the same GSH-conjugate was not detected nor
were any of its further metabolized products, such as the NAC or thiomethyl derivatives
(Mqgs er al., 1997). In addition, due to their reactivity, arene oxides are short lived and
probably would not be able to reach sites (e.g. the bone marrow or skin) distant from the
major site of production, i.e. liver, at sufficient concentrations to cause toxicity. Therefore,
104 the objective of this work was to investigate alternative bioactivation pathways where
reactive metabolites might be generated at the targets of toxicity.
One of the major routes of carbarnazepine metabolisrn in the liver is hydroxylation
of the aromatic ring to yield one of the major carbarnazepine metabolites. 2-
hydroxycarbamazepine, which c m be hirther hydrolyzed to 2-hydroxyiminostilbene, either
in the liver or in other tissues (Lertratanangkoon and Horning, 1982). In this study, we
were able to detect the glucuronide conjugate of the 2-hydroxyiminostilbene by LC/MS.
Two isomers of hydroxyirninostilbene (2-OH and 3-OH-iminostilbene) had been detected
in human urine during an earlier study in which they were characterized as their
trimethylsilyl (TMS) derivatives after enzymatic hydrolysis of the urine sample with
Glusulase (Lertratanangkoon and Horning, 1982). One of the TMS derivatives of the
hydroxyirninostilbene isomers was observed to have the same GC/MS properties as the
TMS derivative of 2-hydroxyirninostilbene (Lertratanangkoon and Horning, 1982).
Although the arnount of the metabolite was too small for us to identify the structure by
NMR, the fact that we also observed a peak due to the iminoquinone in the same sample
suggested that 2-hydroxyiminostilbene glucuronide conjugate must be excreted in the urine
because other hydroxyiminostilbene isomers would not generate the iminoquinone
intermediate upon oxidation. In addition, when the sample was hydrolyzed by P-
glucuronidase to liberate 2-hydroxyiminostiibene, a much larger peak due to the
iminoquinone was observed instead of a peak due to 2-hydroxyiminostilbene (Figure 3-8).
This was not unexpected since we had shown that 2-hydroxyiminostilbene was readily
oxidized to the iminoquinone by HOCl, H102 or even by air. The free 3-
hydroxyiminostilbene released from enzymatic hydrolysis of the glucuronide conjugate was
presurnably oxidized to iminoquinone readily, before it was detected by LC/MS. We also
detected a unnary metabolite with the same molecular weight as the glucuronide conjugate
of 4-methylthio-7-hydroxyiminostilbene. However, we did not obtain enough material to
identim its structure.
105 In this work, we also demonstrated that the iminoquinone reacted with sulfhydryl-
containing nucleophiles. such as GSH and NAC, to form conjugates. The NMR data
confirmed that the sulfur was substituted on the aromatic ring in the meta-position to the
hydroxyl group. This resuit suggested that the iminoquinone is an reactive electrophile.
and it may bind to macromolecules (i.e. proteins) in vivo to cause direct toxicity or act as a
hapten to modulate the immune system. The iminoquinone intermediate could also undergo
redox cycling and generate reactive oxygen species, since it is an oxidizing agent.
In summary, we showed that the P-glucuronide conjugate of 2-
hydroxyiminostilbene was excreted in the unne of patienis taking carbamazepine. We have
also demonstrated that 2-hydroxyiminostilbene was readily oxidized to a reactive
iminoquinone intermediate that can be trapped by GSH and NAC. h i vivo, 2-
hydroxyirninostilbene could be readily oxidized in target organs, such as bone marrow and
skin. by peroxidases or even by oxygen. The ease of oxidation of 2-hydroxyiminostilbene
makes the iminoquinone an attractive candidate for the reactive metabolite of carbamazepine
responsibie for idiosyncratic reactions in the bone marrow and skin.
Chapter 4
Investigating the role of the reactive iminoquinone metabolite
of carbarnazepine in the mechanism of carbarnazepine-induced
idiosyncratic reactions
4.1 Abstract
We have previously shown that 7-hydroxyirninostilbene, a major metabolite of
carbamazepine. can undergo autoxidation to a reactive iminoquinone intermediate. The
iminoquinone intermediate reacrs with sulfhydryl-containing nucleophiles such as GSH and
NAC. It is thought that this iminoquinone intermediate may play a role in carbamazepine-
induced idiosyncratic reactions. Immunoblotting studies with anti-iminoquinone-NAC-
KLH antibodies detected protein binding in the bone marrow of rats treated with
carbamazepine for 4 days. The major modified polypeptides had molecular masses of 1 15
and 133 KDa. The recognition of these polypeptides by the antiserum could be inhibited
by preincubation of the antiserum with 2-hydroxyiminostilbene (1OpM) but not by the
sarne concentration of carbarnazepine or irninostilbene. Protein oxidation possibly caused
by reactive oxygen species generated by redox cycling of the irninoquinone intermediate
was also investigated. Increased protein oaidation was found in the nuclear and cytosol
fractions of the liver from rats treated with carbamazepine comparing to that of the controls.
Several polypeptides with rnolecular masses of 43. 3 1, 30 and 28 KDa were found to be
oxidized in these two subcellular liver fractions isolated from carbamazepine trented rats but
not frorn control rats.
1.2 Introduction
Idiosyncratic drug reactions are frequently life threatening, and they are almost
totally unpredictable. Although the mechanism of idiosyncratic drug reactions are mostly
unknown. there is a large amount of circumsrantial evidence to suggest that reactive
metabolites are involved (Hinson and Roberts. 1992; Park et al., 1995) and some of the
clinical characteristics also suggrsted the invol~ement of the immune system (Pohl et al.,
1988). One proposed mechanism for idiosyncratic dnig reactions is based on the hapten
108 hypothesis. The hapten hypothesis postulates that the drug, or a metabolite. becomes
covalently bound to a macromolecular carrier, such as a protein. and that the resulting dmg-
protein conjugate can be recognized as an irnmunogen (Park et al., 1987). Some drugs,
such as penicillin, captopril and penicillarnine, are chemically reactive and react directly
with proteins. Howevcr, most drugs that cause hypersensitivity rractions are not
intrinsically reactive and it is, therefore, assurned that bioactivation must occur ~ I I vivo.
There is now good evidence that bioactivation of dmgs is involved in immunogen
formation (Park and Kitteringharn, 1990).
Acetaldehyde, the prim;iry metabolite of ethanoi. was shown to bind covalently to
microsomai proteins, and the binding was shown to increase after chronic alcohol
consumption (Nomura and Lieber, 1981). It was found that, in man, chronic abuse is
associated with the appearance of an increased titer of antibodies against acetaldehyde
protein conjugates (Hoerner e t al., 1986). The specificity of antibodies against
acetaldehyde adducts produced in vitro suggested that in vivo sensitization occurs as a
result of acetaidehyde binding to proteins.
Amodiaquine has been associated with two major side effects, rigranulocytosis and
hepatitis (Hatton et ul., 1986; Larrey et al., 1986; Neftel et cil., 1986). S tudies have shown
that amodiaquine is readily oxidized to an electrophilic quinone irnine intermediate and that
both amodiaquine and the quinone imine metabolite are irnrnunogenic in the rat (Clarke et
al., 1990; Maggs e t ai., 1987; Maggs et ai., 1988). The antibodies raised recognize a
common antigenic deterrninant. The clinical relevance of these results obtained in animal
studies is shown by the detection of specific anti-amodiaquine IgG antibodies in man (Park
and Kitteringham. 1990). The specificity of the antibody binding again indicated an
important role of the quinone imine metabolite in dmg sensitization.
Tienilic acid is another example of a drug which requires bioactivation to induce
idiosyncratic hepatotoxic effects. It was shown that reactive metabolite forrned by
oxidation of 1%-tienilic acid by human liver rnicrosomes were irreversibly bound to
109
cytochrome P450-8 (now known as CYP2C9), the liver enzyme responsible for
bioactivation of the drug (Dansette et al., 1989). Sera of patients with tienilic acid-induced
hepatitis contained antibodies which specifically recognized a protein of human liver
microsomes determined to CYP2C9.
Halothane, a widely used anesthetic, is known to cause idiosyncratic liver damage.
Halothane is oxidized in the liver by CYP450 enzymes to a reactive trifluoroacety!chloride
which forms the neoantigen on microsorniil proteins. Immunochernical studies have shown
that sera from the majoriiy of halothane hepatitis patients contain antibodies of the IgG
isotype that recognize trifluoroacetyl modified proteins expressed in the liver of animals or
humans treated with halothane (Pohl et al., 1988). This is the only case where the identity
of the bound metabolite and characterization of the endogenous carrier molecules have been
defined.
In the sera of nine patients with carbarnazepine-induced hypersensitivity syndrome,
autoantibodies (IgG) were found to recognize a 53-Kd protein in rat liver microsomes
(Leeder et OZ., 1992; Riley er al., 1993). No such reactivity was observed in sera from
controls. The protein target was identified as CYP3Al; however, these antibodies did not
recognize related human CYP3A proteins despite the high degree of structural similarity
(Leeder et al., 1996).
We have shown that 2-hydroxyirninostilbene, a major metabolite of carbarnazepine
found in patient's urine, can undergo autoxidation to a reactive irninoquinone intermediate.
Funhermore, the iminoquinone intemediate reacts wit h sulfhydryl-containing nucleophiles
such as GSH and NAC. As discussed earlier, covalent modification of critical endogenous
proteins by reactive metabolites is thought to be important in drug-induced idiosyncratic
toxicity. To further investigate the role of this reactive iminoquinone metabolite in
carbarnazepine-induced idiosyncratic reactions, we raised an antibody against the
iminoquinone epitope and used it to investigate covalent binding of the iminoquinone
intermediate to proteins hi vivo . We demonstrated that 2-hydroxyiminostilbene can be
110 readily oxidized to the iminoquinone intermediate and which not only reacted with GSH or
SAC to form a GSH or NAC conjugate, but mostly was reduced to form 2-
hydroxyirninostilbene. This result suggested that redox cycling may occur in vivo and
result in oxygen activation and possible protein oxidation. Protein oxidation in vivo was
therefore investigated.
4.3 mate rials and Methods
1.3.1 Synthesis of iminoquinone-NAC-conjugated KLH and RSA
The iminoquinone-NAC conjugare (15 mg) was synthesized as described in
Chapter 3 and dissolved in 10 ml N,N-dimethylformarnide which contained
hydroxysuccinamide (230 mg, Sigma). This solution was then slowly added to a 25 ml
dichloromethane solution of 1 -ethyl-3-(3-dimethy1aminopropyi)carbodiimide (EDC, 3 10
mg, Sigma). Dichlorornethane was evaporated under a sueam of N:! after the reaction was
stined for 0.5 hr. The reaction mixture was then added dropwise with stirring to either
Ksyhole limpet hemocyanin (ELH. 9 mg, Sigma) or to rabbit semm albumin (RSA, 9 mg,
Sigma) dissolved in 5 ml phosphate buffer (pH 7.4). The reactions were cmi rd out by
srimng at room temperature for 3 hr. The protein conjugates were dialyzed cxtensively
qainst warer, and then lyophilized.
4.3.2 Production of anti-iminoquinone-NAC-KLH antiserum
Polyclonal anti-irninoquinone-NAC-KLH antibodies were raised in 2.0-2.5 kg
male, pathogen-free New Zealand white rabbits (Charles River, Quebec, Canada). A pre-
immune serum sample was obtained, and the rabbits were immunized with 500 pg of the
iminoquinone-NAC-KLH conjugate emulsified with an equal volume of Freund's complete
111
adjuvant at multiple subcutaneous sites. Injections with 500 pg antigen ernulsified with
Freund's incomplete adjuvant divided into 6-8 subcutaneous sites were repeated 2.4, and 6
weeks after the initial immunization. Exsanguinarion under pentobarbital anaesthesia was
conducted 2 weeks after the final injection and the blood was allowed to clot overnight at
4°C and then centrifuged at 400 g. The serum was recovered and heat-inactivated at 56°C
for 30 min before being aliquoted and stored at -20°C.
43.3 Activity of the anti-iminoquinone-N.4C-KLH antiserum
The activity of the anti-iminoquinone-NAC-KLH antibodies against the
iminoquinone epitope was determined by an enzyme-linked immunosorbent assay
(ELISA). Lminoquinone-NAC-RS A or RSA ( 1ûû u1 of a 15 pglml solution) was incubated
in flat-bottom 96-well plates (Costar, Cambridge. MA) at 4°C overnight. The plates were
then emptied and washed four times with ELISA wash buffer [10 mM Tris-HCl, pH 7.5,
153 rnM NaCI, 0.5% (w/v) casein, and 0.03% (w/v) thimerosal]. After the last wash, the
plates were tapped dry. Various dilutions (11100 to 1/100,000) of the anti-iminoquinone-
SAC-KLH antiserum (100 pl in PBS) were added to the plates and incubated at room
temperature for 3 hr. Plates were again washed four times with ELISA wash buffer and
tapped dry. Alkaline phosphate-conjugated goat anti-rabbit IgG (diluted 15000 in PBS)
was added to each well (100 $I/well) and incubated at room temperature for 2 hr. Plates
subsequently were washed four times with ELISA wash buffer and twice with PBS. A
stock solution of methyl umbelliferyl phosphate (10 mg/& in dimethylsulfoxide, kept at
-20°C) was diluted 1 : 100 in PBS, and this solution was added to each well of the plates
( 1 v e l l ) . Plates were incubated at room temperature for 10 min before fluorescence
was measured with a Fluorescence Concentration Xndyzer (Pandex, Mundelein, IL) set at
365/450 nm (excitation/emission).
4.3.4 Dosing of rats with carbamazepine in vivo
Female Lewis rats (= 200 g) were obtained from Charles River and housed in
standard cages with free access to water and powdered lab chow. After one week
acclimation period. the rats were either treated daily with carbamazepine (250 mg/kg,
gavage) as a suspension in hydroxypropyl cellulose or with hydroxypropyl cellulose alone
(control). At the end of the 4-day treatment, the rats were killed by an i-p. injection of
ketamine (100 m m ) and xylazine (20 mgkg).
43.5 Isolation of rats bone rnarrow cells
Rats femurs were removed. The bone marrow was obtained by pushing a needle
through the femurs and was collected into RPMI 1640 culture medium (University of
Toronto, Media Service). The bone marrow was suspended by passing through a 1-ml
automatic pipette tip a few rimes. After washing the cells twice in RPMI 1640 and once in
Hanks' buffer (HBSS), contaminating red blood cells were lysed by incubation in
ammonium chloride (0.16 M)/Tris (17rnM; pH 7.2) buffer for 10 min. The bone marrow
cells were ihen washed twice in HBSS and counted using a hemocytometer. Bone marrow
cells were lysed in ce11 lysis buffer [10 mM Tris-HCl, pH 7.4. 1 mM EDTA, 0.2% Triton
X-1001. Protein concentration was determined using a BCX protein assay kit (Pierce.
Rockford, IL) with bovine semm albumin as the standard. The samples were diluted to
give protein concentrations of 3 mg/ml; then, an equal volume of sample buffer [8% (w/v)
SDS, 10% ( v h ) glycerol, 0.002% bromophenol blue, 125 mM Tris-HCI, pH 6.81
containing dithiothreitol(6 mghl ) . The samples were boiled at 100°C for 10 min before
analysis by SDS-PAGE.
4.3.6 Preparation of subcelluiar fractions of rat liver
Subcellular fractions of rat liver were prepared frorn freshly isolated livers by
differential centrifugation. Rat livers from control and carbarnazepine treated groups were
pooled, weighed. and minced in five volumes of sucrose buffer (0.25 M sucrose, 15 m M
Tris-HC1, O. 1 rnM EDTA. pH 6.8), then homogenized (Janke-Kunkel hornogenizer, 1000
rpm, 10 strokes), and filtered through two layers of muslin. Subcellular fractions, nuclear
(1000xg pellet, 10 min). mitochondria (10,000xg pellet, 20 min), microsomes (100,000xg
pellet, 90 min) and cytosol(100,000xg supernatant, 90 min), were prepared by sequential
centrifugation of the crude whole homogenate os described by Wade e l ni. (1997) Each
pellet was washed twice by resuspending in buffer using a Dounce homogenizer (loose
fitting pestle) followed by recentrifugation. At each step, the supematants decanted from
the "crude" pellets and those obtained from the subsequent wash steps were cornbined and
then used in the next centrifugation step to obtain the next fraction. The pelleted subcellular
fractions were resuspended in one volume of sucrose buffer, aliquoted and stored at -70°C.
4.3.7 Preparation of rat skin homogenates
A piece of dorsal s h n of rat (2x2 cm) was shaved and cut into small pieces. The
skin samples were hornogenized in sucrose buffer and then filtered through two layers of
rnuslin. Protein concentration was determined using a BCA protein assay kit.
4.3.8 SDS-PAGE and immunoblotting
Samples for analysis by SDS-PAGE were solubilized by boiling for 10 min in
sample buffer [8% (wh) SDS. 20% (vlv) glycerol, 0.002% bromophenol blue, 125 mM
114
Tris-HC1, pH 6.81 containing dithiothreitol (6 mg/ml). Protein (30 pg) was loaded on each
lane for al1 samples (i.e. bone marrow cells. skin homogenates and liver subcellular
fractions). SDS-PAGE was carried out using a minigel system (Mini-PROTEAN II;
BioRad. Mississnuga, Ontario). Stacking and resolving gels were 4% and 10% (or 12%)
acrylamide. respectively. Gels were run at 100 V until the dye front reached the bottom of
the resolving gel (= 45 min). Resolved proteins were transferred ont0 nitrocellulose using
a buffer of 15.7 mM Tris, 120 rnM glycine. pH 8.3, containing 20% (v/v) methanol, for
75 rnin at 100 V using a mini Trans-blot transfer ce11 (BioRad). The subsequent steps were
conducted at room temperature with constant shaking. Before exposure to the antiserum.
the nitrocellulose was blocked by incubation in a solution containing 10 mM Tris-HC1. pH
7.5, 153 mM NaCl, 2.5% (w/v) casein and 0.02% (wlv) thimerosal for 2 hr. The blocked
nitrocellulose was incubated overnight with anti-iminoquinone-NAC-KLH antiserum
( 1500) diluted with ELISA wash buffer [!O rnM TrisaHCI, pH 7.5, 154 mM NaCl, 0.5%
(whl) casein and 0.02% (wlv) thimerosal]. Unbound antibodies were rernoved by washing
the nitrocellulose in wash buffer (3 x 10 min). The nitrocellulose then was incubated for 2
hr wirh horseradish peroxidase-conjugated goat anti-rabbit IgG (H+L chain) antiserum
(diluted 1:10,000 in wash buffer). The nitrocelluIose was washed with ELIS.4 wash
buffer (3 x 10 rnin) followed by washing with Tris buffer [50 mM Tris-HCI. pH 7.1 and
154 m i NaCI] (3 x 5 min). The nitrocellulose sheers were incubated in Super Signal ECL
reagent for 5 min, and bound antibodies were visualized by exposinp the nitrocellulose to
ECL film under safe-light conditions.
1.3.9 Determination of oxidatively-rnodified proteins
Protein oxidation was determined utilizing the method described by Levine et al.
(1994). Protein concentrations of subcehlar rat Iiver fractions were determined and
115 diluted to 10 mg/mi. One volume of 12% sodium dodecyl sulfate (Sigma) was added to the
samples with mixing followed by adding 2 volumes of the 2,4-dinitrophenylhydrazine
solution [20 mM in 10% (v/v) trifluoroacetic acid]. The mixture was allowed to stand for 5
min at room temperature before i t was neutralized by adding 1.5 volume of 2 M Tris
containing 30% glycerol and 19% 2-mercaptoethanol. When the solution was neutralized,
the color changed from light yellow to orange. For SDS-PAGE analysis, the samples (36
mg/lane) were loaded directly ont0 the gel without heating. The subsequent steps for
irnmunoblotting were the sarne as described above. Rabbit polyclonal antibodies against
the 7.4-dinitrophenyl moiety (Sigma. diluted 1: 1000) were used to recognize oxidatively
modified proteins.
4.4 Results
4.4.1 Synthesis of the iminoquinone-NAC-KLH (RSA) conjugate
As shown in Chapter 3. the iminoquinone intermediate reacted with NAC and
formed a conjugate. This inrroduced a carboxyl group on the molecule so that it can be
coupled with amino groups on proteins. (Fig 4-1). In this case EUH was used as the
carrier protein because it is a large foreign protein and has been commonly used in
immunogen synthesis. The irninoquinone-NAC-RSA conjugate was also synthesized in
the same way and i t was used as an artificial nntigen to determine the activity of the
antiserum.
KLH or RSA
Iminoquinone-NAC-Protein conjugate
Fig 4- 1: The structure of the iminoquinone-NAC-Protein conjugate.
4.42 Determination of the activity of the antiserum
The polyclonal antibodies were raised by immunizing rabbits with the
iminoquinone-NAC-KLH conjugate. The activity of the antibodies nsainst the
irninoquinone epitope was detennined by ELISA. ELISA anaiysis (Fig 4-2) demonstrated
that the anti-iminoquinone-NAC-KLH antibodies recognized the iminoquinone-NAC-RSA
conjugate but not RSA itself. However, the misera could not detect covalent binding of
the iminoquinone intermediate to other proteins, such as reduced lysozymes.
4.4.3 Immunoblotting of bone marrow cells isolated from rats treated with
carbamazepine
Using the anti-iminoquinone-NAC-KLH antiserum, it was possible to detect
covalent binding in bone marrow cells of rats dosed with carbamazepine (250 mg/kg/day)
(Fig 4-3A). The major modified polypeptides had molecular masses of 1 15 KDa and 133
KDa. The recognition of these polypeptides by the antiserum could be inhibited by
preincubation of the antiserum with 3-hydroxyimincstiibene (10 PM). Howe~er. the same
amount of carbamazepine and iminostilbene ( I O PM) were not able to inhibit the binding
(Fig 4-3B). Surprisingly, carbamazepine not only did not inhibit the bindin: bu t also
increased the background signal.
4.4.4 Protein oxidation in subcellular fractions of rat liver
Female Lewis rats were rreated with carbamazepine (250 mg/kg/dayl and protein
oxidation in various subcellular fractions of rats liver was studied. An irnrnunochemical
assay (Keller er al., 1993; Levine et al.. 1994) was used to detect carbonyi moieties
(ddehydes and ketones) that result from oxidative darnage to proteins. The carbonyls were
119 reacted with 2.4-dinitrophenylhydrazine, givin; the corresponding hydrazones, which
were detected by Western blotting using a polyclonal anti-dinitrophenyl antibodies. In
nuclear and cytosoi fractions. an increase in protein aldehydes was found in rats treated
with carbamazepine comparing to that in the controls (Fig 4-4). Furthermore, in cytosol
and nuclear fractions, oxidized polypeptides with molecular masses of 43, 3 1, 30 and 28
KDa were detected in the samples from rais treated with carbamazepine but not in the
samples from control rats (Fig 4-4).
4.4.5 Irnrnunoblotting of skin homogenate and subcellular liver fractions
from rats treated with carbamazepine
Proteins of skin homogenates and subcellular liver fractions were separated by
SDS-PAGE. Unfortunately, no covalent binding of the iminoquinone to skin and liver
proteins was detected using the anti-iminoquinone-NAC-EUH antisera.
- T'O
- T O ' O
- T O O ' O
- T000'0
4.5 Discussion
Bioactivation of xenobiotics to highly reactive intermediates in vivo which can
subsequently undergo covalent binding to proteins has been widely implicated as a critical
event in target orgm toxicity (Boelsterli, 1993; Hinson e t al., 1994; Nelson and Pearson.
1990; Vermeulen et al.. 1992). We hypothesized that bioactivation of carbarnazepine to a
reactive metabolite and the subsequent covalent binding of this reactive intermediate to
proteins may play a role in carbarnazepine-induced idiosyncratic reactions. We have shown
that a reactive irninoquinone intermediate was formed readily from oxidation of 2-
hydroxyiminostilbene, a major metabolite of carbarnazepine. B y trapping the irninoquinone
intermediate with NAC and then coupling this conjugate to KLH, i t was possible to
produce an immunogen that subsequently was used to raise the polyclonal antibodies. The
antibodies were shown to recognize the irninoquinone epitope by ELISA experiment. The
possible role of the iminoquinone in carbarnazepine-induced toxicity was investigated using
the raised antiserum. Fernale Lewis rats were treated with carbamazepine (250 rnglkgJday,
gavage) for four days and the liver and bone marrow were isolated at the end of the dmg
treatment. üsing the developed anti-iminoquinone-NAC-KLH antiserum. i t was possible
for us to detect protein binding in the bone marrow cells of rats treated with carbamazepine
but not in that of the control animais. The major modified polypeptides had molecular
masses of 1 15 KDa and 133 KDa. This binding was inhibited by 2-hydroxyiminostilbene
(10 PM) but not by carbamazepine or iminostilbene at the same concentration. This result
suggested that the polypeptides that were recognized by the antiserum were likely to be
covalently modified by the iminoquinone reactive intermediate. Nonspecific binding was
detected in the bone marrow isolated from control rats that had not been treated with
carbamazepine. This c m b e explained by two reasons. First, if the rabbits used to raise
antibodies were not kept in a properly stenlized environment, they could develop antibodies
against various environmental bacteria and pathogens that will cross-react with proteins in
124 the bone marrow. Second. to detect the iminoquinone-modifïed proteins, a low dilution
(1500) of the antiserum had to be used, which rnay also contribute to the background
binding.
In a previous study, we have shown that when the irninoquinone intermediate of
carbarnazepine reacted with GSH or NAC, the GSH or NAC conjugate was formed.
However, the major pathway of this reaction was reduction of the irninoquinone to 2-
hydroxyirninostilbene. This sugpested that the irninoquinone intermediate is both an
electrophile and an oxidizing agent: therefore, it rnay covalently bind to critical proteins or it
may initiate oxidative damage. The iminoquinone intermediate. as an oxidizing agent, may
deplete the ce11 of glutathione and cause oxidative stress. Oxidative stress is generally
associated with production of reactive oxygen species, such as H202, 0 2 - and the highly
reactive -OH. These species may cause lipid peroxidation. DNA damage and oxidation of
protein amine groups. Oxidation of a protein may alter its structure, function and integrity.
Oxidative damage to proteins has been shown to resuit in protein turnover and decreased
enzymatic function, and it has been associated with aging and a number of pathological
processes including emphyserna. atherosclerosis and neurological diseases ( S tadtman and
Oliver, 199 1). Alteration of proteins by oxidation rnay also be rnechanistically important in
the toxicity of various chernicals and drugs.
Various functional groups on a protein may be oxidized and form different types of
products: cysteine-cysceine disulfide linkages, tyrosine-tyrosine linkages. methionine
sulfoxide and aldehydes frorn lysine, arginine and proline. In this study we used an
irnrnunoblotting assay to detect protein aldehyde formation, which may occur in vivo as a
result of oxygen activation via redox cycling between the iminoquinone intermediate and its
reduced product 2-hydroxyiminostilbene. Increased protein oxidation was found in the
nuclear and cytosol fractions of the liver from rats treated with carbarnazepine comparing to
that of the controis. Furthemore, in these two fractions, several oxidized polypeptides
with molecular masses of 43, 31. 30 and 28 KDa were oxidized in the sarnples from
125 carbarnazepine-treated rats but not in that of control rats. This susgested that
carbamazepine treatment caused the oxidation of target proteins in rats in vivo. The pattern
of protein oxidation was also different in carbarnazepine-treated rats than that of the control
rats. However, we do not have direct evidence that the protein oxidation wns due to the
formation of the iminoquinone intermediate il2 vivo. It is possible that the parent drug or
other unidentified metabolites may result in the protein oxidation. Agents that can prevent
the formation of the irninoquinone intermediate may prove whether it plays an important
role in protein oxidation and covalent binding. Since inhibition of the hydrolysis of 2-
hydroxycarbamazepine to 2-hydroxyiminostilbene would prevent the formation of the
iminoquinone in vivo, treating the animals with an acyl amidase inhibitor dong with
carbamazepine should be able to inhibit both the covalent binding and protein oxidation.
In surnmary, we have developed an anti-iminoquinone-NAC-KLH antiserurn and
used the antiserum to investigate the covalent binding of the irninoquinone to the bone
rnarrow cells of rats treated with carbamazepine in vivo. In addition. we have dso detected
increased protein oxidation in the nuclear and cytosol fractions of the liver from rats treated
with carbarnazepine compared to the controls.
Chapter 5
Summary and Discussion
5.1 Summary
The aim of the studies reported in this thesis was to investigate whether
bioactivation of indomethacin and carbamazepine could lead to the formation of reactive
metabolites that rnay be responsible for the idiosyncratic adverse reactions caused by these
two dnigs.
The results from the indomethacin study demonstrated that DMBI, a major
metabolite of indornethacin. can be further oxidized by the MPO system in activated
neutrophils to a reactive iminoquinone intermediate. The identity of this reactive
intermediate was supported by several strong pieces of evidence. The diode-cirray UV
spectrophotometric data showed that when DMBI reacted with HOCl, a new species was
formed that showed a UV absorbance at longer wavelengths (suggesting a quinone-like
structure). The iminoquinone intermediate with a MH+ ion at m/z 7W was detected by MS
in a flow system when the products of the reaction between DMBI and HOCl were
analyzed. Furthemore, this irninoquinone intemediate reacted with sulfhydryl-containing
nucleophiles. such as GSH and NAC, to form conjugates, and the structure of the
irnnoquinone-NAC conjugate was confirmed by proton NMR analysis. The NAC was
bound to the aromatic ring orrlzo to the hydroxyl group. The reactivity of the iminoquinone
intermediate as an elecuophile and its formation by MPO in activated neutrophils suggested
that this reactive irninoquinone intermediate may be responsible for indomethacin-induced
idiosyncratic adverse reactions, especinlly agranuloc ytosis.
It has been suggested that idiosyncratic drug reactions associated with
carbamazepine are due ro bioactivation of carbamazepine by CYP450 to form an arene
oxide and deficiency of epoxide hydrolase is a risk factor for these adverse reactions (Shear
and Spielberg, 1988). However, in patients with a history of carbamazepine
hypersensitivity reaction. the decreased epoxide hydrolase genotype was no more prevelant
than in the control group (Gaedigk et al., 1994: Green et al., 1995). The only direct
128 evidence to support the "arene oxide hypothesis" was the finding of a GSH adduct of
carbamazepine in rat bile (Madden et al., 1996). The structure of this GSH adduct is
consistent with an arene oxide precursor and the GSH was substituted ortho-to the
hydroxyl group (Figure 5- 1); however, such an adduct was not found in humans (Maggs et
al., 1997). In addition. the carbarnazepine hypersensitivity reaction involves many organs,
in which CYP450 is not a major oxidizing enzyme, that are unlikely to be able to form
significant amounts of arene oxide.
We have discovered an alternative metabolic pathway of carbamazepine leading to a
reactive irninoquinone (Figure 3- 1). The formation of 2-hydroxycarbamazepine, which is
the first step in this pathway, is known to be a major metabolic pathway in humans
(Eichelbaum et al., 1984). The second step in the formation of the iminoquinone is
hydrolysis of 2-hydroxycarbamazepine to 2-hydroxyiminostilbene, either in the liver or
peripheral tissues. We have found that, in the urine of three patients taking carbamazepine,
2-hydroxyiminostilbene is a major metabolite. Funhermore, we also demonstrated that 2-
hydroxyiminostilbene is readily oxidized to the reactive irninoquinone and this oxidation
even occurs spontaneously in air. This iminoquinone reacts with GSH and NAC and the
substitution is mrtn-to the hydroxyl group, as opposed ta the orrlio substitution of the
putative arene oxide. Another difference between the GSH adduct of the irninoquinone and
that of the arene oxide is the presence of the intact urea group in the adduct formed from the
arene oxide. In the urine of these three patients, we also found a metabolite that appears to
be a thiomethylderivative of the 3--hydroxyiminostilbene, which presurnably came from
further gut metabolism of a GSH conjugate, although its structure has not been
conclusively demonstrated. However, we did not find any sulfur-containing derivatives of
2-hydroxycarbamazepine. which presurnably is the further metabolite of a GSH adduct of
the arene oxide.
To further investigate the role of the iminoquinone intermediate in carbamazepine-
induced adverse reactions. an antibody (anti-iminoquinone-NAC-KLH) against the
129 irninoquinone epitope was developed and used to study the covalent binding of the
iminoquinone to endogenous proteins. Immunoblotting studies showed that the antibody
was able to detect covalent binding in the bone marrow of rats treated with carbamazepine
for four days. Furthemore. the covalent binding w u inhibited by 2-hydroxyiminostilbene
but not by carbamazepine or irninostilbene. These results suggested that the polypeptides
recopnized by the antiserum were likely to be covalently modified by the iminoquinone
reactive intermediate. Furthermore, although the iminoquinone covalently binds to
sulhydryl groups, the dominant reaction is reduction to 2-hydroxyimjnostilbene, and we
have also detected increased protein oxidation in the nuclear and cytosol fractions from the
liver of rats treated with carbamazepine compared to the coiitrols. The protein oxidation is
probably due to reactive oxygen species generated in vivo during the redox cyling between
the irninoquinone and its reduced product 2-hydroxyirninostilbene (Figure 3-41.
We have demonstrated that the major metabolites of indomethacin (DMBI) and
carbamazepine (2-hydroxyiminostilbene) can be oxidized to reactive iminoquinone
intermediates in one target of toxicity, specifically neutrophils. We have dso shown that
these iminoquinone intermediates are reactive electrophiles and that they react with
sulfhydryl-containing nucleophiles (i.e. GSH and NAC). We were able to dctect covalent
binding to bone manow cells in rats treated with carbamazepine using rhe anrisemm raised
against the reactive irninoquinone epitope. However. covalent binding was not detected in
other tvget organs. such as the liver or skin, from rats treated with carbarnazepine. One
possible reason for this discrepancy is that the antiserum was raised against a specific
antigen in which the iminoquinone was covaiently bound to NAC before binding to protein
and this may not be the same way that the irninoquinone binds to proteins in vivo.
Therefore, in the future, i t will be necessary to develop another antibody against the
Unmunogen in which the irninoquinone direcrly binds to proteins. In addition. although we
have detected covalent binding using the antiserum developed against the iminoquinone
epitope, the role of the reactive irninoquinone in the covalent binding needs ro be funher
130 examined. If the major reactive metabolite responsible for the binding is the irninoquinone.
agents that prevent its formation should inhibit the covalent binding. Since inhibition of the
hydrolysis of 2-hydroxycarbamazepine to 2-hydroxyiminostilbene would prevent the
formation of the iminoquinone i t ~ vivo, treating the animals with an acyl amidase inhibitor
at the sarne time as carbamazepine should be able to inhibit the covalent binding. A positive
result from this experirnent, would suggest that the iminoquinone, not the arene oxide, is
responsible for most of the covalent binding. It is important, in the future. to study the
covalent binding in humans because metabolism may be different in animals than in
humans. The cornmon targets of carbarnazepine-induced toxicity are the liver, skin and
blood. Although obtaining a liver biopsy is difficult, it should be much easier to obtain
blood and skin biopsies from patients who are treated with carbamazepine. If we find
binding in these tissues, we should then be able to determine in which cells and where
within the cells the binding is the greatest. Funhermore, we can make an affinity column
with the antibodies to separate proteins that are rnodified by the reactive metabolite and to
detemiine their sequences.
Carbarnazepine Arene oxide
GSH adduct
Figure 5- 1: Proposed pathway of carbarnazepine bioactivation to an arene oxide
intemediate ,and its reaction with GSH.
5.2 Discussion
Idiosyncratic drug reactions pose a signifiant complication in modem therapy
because of their unpredictable nature and potentially fatal outcome. Although the
rnechanisms involved are poorly understood, there is a large amount of circumstantial
evidence to suggest that chemically reactive metaboiites play a pivotal role. Such reactive
rnetabolites may be directly toxic to the cells or they may becorne covalently bound to a
macromolecular carrier, such as a protein, which rnay initiate an immune-mediated reaction.
132 Chernically reactive metabolites are, in general, electrophiles that c m react with nucleophilic
groups on proteins to become haptens. The nucleophilic groups on proteins include lysyl
and cysteinyl residues, and the imidazole and phenol groups present in histidine and
tyrosine respectively. For example. halothane is oxidized in the liver to reactive metabolite
TFA, which reacts preferentially with lysine residues on hepatic proteins (Kenna et al.,
1988). It has also been demonstrated that patients with halothane-induced hepatitis have
antibodies against specific TFA-modified hepatic proteins. Therefore, it is essential to
identiQ the reactive metabolite of a drug in order to understand their interactions with
cellular macromolecules. Having a clear idea of the chemical nature of the reactive
metabolite also may help in developing strategies to prevent drug-induced adverse
reactions. For example, drugs that have an aromatic amino group are usually oxidized to
highly reactive metabolites. such as hydroxylamine and nitroso derivatives. These reactive
metabolites have been associated with adverse reaction caused by dmgs with a free nmino
group, such as sulfonamides. dapsone and procainamide (Coleman rf cd . . 1989; Rieder er
al., 1989; Uetrecht et al.. 198Sb; Cetrecht. 1990). Although the incidence and clinical
outcome of adverse reactions caused by these drugs are variable, in each case the initial
evenr in drug toxicity is N-hydroxylation whch occurs in most individuals taking the drug.
In both carbamazepine and indomethacin studies, we have demonstrated that reactive
iminoquinone intermediates were formed during the oxidation of the major metabolite of
indomethacin (DMBI) and of carbamazepine (2-hydroxyirninostilbene). The common
feature of these two major metabolites (DMBI and 2-hydroxyirninotilbene is that they both
have an amine and a hydroxyl group in para positions to each other on the same aromatic
ring. This allows to bioactivation of the molecules to irninoquinone species. As discussed
in Chapter 1, it has been s h o w that a number of drugs or their metabolites with similar
strucrural features as DiMBI and 3-hydroxyiminostilbene can be bioactivated to reactive
iminoquinone intermediates by various metabolizing enzymes (e.;. CYP450, MPO or
PHs). Studies have also suggested that the formation of reactive iminoquinone
133 intermediates are responsible for the adverse reactions caused by these drugs. For
exarnple, bioactivation of amodiaquine to a reactive iminoquinone and its covalent binding
to various proteins have been demonstrated in several systems: human liver microsomes,
the horseradish peroxidase system and activated neutrophils. Bioactivation of
acetaminophen to a reactive N-acetylbenzoquinone imine by CYP450. MPO and PHs
systems has also been associated with renal and hepatotoxicity in cases of aceraminophen
overdoses. Therefore, a knowledge of the functional groups on a molecule which lead to
bioactivation and formation of a reactive metabolite may dlow the development of analogs
which do not contain such functional groups but still retain their therapeutic propenies.
Although i t is comrnonly accepted that reactive metabolites are involved in
idiosyncratic drug reactions, in most cases, this has not been rigorously proven.
Identification of a reactive metabolite of a dmg does not equal proving its role in cciusing
toxicity. It is possible that other undiscovered reactive metabolites are more imponant;
even if the identified reactive metabolite appears to be responsible for the toxicity, there
could be other risk factors for idiosyncratic reactions besides formation of a reactive
metabolite. ~Most drugs can be metabolized to chemically reactive metabolites: however,
they do not al1 cause a high incidence of idiosyncrütic reactions. This can be explained by
several possibilities. First. the reactive merabolites can be detoxified. in many cases.
before rhey can initiate tissue damage. It has been demonstrated that a number of drugs,
which are associated with occasional irnmunological reactions, may undergo bioactivation
by human liver microsornes to chemically reactive metabolites in vivo (Park and Coleman,
1988). However. parallel iri vivo studies have shown that such bioactivation is normally
precludrd or severely restricted by competing oxidation and conjugation reactions. When
bioactivation does occur, the chemically reactive metabolites are rapidly detoxified by
cellular defense mechanisms such as conjugation by glutathione (or glutathione transferase)
and hydrolysis by epoxide hydrolase. Therefore, the production of haptens. which could
stimulare the immune system, would be prevented (or reduced). However, the normal
134 balance between the bioactivation and detoxication pathways may be disturbed, in which
case the reactive metabolite cm escape detoxication.
Second, the chernical reactivity of the reactive metabolite is a major facror in
determining the degree and character of toxicity (Gillette, 1974a; Gillette. 197Jb: Park and
Kitteringham. 1990). If a reactive metabolite has low reactivity. it can be selecrively
detoxified before binding to some criticai molecules. At the other extreme. if a reactive
metabolite is too reactive. i t rnay react with anything i t encounters, such as water or the
enzyme that formed it, and have little chance to bind to other important molecules
(Uetrecht, 1992). For example, acetaminophen is associared with a low incidence of
idiosyncratic reactions. The reactive metabolite of acetaminophen is the
rtcetylbenzoquinone irnine and the low incidence of xetaminophen-associated idiosy ncratic
reactions is probably due to the selectivity of its reactions. The acetylbenzoquinone imine
metabolite is a soft electrophilr and preferentially r e m s with soft nucleophiles. such as
glutathione. However, its reaction with GSH is relatively slow in the absence of
glutathione transferase (Coles et al., 1988). Therefore. there is little chance for covalent
binding to other important rnolrcules, Le. proteins. Cysteine and lysine are probably the
two most comrnon nucleophilic arnino acids. The reactivity of the reactive metabolite and
whether it is 3 "soft" or "hard" electrophile also determine the amino acid residue to which
it binds (,L'etrecht. 1992). Funhermore, the amount of reactive metabolites binding to
proteins is also important. In jenerai. if a molecule is seing to induce an immune-mediated
reaction by acting as a hapten. the higher the hapten density (nurnber of dnig molecules
conjugated per molecule of protein), the higher intensity of the immune response.
Third. the site of reactive rnetabolite formation and the reactivity of the intermediate
c m also determine the target organ for toxicity. If the reactive metabolite is only formed in
one organ and is too reactive to escape that organ. then the toxicity should be confined CO
that organ. For exampie, halothane appears to be oxidized exclusively by CYP450 in the
liver to form a very reactive metabolite, TFA. As would be expected, the idiosyncratic
135 reactions associated with halothane are limited to the liver. Since liver is the major site of
drug oxidation, it may be considered to be particularly vulnerable to toxic effects of drugs
and their metabolites. However, many idiosyncratic reactions do not involve the liver.
This can be explained by the high capacity of cellular detoxication systems and the large
reserve of glutathione in the liver.
Founh, the irreversible binding of the reactive metabolite to specific proteins in vivo
is presumably important for initiating an immune reaction. For example, captopril can
extensively and covalently bind to cysteine residues in plasma proteins. However,
disposition studies have shown that the disulfide linkage is biochernically labile and can be
readily dissociated by endogenous thiols such as glutathione, which possibly explains why
captopril is only very wenkly immunogenic in both humans and experimental ünimals
(Coleman et al., 1988).
Fifth, the probability of a reactive metabolite of a drug to cause adverse reactions is
dependent on its toxicity to the cells and its efficiency in protein binding. The efficiency in
protein binding of a reacrive metabolite is increased by the therapeutic dose of the drug, the
percentage of the drug that can be bioactivated to the reactive metabolite and the rextivity of
this metabolite to specific proteins.
If al1 idiosyncratic drug reactions involve a reactive rnetabolite. it might be expected
that al1 drugs that can form a similar reactive metabolite would cause the same type of
reactions. However, this is often not the case. For example. i t has been suggested that the
hydroxylarnine rnetabolite of procainamide, which can be nonenzymatically oxidized to a
reactive nitroso-derivative, plays an important role in the mechanisrn of procainamide-
induced lupus. However. dapsone, which is also an arylarnine and can be oxidized to a
hydroxylamine, causes several different types of hypersensitivity reactions. Specifically
they both cause agranulocytosis but procainamide causes lupus and dapsone does not,
while dapsone causes methemoglobinemia and procainarnide does not. In this thesis, we
found bioactivation of carbarnazepine and indornethacin lead to the formation of suucturally
136 similar reactive metabolites (Le. the irninoquinone species); however, the patterns of
idiosyncratic drug reaction causzd by these two dmgs are somewhat different. The major
target of indomethacin-induced idiosyncratic dmg reactions is the blood: but the most
common serious adverse reaction associated with the use of carbamazepine is
"hypersensitivity " reaction, which c m affect any organ. This difference is probably due to
the following reasons. First, indomethacin is given in lower doses (75 mg/day) than
carbarnazepine (700 mg/day). Second, in contrast to carbamazepine. which is usually used
chronically, indomethacin is usually given in acute situations (such as gout) for a short
period of time. Third, Our studies have shown that 2-hydroxyiminostilbene is more readily
oxidized to the iminoquinone intenediate, in fact it undegoes autoxidation when rxposed
in air. Therefore, presumably the iminoquinone of carbamazepine can be formed in any
tissue where 7-hydroxy iminostilbene reaches. Fourth, although both reactil-e metabolites
are irninoquinone species. their chernical reactivities are not identical. We showed that the
irninoquinone of indornethacin rems with both N- and S- containinj nucleophiles. but the
iminoquinone of carbamazepine appears to only react with S-containing nucleophiles. In
addition, we found ihat the iminoquinone of carbamazepine c m dso undergo redox cycling
which could lead to different toxicological consequences than protein binding i~z vivo.
I t is thought that many dmg-induced toxicities are due to the covalent binding of
renctive metabolires to tissue proteins. It has also been suggested that protein bindin; is not
random, but rather selective wirh respect to the proteins targeted (Cohen et al.. 1997). The
selective binding may influence homeostatic or other cellular responses which in turn
contribute to drug toxicity, hypersensitivity or autoimmunity. Modern biochemical,
molecular, and immunochemical approaches have made i t possible to srudy covalent
bindin; of chemically reactive metabolites to cellular proteins and to identifi the specific
protein targets. For example, several protein targets modified by the reactive metabolite of
halothane, TFA. have been isolated frorn liver rnicrosomes of halothane-treated rats and
identified. The 57, 58, 59, 63, 80. 52 and 100 KDa proteins have been identified as
137 protein disulfide isomerase, a disulfide isomerase isoform, a carboxylesterase, calreticulin,
72 KDa endoplasmic reticulum protein, 78 KDa glucose-regulated protein and 94 KDa
ducose-regulated protein, respectively (Amouzadeh and Pohl. 1995). Results from other C
studies indicate that s imilx proteins are present in the livers of humans (Smith et al., 1993)
and they appear to become covalently modified by the TFA moiety after patients have been
administered halothane (Pohl et al.. 1989). The ability to identify individual proreins which
become modified by reactive intermediates may greatly increase our understanding of the
rote of such binding in dmg-induced idiosyncratic reactions. Once these protein targets of
reactive metabolites have been purified. they c m serve as antigens for identifying sensitized
individuals who have experienced a hypersensitivity reaction to the dmg. This information
c m be used to prevent not only an allergic reacrion to the dmg, but possibly cross-reactions
to orher dnigs that are stmcturally related. Another important application of these studies is
the design of safer alternative drugs that will not produce structurally similar reactive
metabolites.
Although protein binding is important. it may not be the only way that a reactive
metabolite can modify proteins and initiate an immune response. Chemically reactive
rnetaboiites c m also cause oxidative stress, which may in turn, initiate an innare immune
response. The innate immune system, althouoh primitive, is an essential part of Our
defense system against infections. An innate immune response involves recognition of
certain chernical features shared by groups of microorganisms but not by the host. such as
the lipopolysaccharide of Gram-negative bacterial ce11 walls; and it d s o appears to be able
to detect cells that have been stressed (Fearon. 1997; Fearon and Locksley, 1996: Poccia et
ai.. 1998). There is also evidrnce that the innote immune response communicates its
recognition to the adaptive system by providing the "danger" signal, without which a new
antigen usually induces tolerance in the adaptive system (Bendeiac and Fearon, 1997).
Some reactive metabolites, which are oxidizing azents, can cause oxidative damage of the
cells either directly or through reactive endogenous oxygen species. Stressed or injured
138 cells can be detected by the innate immune systern, which can destroy the cells or may
provide "danger" signals to the adaptive immune system. This will ultimately lead to tissue
darnage.
In my discussion of the mechanisms involved in idiosyncratic drug reactions, one
question that must be asked is why only certain individuals are exceptionally susceptible to
the toxicity. A number of possibilities exist to explain this (Park et al., 1992; Pohl el al.,
1996; Uetrecht, 1990). Individual susceptibility to toxicity will depend on the balance
between the relative roles of drug bioactivation and detoxication of both parent drug and the
metabolite. Sorne people may have abnormally high levels of an enzyme that bioactivates
the drug to a reactive metabolite or an allelic variant of the enzyme that is catalytically more
active than the normal enzyme. Altematively individuais that develop a particular drug
reaction rnay have abnormally low levels or activities of enzymes that detoxify reactive
metabolites, such as glutathione S transferases, epoxide hydrolase or N-acetyl transferase.
However, abnormal drug metabolism cannot explain why only a srnall number of
parient are susceptible to idiosyncratic drug reaction. For example, halothane is
metaboiized to an acylhalide by CYP450 and the reactive metabolite covalently binds to
proteins to form neoantigens. Studies have shown thnt al1 experimental animals and
patients exposed to the drug generate the antigen (Kenna er ni., 1988); however. the
incidence of halothane hepatitis is between 1 in 35.000 and 1 in 350,000 (Park et di..
1992). Thus it is rhought that the difference in susceptible patients is more likely to be in
the immune response to the antigen rather than in neoantigen formation (Kenna et al.,
1988).
The ability to initiate an immune response on antigen exposure is controlled by the
major hisrocompatibility (MHC) genes, which are the most polyrnorphic genes known in
higher vertebrates (Park et al., 1992). Such a high level of polymorphism could
theoretically result in individuals who are more efficient at recognizing certain epitopes than
others with the result that only these individuais are likely to rnount a vigorous immune
139 response to drug-related antigens. The relationships between idiosyncratic drug reactions
and dmg-related antigens associated with the MHC expressed on accessible cells have not
been established; however. epidemiological studies have shown that certain pol y morphism
of MHC genes are weakly associated with increased susceptibilities to certain antoimmune
diseases such as insulin-dependent diabetes mellitus (Baisch et al.. 1990) and coeliac
disease (Bugawan et al., 1989).
Although initiation of a drug-induced immune response is likely the primary event
in drug hypersensitivity, it is not a pathoiogical process. Many patients with anti-drug
antibodies or drug-induced antoantibodies remain asymptomatic. For example, with
chronic procainarnide therapy, most patients develop antinuclear antibodies and only about
204 develop symptornatic lupus. Therefore, it is likely that there are individual risk factors
associated with the translation of an immune response into tissue damage. The factors in
detennining when sensitization is translated into tissue damage could be the amount and site
of dmg antigen formation. the half-life of the antibodies, the magnitude of the immune
response and the type of the immune response, Le. IgE, IgG or cell-mediated.
Furtherrnore, some individuals with certain diseases or infections may increase their
susceptibility to drug-induced adverse reactions. For examplr. AIDS is associated with an
increase in the incidence in sulfonamide hypersensitivity reactionç (Fischl et al, 1988) and
mononucleosis is associated with an increased incidence of ampicillin rash (Pohl et al.,
1988). Aspirin hepatotoxicity and other types of idiosyncratic drug reactions appear to be
more common in patients with diseases such as lupus (Carneron and Ramsay, 1984;
Konttinen and Tuominen. 197 1; Uetrecht, 1990).
Each of these facrors in itself rnay not be sufficient to produce toxicity, but a
combination of factors acting collectively in a certain individual rnay lead to serious
toxicity. At present. there is no simple screening test with which to predict which dmgs are
likely to cause adverse reactions and to identify those individuals who rnay be susceptible
to drug-induced hypersensitivity. However, studies to identify possible reactive
140 rnetabolites, to identify and purify the protein targets of reactive metabolires and to analyze
the genetic polymorphism, both with respect to immune funcrion and drug metabolism, in
susceptible individuals may provide some insight into the mechanism of idiosyncratic dnig
reactions.
References
Ackroyd JF (1975) Immunological mechanisms in drug hypersensitivity., in Cli>iicol
aspects of irnmunology (Gel1 PGH, Coombs RRA and Lackmann PJ eds), Blackwell
Scientific Publications, Oxford.
Ackrovd JF (1962) The immunological mechanisms in drug hypersensitivity. Proc R Soc
Med 55: 30-36.
Amore BM, Kalhorn TF, Skiles GL, Hunter AP, Bennett GD, Finnell RH, Nelson SD and
Slattery JT (1997) Chvacterization of carbamazepine metabolism in a mouse mode1 of
carbarnazepine teratogenicity . Dnig Mem b Dispos 25: 953-962.
Amouzadeh HR and Pohl LR (1995) Processing o f endoplasmic reticulum luminal antigens
associated with halothane hepatitis in rat hepatocytes. Hepatology 22: 936-943.
Anderson JA ( 1992) Allergic reactions to drugs and biological agents. JAMA 268: 2845-
2857.
Askmark H and Wiholm B (1990) Epidemiology o f adverse reactions to carbamazepine as
seen in a spontaneous reporting system. Acta New01 Scmd 81: 13 1-140.
Baisch JM. Weeks T, Giles R, Hoover M. Stastny P and Capra JD ( 1990) Analysis of
HLX-DQ genotypes and susceptibility in insulin-dependent diabetes mellitus. New
Dig l J bled 322: 1836- 184 1.
Barrett AJ. Weller E, Rozengurt N, Lonzhurst P and Humble JG (1976) Amidopyrine
a_oranulocytosis: drug inhibition of granulocyte coionies in the presence of patient's
serum. Br Med J 2: 850-85 1.
Bendelac A and Fearon DT (1997) Innate pathways that control acquired immunity. C w r
Opin Immttnol 9: 1-3.
Billings RE (1985) Mechanisms of catachol formation from aromatic compounds in
isolated rat hepatocytes. Dnig Metab Disp 13: 287-290.
142 Billings RE and Fischer LJ ( 1985) Oxygen-18 incorporation studies of the rnetabolism of
phenytoin to the catechoi. Drtcg Metab Disp 13: 3 12-3 17.
Boelsterli UA (1993) Specific targets of covalent dmg-prorein interactions in hepatocytes
and their toxicological significance in dmg-induced liver injury. Drug Metab Rev 25:
395-45 1.
Boyd JA and Eling TE (198 1 ) Prostaglandin endoperoxide synthetase-dependent CO-
oxidation of acetaminophen to intermediates which covaienily bind in vitro to rabbit
rend medullary rnicrosomes. J Pharmacol ExpTher 219: 659-664.
Boyum A (1984) Separation of lymphocytes, granulocytes and monocytes from hurnan
blcod using iodinated density gradient media. Methods in Enzyinology 108: 88- 102.
Brodie BB, Reid WD, Cho AK, Sipes G, Krishna G and Gillette JR (1971) Possible
mechanism of liver necrosis caused by aromatic organic compounds. Proc Natl Arad
Sci 68: 160- 164.
Brown LP, Flint OP, Orton TC and Gibson GG (1986) Chemical teratogenesis: testing
methods and the role of metabolism. Dnrg Metab Rev 17: 22 1-760.
Bugawan TL, Angelini G, Larrick J, Auricchio S, Ferrara GB and Erlich HA (1989) A
combination of a particular HLA-DP beta allele and an HLA-DQ heterodimer confers
susceptibility to coeliac disease. Notwe 339: 470-373.
Cameron HA and Ramsay LE (1984) The lupus syndrome induced by hydralazine: ü
common complication with low dose treatment. Br Med J 289: 4 10-412.
Carmela C, Vittorio MD, Jennie J and Muglia MD ( 1995) Anticonvulsant hypersensitivity
syndrome. Arch h tem Med 155: 2285-2290.
Cereghino JJ, Brock JT, van Meter JC, Penry JK. Smith LD and White BG (1974)
Carbarnazepine for epilepsy. Neirrology 24: 40 1-1 10.
Cereghino JJ, van .Meter IC, Brock JT, Penry IK, Smith LD and White BG (1973)
Preliminary observations of serum carbarnazepine concentration in epileptic patients.
Neiirology 23: 357-366.
143 Chang VHT ( 1983) Synthesis of 2-hydroxycarbamazepine: a metabolite of carbamazepine.
J Heterocyclic Chem 20: 237-238.
Christie G, Breckenridge AM and Park BK (1989) Detection of antibodies towards the
antirnalarial amodiaquine and its quinone imine metabolite in man and the rat. Biochem
Ptzarmacol 38: 145 1 - 1458.
Clarke JB, Maggs JL, Kitteringham NR and Park BK (1990) Immunogenecity of
amodiaquine in the rat. Iut Arcli Allergy Appl Immunol 91: 335-342.
Cohen SD, Pumford NU, fiairallah EA, Boekelheide K, Pohl LR, Amouzadeh HR and
Hinson JA (1997) Selective protein covalent binding and target organ toxicity. Toxic
Appl Phannacol 143: 1 - 12.
Coleman J, Foster A, Yeung JHK and Park BK (1988) Dry-protein conjugates XV. A
study of the disposition of D-penicillamine in the rat and its relationship to
imrnunogenicity. Biocliem Phannac 37: 737-742.
Coleman MD, Breckenridge AM and Park BK (1989) Bioactivation of dapsone to a
cytotoxic metabolite by hurnan hepatic microsomal enzymes. Br J ClUi Pltanmcol 28:
389-395.
Coles B, Wilson 1, Wardman P, Hinson JA, Nelson SD and Ketterer B (1988) The
spontaneous and enqrnatic reaction of N-acetyl-p-benzoquinoneimine with glutathionr:
a stopped-flow kinetic study. Arclz Bioclienz Biophys 261: 253-260.
Coombs RRA and Gell PGH (1963) The classification of allergic reactions underlying
disease., in Cli~zical nspecrs of inimtinology (Gell PGH and Coombs RUA eds) pp ,
Blackwell Scientific Publications, Oxford.
Cooper DS (1984) Antithyroid dmgs. New Ejzgl J Med 311: 1353-1362.
Cribb AE, iMiller M. Tesoro A and Spielberg SP (1990a) Peroxidase-dependent oxidation
o f sulfonarnides by monocytes and neutrophils from humans and dogs. Mol Plzarmacol
38: 744-751.
144 Cnbb AE and Spielberg SP (1990b) Hepatic microsomal metabolism of sulfamethoxazole
to the hydroxylamine. Dnig Metab Dispos 18: 784-787.
Cribb AE, Spielberg SP and Griffin GP ( 1995) NJ-hydroxy lation of sulfamethoxazole by
cytochrome P450 of the cytochrome P450 2C subfamily and reduction of
sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drrig Metab
Dispos 23: 406-414.
C d 1 WE (1 973) Dmgs 5 years later: carbarnazepine. A m h t e m Med 79: 844-817.
Cuthben MF (1974) Adverse reactions to non-steroidal antirheumatic drugs. Cwr Med Res
Opin 2: 600-6 10.
Dansette PM. Amar C, Smith C, Neau E, Pons C and Mansuy D (1989) I j i vitro. the 5-
hydroxylation of tienilic acid is catalyzed by cytochrome P350 in rat and human
microsomes., in Cyrochroine P-450, Bioche~nisrry cind Biopkysics (Sc huster 1 eds)
pp 75 1-754, Taylor and Francis. New York.
Dansette PM, Amar C, Valadon Pl Pons C, Beaune PH and Mansuy D (1991)
Hydroxylation and formation of electrophilic metabolites of tienilic acid and its isomer
by human liver microsornes. Catalysis by a cytochrome P450 IIC different from that
responsible for mephenytoin hydroxylation. Biochem Pliarr~rcicol 41: 553-560.
Dodrill CB and Troupin AS (1977) Psychotropic effects of carbarnazepine in rpilepsy. A
double-blind comparison with phenytoin. 1Vr~rrology 27: 1023- 1025.
Duzgan DE. Hogans AF, Kwan KC and McMahon FG (1972) The rnetabolisrn of
indomethacin in man. J Phanmzcol Expnier 181: 563-375.
Dunk AA, Walt RP, Jenkins WJ and Sherlock SS (1982) Diclofenac hepatitis. Br Med J
Clin Res 284: 1605- 1606.
Durelli L, Massazza U and Cavallo R (1989) Cnrbamazepine toxicity and poisoning:
incidence. clinical features and management. Merl To.rAdv Drug Ekp 4: 95-107.
145 Eastrnond DA, Smith MT and Irons RD (1987) A n interaction of benzene metcbolites
reproduces the myelotoxicity observed wirh benzene exposure. Toxicol Appl
Plzanrzacol 91: 85-95.
Eastrnond DA, Smith MT. Ruzo LO and Ross D (1986) Metabolic activation of phenol by
human myeloperoxidase and horse-radish peroxidase. Mol Phamacol 30: 674-679.
Eichelbaum M, Jensen C, von Sassen W, Bertilsson L and Tomson T (1984) Ii2 vivo and
iti vitro biotransformation of carbarnazepine in man and rat, in Metabolisin of
anriepileptic dncgs. (Levy RH, Pitlick WH, Eichelbaum M and Meijer J eds) pp 27-33,
Raven Press, New York.
Eling TE, .Mason RP and Sivarajah K (1985) The formation of aminopyrine cation radical
by the peroxidase rtctivity of prostaglandin H synthase and subsequent reactions of the
radical. J Biol Chem 260: 160 1 - 1607.
Ellrodt AG, Murata GH, Reidinger MS, Stewart ME, Mochizuki C and Gray R ( 1984)
Severe neutropenia associated with sustained-release procainamide. Ann Inter Med
100: 197-201.
Epstein M, Vickars L and Stein H (1990) Diclofenac induced immune thrornbocytopenia. J
Rltertrnatol 17: 1303- 1403.
Eustace S. O'Neill T, McHale S and Molony J (1989) Fatal aplristic anaemia following
prolon jed diclofenac use in an elderl y patient. Ir J Med Sci 158: 2 17.
Fearon DT (1997) Seeking wisdom in innate immunity. Nature 388: 323-324.
Fearon DT 'and Locksley RM (1996) The instructive role of innate immunity in the acquired
immune response. Science 272: 50-53.
Fischer V. Haar JA, Greiner L, LLoyd RV and Mason RP (199 1) Possible roIe of free
radical formation in clozapine (clozad)-induced agranulocytosis. Mole Plion?mcol JO:
846-853.
146 Fischl MA, Dickinson GM and La Voie L (1988) Safety and efficacy of sulfamethoxazole
and trimethoprim chemoprophylaxis for pneumocystis carinii pneumonia in AIDS.
JAMA 259: 1 185- 1 189.
Fleming CM, Branch RA, Wilkinson GR and Guengerich FP (1992) Human liver
microsomal N-hydroxylation of dapsone by cytochrome P-450 3A4. Mol Plznrmncol
41: 975-980.
Freudenthal RI and Jones PW ( 1976) Poly?zuclear nronlatic hydroc~rbons: chetnistry,
metabolism, and carcinogenesk Raven Press, New York.
Gaedigk A, Spielberg SP and Grant DM (1994) Characterization of the microsornal
epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions.
Phannacagerzetics 4: 142- 1 5 3.
Gelboin HV ( 1980) Benzo(a)pyrene metabolism, activation and carcinogenesis: role and
regulation of mixed-funtion oxidases and related enzymes. Physiol Rev 60: 1107-
1166.
Gelboin HV and Ts'o POP ( 1978) Polycylic lzydrocarbotrs and cancer. Academic Press,
New York.
Gerson WT, Fine DG. Spielberg SP and Sensenbrennrr LL (1983) Anticonvulsant-
induced aplastic anernia: increased susceptibility to toxic dmg metabolites in vitro.
Blood 61 : 889-893.
Gill HJ, Tingle MD and Park BK (1995) N-hydroxylation of dapsone by multiple enzymes
of cytochrome P450: implicatins for inhibition of haemotoxicity. Br J Clin Pliannucol
40: 53 1-539.
Gillette JR (1974a) h perspective on the role of chemically reactive metabolites of foreign
compounds in toxicity. 1. Correlation of changes in covalent binding of reactivity
metabolites with changes in the incidence and severity of toxicity. Biocliern Plzïirnzocol
23: 2785-2794.
147 Gillette JR ( 1971b) A perspective on the role of chemically reactive metabolites of foreign
compounds in toxicity. II. Alterations in the kinetics of covalent binding. Biochem
Phannacol 23: 2927-2938.
Gilliland BC (1991) Drug-induced autoimmune and hematologic disorders. Imnicnol
Allergy Clin North Am 11: 525-553.
Goldstein RA and Patterson R ( 1 984) Sumrnary. J Allergy Clin Im>nuuol 74: 643-644.
Gram L and Jensen P (1989) Carbarnazepine toxicity., in Antiepileptic h g s . (Levy R,
Mattson R, Meldrum 8, Penry JK and Dreifuss FE eds) pp 555-565, Raven Press.
New York.
Green VJ, Pirmohamed M. Ketteringham NR, Gaedigk A. Grant DM, Boxer M, Burchell
B and Park BK (1995) Gznetic analysis of microsornal epoxide hydrolase in patients
with carbarnazepine hy persensit ivi ty. Biochem Pharnlncof 50: 13 53 - 1 359.
Greenlee WF, Sun JD and Bus JS (1981) A proposed mechanism of benzene toxicity:
formation of reac tive in termediates from pol yphenol metabolites. Toxicol Appl
Plzarmacol 59: 187- 195.
Hansen DK (199 1) The embryotoxicity of phenytoin: an update on possilbe rnechanisms.
Proc Soc Exp Bio Med 197: 36 1-368.
Hrinzlik RP, Hogberg K and Judson CM ( 1984) Microsomal hydroxylation of specifically
deuterated rnonosubstituted benzenes: evidence for direct aromatic hydroxylation.
Bioclternistq) 23: 3015-3055.
Haque KE and Proctor GR ( 1968) Dibenzo[b, f l azepine-Zone. Chem Cornrmm : 1412-
1413.
Haman RE, Meisinger MAP. Davis GE and Kuehl FA (1964) The metabolites of
indomethacin, a new antiinflammatory dmg. J Phannacol Ekp Thrr 143: 2 15-720.
Hatton CSR, Peto TEA. Bunch C and Pasvol G (1986) Frequency of severe neutropenia
associated with arnodiûquine prophylaxis against malaria. Limer 1: 41 1-3 13.
248 Helfgott SM. Sandberg-Cook J. Zakim D and Nestler J (1990) Diclofenac-associated
hepatotoxicity [see comments]. JAMA 264: 2660-2662.
Hinson IA , Pumford NR and Nelson SD (1994) The role of metabolic activation in dmg
toxicity. Dnrg Metab Rrv 26: 395-412.
Hinson JA and Roberts DW ( 1992) Role of covalent and noncovalent interactions in ceil
toxiciiy : effects on proteins. A i n i < Rev Pltommacol To-ricol 32: 47 71 -5 10.
Hoerner M, Behrens UJ, Worner T and Lieber CS (1986) Humoral immune response to
acetaldehyde adducts in alcoholic patients. Res Commun Cheni Porhol Pl~an~zncol 54:
3- 12.
Horowitz S, Patwardhan B and Marcel1 E (1988) Hepatotoxic reactions associated with
carbarnazepine therapy. Epilepsin 29: 149- 154.
Huberman E, Sach SL, Yang SK and Gelboin HV (1976) Identification of mutagenic
rnetabolites of benzo(a)pyrene in mammalian cells. Proc Nari Acnd Sci USA 73: 607-
61 1.
Hucker HB, Zacchei AG, Cox SV, Brodie DA and Cantwell NHR (1966) Studies on the
absorption, distribution and excretion of indomethacin in various species. J Plinnnncol
Exp Ther 153: 237-219.
Isildar M, Abou-Khalil WH, Jimenez JJ, Abou-Khalil A and Yunis AA \ 1988) Aerobic
nitroreduction of dehydrochlorarnphenicol by bone marrow. Tosicol Appl Plinrmcrcol
94: 305.
Islam 1 and Skibo EB (1991) Structure-activity studies of antiturnor agents based on
pyrrolo [ 1.2-31 benzimidazoles: new reduc tive alkylating DNA cleaving agents. J Med
Chern 34: 2954-296 1.
Ivanetich KM, Ziman MR and Bradshaw .JJ ( 1982) 1,1,l-Trichloropropene-2.3-oxide; an
alternate rnechanism for its inhibition of cytochrome p-450. Res Cornm~oz Cliern Patlz
Phannacol 35: 111-119.
149 Jeffrey AM, Weinstein IB, Jennette KW, Grzeskowiak K, Nakanishi K, Harvey RG,
Aurmp H and Horris C (1977) Structures of benzo(a)pyrene nucleic acid adducts
formed in humna and bovine bronchial expiants. Natru-e (Land) 269: 348-350.
Jerina DM and Dalay JW (1971) Arene oxides: a new aspect of drug metabolism. Science
185: 573-582.
Jewell H, Maggs JL, Harrison AC, O'Neill PM. Ruscoe JE and Park BK (1995) Role of
hepatic metabdisrn in the bioactivation and detoxication of amodiaquine. Xmobiotica
25: 199-217.
Kalyanaraman B and Sohnle PG (1985) Generation of free radical intermediates from
foreign compounds by neutrophils-derived oxidants. J Clin Invest 75: 16 18- 1622.
Kapitulnik J, Levin W, Conney AH, Yagi H and Jerina DM (1977) Benzo(a)pyrene 7,8-
dihydrodiol is more carcinogenic than benzo(a)pyrene in newbom mice. Nature (Lorid)
266: 378-3 80.
Kaplowitz N, Aw TY, Simon FR and S tolz A ( 1986) Drug-induced hepatotoxicity. Alitt
Inrem Med 104: 826-839.
Kaufman DW, Kelly JP, Jurgelon JM, Anderson T. Issaragrisil S, Whiholm B-E, Young
NS, Leaverton P, Levy M and Shapiro S (1996) Drugs in the aetiology of
a~ranulocytosis and aplastic anaemia. Eur 3 Hoemnrol 57: 23-30.
Kaufman DW, Kelly JP, Levy M and Shapiro S (199 1) The drtcg etiology of
ugranulocpsis and nplastic anemia. Oxford University Press, New York.
Kelder PP, de Mol NJ, 'T Hart BA and Janssen LH (1991) Metabolic activation of
chlorpromazine by stimulated human polymorphonuclear leukocytes. Induction of
covalent binding of chlorpromazine to nucleic acids and proteins. Chem Bi01 I~zterizct
79: 15-30.
Keller RI, Halrnes NC, Hinson JA and Pumford S R (1993) Immunochernicai detection of
oxidized proteins. Chem Res Toxicol 6: 130433.
150 Kendall PM, Johnson JV and Cook CE (1979) Synthetic route to an aromatic analogue of
siiigol. J Org Clleni 44: 1421-1424.
Kenna JG, Satoh H. Christ DD and Pohl LR (1988) Metabolic b a i s for a drug
hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver
neoantigens that contain the tri fluoroacetyl group derived from halotbane. J Pharmacol
Exp Ther 245: 1 103- 1 109.
Kim HL and Kovacs MJ ( 1995) Diclofenac-associated thrombocytopenia and neutropenia.
Ann Pharmacother 29: 7 1 3-7 15.
Klebanoff SJ (1968) Myeloperoxidase-halide-hydrogen peroxide antibacterial system. J
Bacteriof 95: 2131-3138.
Knowles SR, Shapiro L and Shear NH (1996) Serious adverse reactions induced by
minocycline. Arch Dermatol 132: 934-939.
Konttinen YP and Tuominen L (197 1) Reversible procainamide-induced agranulocytosis
twice in one patient. Lancer 2: 925.
Krarner MR, Levene C and Hershko C (1986) Severe reversible antoimmune haemolytic
anaernia and thrombocytopenia associated with diclofenac therapy. Scand J H~zonatol
36: 118-120.
Lam DCC and Lindsay RH (1 9793) Accumulation of 2-[14~]propylthiouracil in human
polymorphonuclear leukocytes. Biochern Phannacol 28: 289-2296.
Lam DCC and Lindsay RH (1979b) Oxidation and binding of [2-14~]propylthiouracil in
hornan polymorphonuclear leukocytes. D m g Metab Dispos 7: 285-289.
Larrey D, Castot A, Pessayre D, Merigot P, Machayekhy JP, Feldarnn G, Lenoir A, Ruelt
B and Benhamoi* .JP (1986) Amodiaquine-induced hepatitis. A m Intern med 104:
80 1-803.
Lazarou J, Pomeranz BH and Corey PN (1998) Incidence of adverse drug reactions in
hospitalized patients: a rneta-analysis of prospective studies. JAMA 279: 1200- 1205.
151 Lee E, Miki Y, Hosokawa M. Sayo H and Kariya K (1988) Oxidative metabolism of
propylthiouracil by peroxidase frorn rat bone marrow. Xenobiorica 18: 1 135- 1 142.
Leeder JS, Gaedigk A, Lu X and Cook VA (1996) Epitope mapping studies with hurnan
anti-cytochrorne P45O 3A antibodies. Mol Pharmacol 49: 234-243.
Leeder JS, Riley RJ, Cook VA and Spielberg SP (1992) Human anti-cytochrome P450
antibodies in aromatic anticonvulsant-induced hypersensitivity reactions. J Pharmacol
Exp Ther 263: 360-367.
Lertratanangkoon K and Homing MG (1982) Metabolism of carbamazepine. Dmg Memb
Dispos 10: 1- 10.
Levine RL, Williams JA, Stadtman ER and Schacter E (1994) Carbonyl assays for
determination of oxidatively modified proteins. Metlzods E~zzynol 233: 346-357.
Lillibridge JH, Arnore BM, Slattery JT. Kalhorn TF, Nelson SD, Finnell RH and Bennett
GD ( 1996) Protein-reactive metabolites of carbamazepine in mouse liver microsornes.
D m g Metab Dispos 24: 509-5 14.
Liu ZC and Uetrecht JP (1995) Clozapine is oxidized by activated humün neutrophils to a
reactive nitrenium ion that irreversibly binds to the cells. J Phanmzcol E.rp Ther 275:
1476-1483.
Lynn RK, Smith RG. Thornpson RM. Deinzer ML. Griffin D and Gerber N (1978)
Characterization of glucuronide metabolites of carbamazepine in human urine by gas
chromatography and mass spectrometry. Dncg Metnb Dispos 6: 494-50 1 .
Madden S. ~Maggs JL and Park BK (1996) Bioactivation of carbamazepine in the rats in
vivo: evidence for the formation of reactive arene oxide(s). Drug Merab Dispos 224:
469-379.
Madden S, Spaldin V, Hayes RN, Woolf TF, Pool WF and Park BK (1995a) Species
variation in the bioactivation of tacrine by hepatic microsomes. Xenobiotica 25: 103-
116.
2 52 Madden S, Spaldin V and Park BK (199%) Clinical pharmacokinetics of tacrine. Clin
Phamacokinef 28: 449-457.
Madden S. Woolf TF, Pool WF and Park BK (1993) An investigation into the formation of
stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with
h u m a and rat liver microsornes. BiocCrertr Phannacol 46: 13-20.
Madison FW and Squier TL ( 1934) The etiology of primary granulopenia (agranuiocytic
angina). JAMA 102: 755-759.
~Maggs JL, Kitteringham NR, Breckenridge AM and Park BK (1987) Autoxidative
formation of a chernically reactive intermediate from amodiaquine, a myelotoxin and
hepatotoxin in man. Bioclicm Phannucol 36: 206 1-2062.
LMaggs .IL, Pirmohamed M, Kitteringham NR and Park BK (1997) Characterization of the
metabolites of carbarnazepine in patient urine by Iiquid chromatography/mass
spectrometry. Dnig Metab Dispos 25: 275-280.
Maggs L, Tingle NR, Kitteringham NR and Park BK (1988) Mechanisms of formation of
protein-aryiating intermediates from amodiaquine, a myelotoxin and hepatotoxin in
man. Bioclzertt Plrannacol 37: 303-3 1 1.
Magis CC, Barge A and Dausset 1 (1968) Serological study of an ailergic agranulocytosis
due to noramidopyrine. Clin Exp Itnrnirriol 3: 989.
.Maguire IH, Kraus BL. Butler TC and Dubley KH ( 1979) Determination of 5-(3,4-
dihydroxy- 1 $5-cyclohexadien- 1 -yl)-5-phenylhydantoin (dihydrodiol) and quantitative
studies of phenytoin metabolism in man. Ther Dnig ~çianifori~zg 1: 339-370.
Mansuy D, Valadon P, Erdelmeier 1, Lopez-Garcia P, Arnar C1 Girault I and Dansette PM
(199 1) Thiophene S-oxides as new reactive metabolites: formation by cytochrome P450
dependent oxidation and reaction with nucleophiles. J Am Chem Soc 113: 7825-
7826.
153 Marnett LJ and Bienkowski MJ (1980) Hydroperoxide-dependent oxygenation of trans-
7,8-dihydrobenzo(a)pyrene by ram seminal vesicle microsomes. Biochern Biophp Res
Cornrnun 96: 639-647.
Mason RP (1979) Free radical metabolites of foreign compounds and their toxicological
significance.. in Reviervs in biocheniical tosicology. (Hodgson E . Bend JR and
Philpot RM eds) pp 15 1-200. Elsevier-North Holland, New York.
Mathews KP (1984) Clinical spectrum of allergic and pseudoaflergic drug reactions. J
Allergy Clin Immurioi 74: 558-566.
McOmie JFW, Watts ML and West DE (1968) Demethylation of aryl methyl ethers by
boron tribromide. Tetrahedron 24: 2289-2292.
Merk HF and Hertl M (1996) Immunologie mechanisms of cutaneous drug reactions.
Sernin Crtrarz Med Srrrg 15: 228-235.
Miller EC (1978) Some current perspectives on chemical carcinogenesis in humans and
experimental animals: presidential address. Cmcer Res 38: 1479- 1496.
Mitra AK, Thurnmel KE. Kalhom TF, Kharnsch ED. Unadkat JD and Slattery JT ( 1995)
Metabolism of dapsone to its hydroxylamine by CYPZEl in vitro and in vivo. Clin
P/iurmacol Tlier 58: 556-566.
,Miyamoto G, Zahid N and Uetrecht JP (1997) Oxidation of diclofenac to reactive
intermediates by neutrophils, myeloperoxidase, and hypochlorous acid. Clzein Res
Toxicol 10: 4 14-4 19.
Mockenhaupt M and Schopf E (1996) Epiderniology of drug-induced severe skin reactions.
Sernin Crrtan Med Surg 15: 236-243.
~Moeschlin S and Wagner K (1952) Agranulocytosis due to the occurrence of leukocyte-
agglutinins. Acra Huemat 8: 29-40.
Moldeus P and Rahimtula A (1980) Metabolism of paracetamol to a glutathione conjugate
catalysed by prostaglandin synthetase. Bioclzern Biophys Res Comnrun 96: 469-475.
154 Morselli PL and Figerio A ( 1975) Metabolism and pharmacokinetics of carbarnazepine.
Dncg Metab Rev 4: 97- 1 13.
Munns AJ. de Voss JI, Hooper WD, Dickinson RG and Gillam EM (1997) Bioactivation
of phenytoin by human cytochrorne P450: characterization of the mechanism and
targets of covalent adduc t formation. Chem Res Toxicol 10: 1 049- 105 8.
Naisbitt DJ, Ruscoe JE. Williams D, O'Neill PM, Pirrnohamed M and Park BK (1997)
Disposition of amodiaquine and related antirnalarial agents in human neutrophils:
implications for dmg design. J Phannacol Exp Ther 280: 884-893.
Nakajima M, Inoue T. Shirnada N, Tokudome S. Yamamoto T and Kuroiwa Y (1998)
Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver
microsomes. Dricg Metab Dispos 26: 26 1-266.
Neftel KA, Woodtly W, Schrnid M, Frick PG and Fehr 1 (1986) Amodiaquine induced
agranulocytosis and liver damage. Br Med J 292: 72 1-723.
Nelson SD and Pearson PG (1990) Covalent and noncovalent interactions in acute lethal
ce11 injury caused by chemicals. Annu Rev Phamcol Toxicol 30: 169- 195.
Neuberger J and Kenna JG (1987) Halothane hepatitis: a mode1 of immune mediated drug
hepatotoxicity. Chi Sei 72: 263-270.
Nomura F and Lieber CS (1981) Binding of acetaldehyde to rat liver rnicrosomes:
enhancement after chronic alcohol consumption. Biocltem Biophys Res Commun
100: 131-137.
Oesch F ( 1973) Mammalian epoxide hydrases: inducible enzymes catal ysing the
inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and
olefinic compounds. Xet2obiotica 3: 305-340.
Park BK and Coleman JW (1988) The immunological basis of adverse drug reactions. A
report on a Symposium held in Liverpool on 6th April 1988. Br J Clin Phamac 26:
49 1-495.
155 Park BK, Coleman JW and Kitteringham NR (1987) Drug disposition and drug
hypersensitivity. Biochem Phannacol 36: 581-590.
Park BK and Kitteringham NR (1990) Dmg-protein conjugation and its immunoiogical
consequences. Drug Metab Rev 22: 87- 144.
Park BK, Pirmohamed M and Kitteringham NR (1992) Idiosyncratic drug reactions: a
mechanistic evaluation of risk factors. Br J Clin Phannac 34: 377-395.
Park BK, Pirmohamed M and Kitteringham NR (1995) The role of cytochrome P450
enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther 68: 385-
424.
Parker CW (1982) Allergic reactions in man. Plramacol Rev 34: 85- 104.
Piurish DD, Schlosser MJ. Kapeghian JC and Traina VM (1997) Activation of CGS 12094
(Prinomide metabolite) to 1,4-benzoquinone by myeloperoxidase: implications for
human idiosyncratic agranulocytosis. Fitnd Appl Toxicol 35: 197-204.
Pellock IM (1987) Carbamazepine side effects in children and adults. Epilepsia 28: S64-
S70.
Pessayre D, Wandscheer JC, Descatoire V, Artigou JY and Benhamou JP (1979)
Formation and inactivation of a chemically reactive metabolite of vinyl chloride. Toxicol
Appl Pharmacol 49: 505-5 15.
Petzc D and Fudenberg HH (1976) Irnmunologic mechanisms in dnig-induced cytopenias.,
in Progress in Hemarology (Brown EB eds) pp , Grune and Stratton, New York.
Pimohamed M. Kitteringharn NR, Breckenridge AM and Park BK (199%) The effect of
enzyme induction on the cytochrome p45O-mediated bioiictivation of carbamazepine by
mouse Iiver microsomes. Biochern Phannacol 44: 2307-23 13.
Pirmohamed M. Kitteringham NR, Guenthner TM, Breckenridge AM and Park BK
(1992b) An investigation of the formation of cytotoxic, protein-reactive and stable
metabolites from carbamazepine in vitro. Biochern Phannacol 43: 1675- 1682.
156 Pirmohamed M, Kitteringham NR and Park BK (1994) The role of active metabolites in
dnig toxicity. Drug Safery 11: 1 14- 144.
Pirmohamed M. Madden S and Park BK (1996) Idiosyncratic dnig reactions: metabolic
bioactivation as a pathogenic mechanism. Clin Pharmacol 31: 2 15-230.
Pisciotta AV, Ebbe S, Lennon EJ. Metzger GO and Madison FW (1958) Agranulocytosis
following administration of phenothiazine derivatives. Am J Med 25: 2 10-223.
Poccia F, Gougeon ML, Bonneville M, Lopez-Botet M. Moretta A, Battistini L, Wallace
M. Colizzi V and Malkovsky M (1998) Innate T-ce11 irnmunity to nonpeptidic antigens.
Immrrnol Today 19: 253-256.
Pohl LR (1990) Drug-induced aliergic hepatitis. Semin Liver Disense 10: 305-3 15.
Pohl LR, Kenna JG, Satoh H. Christ DD and Martin JL (1989) Neoantigens associated
with halothane hepatitis. Drug Metab Rev 20: 203-2 1 7.
Pohl LR, Pumford NR and Martin L (1996) LMechanisms. chernical structures and drug
metabolism. Eur J Haernatol 57: 98- 104.
Pohl LR, Satoh H, Christ DD and Kenna JG (1988) The irnmunologic and metabolic basis
of drug hypersensitivities. A m Rev Pltannacol 28: 367-3237,
Potter DW and Hinson JA (1987) The 1-electron and 2-electron osidrition of
acetaminophen catalyzed by prostaglandin-H synthase. J Biol Chein 262: 974-980.
Raucy JL, Lasker .TM, Lieber CS and Black M (1989) Acetarninophen activation by human
liver cytochromes P-450IIEI and P-450IAII. Arch biochem Biophp 271: 270-2 53.
Regnaud L. Sirios G and Chakrabarti S (1988) Effect o f four-day treatrnent with
carbarnazepine at different dose levels on microsomal enzyme induction. drug
metabolism and dnig toxicity. Pharmacol Toxicol 62: 3-6.
Reid WD and Krishna G (1973) Centrolobular hepatic necrosis related to covalent binding
of metabolites of halogenated aromatic hydrocarbons. Exp Mol Pathoi 18: 80-99.
Rickert DE, Baker TS, Bus JS, Barrow CS and Irons RD (1979) Benzene disposition in
the rat after exposure by inhalation. Toxicol Appi Pharmacol 49: 417-423.
157 Rieder MJ (1994) Mechanisms of unpredictable adverse drug reactions. Dnrg safew 11:
196-3 12.
Rieder MI. Uetrecht JP, Shear NH, Cannon M, Miller M and Spielberg SP (1989)
Diagnosis of sulfonamide hypersensitivity reactions by in vitro 'rechallenge' with
hydroxylarnine metabolites. Ann h t e m Med 110: 286-289.
Rietjens IM, den Besten C , Hanzlik RP and van Bladern PJ (1997) Cytochrome P450-
catdyzed oxidations of halobenzene. Chem Res Toxicol 10: 629-635.
Riley RJ, Kitteringham NR and Park BK (1989) Structurai requirements for bioactivation
of anticonvulsants to cytotoxic rnetabolism in vitro. Br J Clin Pliamacol 28: 482-487.
Riley RJ, Smith G, Wolf CR, Cook VA and Leeder JS (1993) Human anti-endoplasmic
reticulurn autoantibodies produced in aromatic anticonvulsant hypersensitivity reactions
recognise rodent CYP3A proteins and a similady regulated human P450 enzyme (s).
Biochem Biophys Res Comm 191: 32-40.
Sadler A, Subrahmanyam VV and Ross D (1988) Oxidation of catechol by horseradish
peroxidase and human leukocyte peroxidase: reactions of O-benzoquinone and o-
benzosemiquinone. Toxicol Appl Pharmacol 93: 61-7 1.
Salama A, Gottsche B and Mueller-Eckhardt C (1991) Autoantibodies and drug- or
metabolite-dependent antibodies in patients with diclofenac-induced immune
haernolysis. Br J Haernarol 77: 546-549.
Salama A, Schutz B, Kiefel V, Breithaupt H and Mueller-Eckhardt C (1989) Immune-
mediared agranulocytosis related to drugs and their metabolites: mode of sensitization
and heterogeneity of antibodies. Br J Haentatol 72: 12% 132.
Sawchuk RI, Maloney JA, Cartier LL, Rackley RJ, Chan KK and Lau HS (1995)
Analysis of diclofenac and four of its metabolites in human urine by HPLC. Pham Res
12: 756-762.
Sayo H and Saito M (1990) The mechanism of myeloperoxidase-catalysed oxidation of
aminopyrine. Xenobiotica 20: 957-965.
158 Schwartz MA (1969) Chernical aspects of penicillin allergy. J Phmm Sci 58: 643-66 1.
Shapiro S (1986) Risks of agranulocytosis and aplastic anemia: a first report of their
relation to drug use with special reference to analgesics. J M A 256: 1749- 1757.
Shear NH and Spielberg SP (1988) Anticonvulsant hypersensitivity syndrome. 112 vitro
assessrnent of risk. J Clin hvest 82: 1826- 1832.
Shulman NR (1958) Immunoreaction involving platelets. 1. A steric-kinetic mode1 for
formation of a complex frorn a human antibody. quinidine as a hapten, and platelets;
and for fixation of complement by the complex. J Exp Med 107: 665-690.
Sims P and Grover PL (1974) Epoxides in polycyclic aromatic hydrocarbon metabolism
and carcinogenesis. Adv Camer Res 20: 165- 174.
Smith DB, Mattsen RH. Cramer JA, Collins IF, Novelly RA and Craft B ( 1987) Results
of a nationwide veterans administration cooperative study comparing the side effects
md toxicity of carbarnazepine, phenobarbitol, phenytoin and prirnidone. Epilepsin 28
(Suppl 3): 50-58.
Smith GC, Kenna JG, Harrison DJ, Tew D and Wolf CR ( 1993) Autoantibodies to hepatic
rnicrosomal carboxylrsterase in halothane hepatitis. Lancer 312: 963-964.
Smith MT, Yager JW, Steinmetz YL and Eastmond DA ( 1989) Peroxidase-dependent
metabolism of benzene's phenolic rnetribolites and its potential role in benzene toxicity
and carcinogenicity. Eitviroti Heallh Perspect 82: 23-29.
Snyder R and Kocsis JJ (1975) Current concepts of chronic benzene toxicity. CRC Crit
Rev Toxicol 3: 365-25s.
Spaldin V. Madden S. Pool WF, Woolf TF and Park BK (1994) The effect of enzyme
inhibition on the metabolism and activation of tacrine by human liver rnicrosomes. Br J
Clin Phannacol 38: 15-22.
Spielberg SP, Gordon GB, Blake DA, Melliîs ED and Bross DS (198 1) Anticonvulsant
toxicity in vitro: possible role of arene oxides. J Phannacol Exp Ther 217: 386-389.
159 Stadtman ER and Oliver CN (1991) Metal-catrilyzed oxidation of proteins: Biochemical
mechanism and biological consequences. Free Rndic Bi01 Med 9: 3 15-325.
Stricker BHC and Spoelstra P ( 1985) Dmg-induced Izepatic injury. A compreliensive
slrrvey of the literatrtre on ndcerse drrig reactions L(P to Jnn~iary 1985. Elsevier,
Amsterdam.
Terashima K, Takai S, Usami Y, Adachi T, Sugiyama T, Katagiri Y and Hirano K (1996)
Purification and partial characterization of an indomethacin hydrolyzing enzyme from
pig liver. P h a m Res 13: 132% 1335.
Thornpson PF and Trimple MU (1982) Anticonvukant drugs and cognitive functions.
Epilepsia 23: 53 1-544.
Thummel KE, Lee CA, Kunze KL, Nelson SD and Slattery JT (1993) Oxidation of
acetaminophen to N-acetyl-p-arninobenzoquinone irnine by human CYP3A1. Biocliem
Phamtacol 45: 1563- 1569.
Timbre11 JA (1983) Drug hepatotoxicity. Br J Clif1 Pharnzacol 15: 3- 14.
Uetrecht J, Zahid N and Rubin R (1988a) Metabolism of procainarnide to a hydroxylamine
by human neutrophils and rnononuclear leukocytes. Cllem Res Toxicd 1 : 74-78.
Uetrecht J. Zahid N, Shear NH and Biggar WD (1988b) Metabolism of dapsone to a
hydroxylamine by human neutrophils and mononuclear cells. J Pliannacol E-rp Tlier
245: 274-279.
Uetrecht JP (1990) Drug metabolism by leukocytes and its role in dmg-induced lupus and
other idiosyncratic dmg reactions. CRC Crit Rev Taxicol 20: 313-235.
Uetrecht JP (1996) Reactive metabolites and agranulocytosis. Eur / Hnenrnrol 57: S83-
S88.
Uetrecht JP (1985) Reactivity and possible significance of hydroxylaminr and nitroso
metabolites of procainamide. J PIzamocol Exp Ther 232: 420-425.
Uetrecht SP (1992) The role of leukocyte-generated reactive metabolites in the pathogenesis
of idiosyncratic dmg reactions. Drug Metab Rev 24: 299-366.
160
Uetrecht JP, Ma HM, MacKnight E and McClelland R ( 1995) Oxidation of aminopyrine by
hypochlorite to a reactive dication: possible implications for arninopyrine-induced
agranulocytosis. Chem Res Toxicol 8: 226-233.
Uetrecht JP, Sweetman BJ. Woosley RL and Oates JA (1984) Metaboiism of procainarnide
to a hydroxylamine by rat and human hepatic rnicrosomes. Dmg Metab Dispos 12: 77-
8 1 .
Uetrecht JP and Zahid N ( 199 1 ) N-chlorination and oxidation of procainamide by
myeloperoxidase: toxicological implications. Chern Res Toxicol 4: 2 18-22.
Uetrecht JP, Zahid N and Whitfield D (1994) Metabolism of vesnarinone by activated
neutrophils: implications for vesnarinone-induced agranulocytosis. J Pltnrmzcol E.rp
Ther 270: 565-572.
van Zyl JM, Basson K, Kriegler A and van der Walt BJ (1990) Activation of
chlorpromazine by the myeloperoxidase system of the human neutrophil. Bioclzeni
Phannacol 40: 947-954.
Vermeulen NP, Bessens JGM and van de Straat R (1992) Molecular aspects of
paracerarnol-induced hepatotoxicity and its mechanism-based prevention. Dnrg Merab
Rev 24: 367-407.
Wade L. Kenna JG and Caldwell J (1997) Lmunochemicai identification of mouse hepatic
protein adducts derived from the nonsteroidal anti-intlarnrnatory drugs diclofenac,
sulindac, and ibuprofen. Clzeni Res Tosicol 10: 546-555.
Waldhauser L and Uetrecht J (199 1) Oxidation of propylthiouracil to reactive metabolites
by activared neutrophils: implications for agranulocytosis. D m g Metnb Dispos 19:
354-359.
Weiss SJ (1989) Tissue destruction by neutrophils. New EnglJ Med 320: 365-376.
Winn LM and Wells PG ( 1995) Free radical-mediated mechanisms of anti-convulsant
teratogenicity. Eur J Nerrro 3: 5-29.
161 Wood AW, Chang RL, Levin W, Yagi H, Thakker DR. Jerina DM and Conney AA (1977)
Differences in mutagenicity of the optical enantiomers of the diastereomeric
benzo(a)pyrene 7,8-diol-9.10 epoxides. Biochem Biophys Res Cornmiin 77: 138%
1396.
Zirnmerman HJ (1978) Hepntotoxicity. The adverse e f f e c ~ of dnigs and other chernicals
on the liver. Appleton-Century Crofts. New York.